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November 2016. 
 
Amyloidosis is defined as the misfolding of native proteins into insoluble fibrils 
that are deposited within tissues and extracellular organs. 30+ structurally and 
sequentially unrelated proteins have the ability to form amyloid aggregates, all of 
which contain characteristic features. ApoA-I, the main component in high-
density lipoprotein, aggregates and becomes deposited as amyloid, either full-
length apoA-I fibrils within atherosclerotic plaques, or N-terminal fragments of 
mutant apoA-I within organs. The work here aims to further the understanding 
of conditions that promote the aggregation of apoA-I in vitro, allowing the 
structural study of aggregated apoA-I at a molecular level.  
ApoA-I remains soluble at neutral pH, maintaining a predominantly α-
helical conformation. Upon acidification to pH 4, apoA-I readily assembles into 
aggregates that, despite being responsive to the amyloid characteristic ThT dye, 
do not have the typical amyloid morphology and do not produce XRD diffraction 
patterns suggestive of β-sheets. The inclusion of heparin, and chemical oxidation 
of apoA-I methionine residues, in order to mimic physiological conditions, results 
in an increased ThT response and aggregated material more characteristic of 
amyloid. 
Solid-state NMR spectroscopy reveals for the first time that all three 
aggregation inducing conditions produce aggregates that give rise to cross-peaks 
 III 
corresponding to both α-helical and novel β-sheet structures. This leads to a 
refinement in the current theory describing apoA-I aggregation. In native apoA-I, 
the N-terminal 4-helical bundle protects the 3 hot spot regions from self-
association into β-sheets. Acidification of apoA-I leads to the destabilisation of 
this N-terminus, and a conversion of residues 1-90 into β-sheet structures, whilst 
the C-terminus retains its α-helical structure.  
EGCG, an inhibitor of Aβ, α-synuclein and huntingtin amyloidosis, is 
shown here to bind to apoA-I with micro-molar affinity. However, rather than 
inhibit amyloidosis, EGCG causes a structural rearrangement of the aggregated 
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 1 
1. Introduction to amyloid 
1.1. Amyloid Background 
The term amyloid was first coined by the German physician Rudolph Virchow in 
1854, to describe protein abnormalities taken from cerebral corpora amylacea, 
which stained positively with iodine reactions (Howie and Brewer, 2009; Sipe 
and Cohen, 2000; Sipe et al., 2012). Virchow initially presumed these “plaques” 
consisted mainly of starch, until in 1959 when Freidreich and Kekule discovered 
not only the absence of carbohydrates but the presence of protein, detected by 
the high nitrogen content of the plaques (Sipe and Cohen, 2000). Initially 
Virchow used the iodine-sulphuric acid reaction, common practice in 1814, in 
order to detect starch. However, the positive results from this test were 
attributed to the accessory components and associated glycosaminoglycans, 
rather than the core material, which was later shown to be aggregated protein 
(Aterman, 1976). Due to the development of more advanced techniques, such as 
polarising light microscopy, it was possible to detect an apple green 
birefringence when amyloid deposits were stained with Congo-red (Gillam and 
MacPhee, 2013; Serpell, Blake, et al., 2000; Sipe and Cohen, 2000). This mode of 
measurement, now a classifying criterion for all 20 plus amyloid species, was 
first used on amyloid by Missmahl and Hartwig in 1953 (Howie and Brewer, 
2009). The exact mechanism by which Congo red binds to amyloid is still 
unknown, nevertheless, the resultant birefringence when Congo red stained 
amyloid is visualised under polarised light is similar to the results observed with 
cellulose fibrils. This also explains why Virchow came to his inaccurate 
conclusion that the deposited plaques were composed of starch. 
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Bottiger first developed Congo red dye in 1884 as a dye for starch rich cottons. 
The dye works by aligning itself against the cellulose structures, stabilised by the 
hydrogen bonds between the dye and cellulose. These interactions are expected 
to be similar to the interaction between the dye and the amyloid fibril. This is due 
to the linear orientation of both amyloid and cellulose fibrils, as opposed to a 
branched or helical orientation seen in most other tissues (Howie and Brewer, 
2009; Puchtler et al., 1962). 
 
1.1.1. ISA defined amyloid  
The International Society for Amyloidosis (ISA) defines amyloid as a protein 
deposited as insoluble fibrils in tissues and extracellular spaces of organs, after a 
sequence of changes referred to as amyloidosis. Amyloidosis produces non-
branching fibrils, approximately 10nm in diameter, which have the ability to bind 
Congo red dye and exhibit an apple green birefringence when viewed with a 
polarised lens. Amyloid species must also be identified by their amino acid 
sequence, meaning it is insufficient for a mutation of an amyloidogenic protein to 
be automatically classed as amyloid itself (Sipe et al., 2012). ISA recognises 30 
human and 9 animal species of amyloid, many of which have a pathological link 
to a variety of disease states (Sipe et al., 2014).   
 
1.1.2. Amyloid associated diseases 
The misfolding of proteins into amyloid species has been shown to be associated 
with a wide range of human diseases (Table 1.). Proteins involved in amyloid 
disease can be either: biological peptides (amylin and insulin), full-length 
proteins (α-synuclein and transthyretin (TTR)), fragments of larger peptides (Aβ 
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and apoA-I), or caused through general protein decay (Stefani, 2007). In order to 
classify the different types of amyloid, the 30 species are subdivided into several 
classes, including whether the amyloid deposits are localised or systemic. 
Localised species affect only singular tissue types, such as β-amyloid, which 
deposits solely in the basal forebrain, leading to Alzheimer's disease (Chiti and 
Dobson, 2006; Whitehouse et al., 1982). However, systemic species are able to 
affect multiple tissue types and organ systems, such as apolipoprotein AI (apoA-
I), the protein of interest in this study. ISA recognises apoA-I derived amyloid 
deposits in the heart, liver, kidney, peripheral nervous system, testes, larynx and 
skin, the latter two being C-terminal variants (Sipe et al., 2012).  
Amyloidosis is split into 2 groups: either acquired through random 
mutation of the native protein, such as with serum amyloid A, or hereditary, such 
as Aβ. ApoA-I is linked to both acquired and hereditary forms of amyloidosis. 
Random mutations in the apoA-I sequence lead to the aggregation of full-length 
apoA-I (Das et al., 2016; Mucchiano, et al., 2001; Ramella et al., 2011; Ramella et 
al., 2012; Wong et al., 2010; Chan et al., 2015), whilst hereditary mutations 
induce the release of an extremely amyloidogenic N-terminal fragment, referred 
to as familial apoA-I amyloidosis  (Raimondi et al., 2011; Das et al., 2016; 
Andreola et al., 2003; Adachi et al., 2012). ApoA-I amyloidosis will be discussed in 






Table 1.1 ISA recognised amyloid associated human diseases, caused by the 
deposition of amyloid fibrils. Table taken from Chiti and Dobson (2006). 








Frontotemporal Dementia Parkinson’s 
Amylotrophic Lateral Sclerosis 
Huntington’s 
Familial British/Danish Dementia 
Spinocerebella Ataxia 
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Finnish Hereditary Amyloidosis 
Lysosome Amyloidosis 
Fibronogen Amyloidosis 





Ig Light Chain 
Serum Amyloid A Protein 
Wild-typeTransthyretin 
Mutant Transthyretin 
(N-terminal) Apo AI 
(N-terminal) Apo AII 








All β, Ig like 
All α 
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Non Neuropathic Localised 
 
Type II Diabetes 




Injection Localised Amyloidosis 
Aortic Medial Amyloidosis 
Hereditary Lattice Corneal Dystrophy 
Corneal Amyloidosis (Trichiasis) 
Cataract 
Pulmonary Alveolar Proteinosis 
Inclusion Body Myositis 
Cutaneous Lichen Amyloidosis  







Atrial Natriuretic Factor  








Lung Surfactant Protein C 









All α, 4 helical  
All α, insulin like 
Unknown 
Unknown 
α and β 



























1.1.3. Amyloid disease pathology 
Despite the research into the various amyloid associated diseases, detailed in 
Table 1, a definitive pathology of the aetiology of amyloid associated diseases 
remains unknown. Many amyloid species are formed through the conversion of 
monomeric proteins, via soluble oligomeric intermediates, into the insoluble 
amyloid fibril structures. It is still debated whether the fibrillar deposits are the 
cause of the disease phenotype, or whether they are an end product of the 
disease progression. This pathology could be initiated by the oligomeric species 
which, across the different diseases, have a common structure and are often toxic 
(Gillam and MacPhee, 2013; Janson et al., 1999; Kayed, 2003; Stefani, 2007). It 
would appear that the causal species varies with each disease. 
 
1.1.4. Oligomer induced pathology 
Oligomeric species of amyloidogenic proteins have been shown to be the cause of 
many disease phenotypes. For example, in non-insulin dependent diabetes 
mellitus (NIDDM), by selecting for the formation of oligomeric species in the 
amyloidosis process, rather than the fibril end product, the oligomers have been 
shown to be toxic and thus the cause of the disease state (Janson et al., 1999; 
Kayed, 2003). Rifampicin is a drug commonly used to treat bacterial infections by 
inhibiting the bacterial RNA polymerase. However, Rifampicin has also been 
shown to have inhibitory effects on the formation of islet amyloid polypeptide 
(IAPP) fibrils, but not the oligomeric species, as described in Figure 1.1. 
Inhibition of fibril formation still resulted in β-cell apoptosis, confirming that it is 




Figure 1.1 Schematic of the amyloidosis of human islet amyloid polypeptide, 
detailing the conversion from monomeric peptide through oligomeric species 
into the amyloid fibril. Rifampicin inhibits the formation of fibrils leading to an 
increased oligomer concentration and subsequent toxic species. Image replicated 
from Meier et al. (2006).  
 
Other examples of oligomer-induced disease pathology include Alzheimer's 
(Ahmed et al., 2010; Huang et al., 2000; Näslund et al., 2000), Parkinson’s, 
Huntington’s, and Familial British dementia (Haass and Selkoe, 2007; Walsh et 
al., 2002). In Alzheimer's disease, the extent of disease progression is directly 
correlated to the accumulation of the soluble oligomeric form of the amyloid β 
protein in the brain, rather than the extent of fibril plaque deposition. This is 
despite the presence of plaques correlating with the severity of the disease 
(Berthelot et al., 2013; Kayed, 2003; Näslund et al., 2000). This implies that the 
amyloid deposits are merely an end product of the disease pathology. This is 
further confirmed by the presence of plaques many years prior to the disease 
onset (Perrin et al., 2009).  
 7 
The structure of the oligomers in amyloidosis varies depending on the 
particular protein. In Alzheimer's disease, for example, the Aβ (1-42) peptide has 
the ability to form stable trimeric, tetrameric and pentameric oligomer 
complexes, in stark contrast to the Aβ (1-40) which does not (Ahmed et al., 
2010). This is despite both peptides being able to form full-length amyloid 
species in the correct conditions. 
The proposed mechanism of how oligomeric intermediates manifest into 
the disease phenotype involves their interaction and disruption of lipid 
membranes, leading to a loss of selectivity in ion permeability cumulating in cell 
apoptosis. The oligomeric interactions damage a cell’s permeability through a 
range of methods, described in Figure 1.2, including: detergent effects, raft 
formations, carpeting effects and pore formation. The carpeting and raft-like 
formations involve the assembly of amyloid fibrils on, or within, the membranes, 
inhibiting the membrane’s normal function (Berthelot et al., 2013), leading to 
apoptosis. In addition to apoptosis, increased cellular Ca2+ levels lead to an 
increase in reactive oxygen species (ROS), potentially through activation of the 
citric acid cycle in order to produce excessive ATP, required for the removal of 
the excess calcium (Stefani, 2007). The exact method of how the oligomers open 
up the calcium pores is disputed, with two main theories varying in the origin of 
the oligomers, either outside the cell or after internalisation, prior to interacting 
with the calcium pores (Demuro et al., 2011). Soluble oligomeric species have 
also been shown to bind metals, and induce the production of reactive oxygen 
species (Maynard et al., 2005) 
Inhibition of protein aggregation which would retain a protein in its non-
toxic monomeric form (Walsh et al., 1997), or its toxic oligomeric form, whilst 
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enhancement of amyloidosis into full-length fibrils, thus avoiding the toxic 
oligomeric stage (Madine and Middleton, 2010), are both potential therapeutic 
techniques. However, not all oligomers in amyloidosis are harmful (Berthelot et 
al., 2013; Stefani, 2007) and in some cases can be used as potential fibril 
inhibitors (Uversky, 2010).  
 
Figure 1.2 Models depicting the interactions between lipid membranes and 
amyloid that leads to membrane destabilisation and subsequent cell death, via 
apoptosis. Image taken from Bertheloti (2013).  
 
1.1.5. Amyloid associated components 
Amyloid deposits involved in Parkinson’s, Alzheimer’s and prion associated 
diseases have all been associated with assemblies that contain non-fibrillar 
components (Madine et al., 2013) including: other proteins, polysaccharides, 
proteoglycans and serum amyloid P component (Desai et al., 2010; Chan et al., 
2015). There is also evidence for a high concentration of metal ions such as 
copper, zinc and iron included within the amyloid deposits. These ions have the 
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ability to induce aggregation via an overall reduction in protein charge or by 
bridging two peptides. Alternatively, metal ions are also able to inhibit 
aggregation of amyloidogenic proteins by increasing the net charge of the protein 
or by interfering with β-sheet stabilising bonds (Alies et al., 2013). The effects of 
ions are dependent on the specific amino acid sequence. 
Proteoglycans, including the long, unbranched glycosaminoglycans 
(GAG’s): heparin, dermatan, keratin and chondroitin sulphates have all been 
found in amyloid deposits. These GAGs have been shown to initiate the formation 
of fibrils, in addition to providing stability and resistance to proteolysis 
(Cohlberg et al., 2002; Madine et al., 2013; Papy-Garcia et al., 2011).  
 
1.1.5.1. Heparin 
Heparin, a highly sulphated GAG, is comprised of disaccharide repeats containing 
an uronic acid, either glucuroinic or iduronic acid, followed by an amino sugar 
(Casu et al., 2015; Khan et al., 2010). The most common pairing of these involves 
L-idopyranosyluronic acid 2-sulfate (IdoA2) and 2-deoxy-2-sulfamino-D-
glucopyranose-6–phosphate (GlcNS,6S) (Figure 1.3A), which accounts for 75–85 
% of heparin species within amyloid plaques (Gatti et al., 1979; Casu et al., 2015).  
The three sulphate groups on this disaccharide repeat highlights the strong 
charge carried on all heparin molecules, making it one of the most negatively 
charged molecule in nature. Figure 1.3B shows a molecule of heparin consisting 





Figure 1.3 (A) Disaccharide of IdoA2-GlnNS,6S and (B) a molecule of heparin 
consisting of 12 of IdoA2-GlnNS,6S repeats (PDB 3IRJ). 
 
Heparin promotes aggregation of the amyloidogenic protein α-synuclein 
(Cohlberg et al., 2002; Madine et al., 2013), measured both by an increase in fibril 
yield and rate of aggregation. The ratio of heparin to α-synuclein, and the 
inclusion of fluorescently labelled heparin within fibrils structures, indicates that 
the heparin does not merely act as a catalyst for aggregation, but is incorporated 
into the fibril during its formation (Cohlberg et al., 2002). Heparin is believed to 
act as a scaffold protein, aligning the α-synuclein monomers in an orientation 
that favours the formation of β-sheet structures, and promotes stabilising bonds 
between protein molecules (Madine et al., 2013). Heparin has promoted the 
formation of ThT responsive fibrillar species in proteins that have no natural 
propensity to aggregate, such as residues 1-23 of phospholamban (PLB). The 
peptide PLB (1-23) is predicted to have a low natural propensity to form 
amyloid. However, in the presence of heparin, a dramatic increase in ThT 
fluorescence was observed, suggesting amyloid formation (Madine et al., 2013).  
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1.2. Protein folding and misfolding 
Proteins are synthesised as long polypeptide chains with no secondary structure. 
Consequently, the protein has to determine its own final structure through a 
specific folding pathway, via intermediates. This leads to the most stable 3D 
structure (Radford, 2000), with the exception of several unfolded functioning 
proteins, such as α-synuclein and tau, both of which have increased propensity to 
aggregate, due to their unfolded nature (Fowler et al., 2007). The 3D structure of 
each protein is essential to its individual function, in conjunction with the specific 
amino acid sequence of the protein, and the environment in which the protein is 
located. All three variables work in co-operation to place the relevant amino 
acids in the required position, in relation to all other residues, in order for the 
protein to carry out its biological function.   
If the folding pathway becomes disrupted, leading to a novel fold, the 
protein will usually lose its native function and, in some cases, gain a novel 
function, according to the new fold. This can lead to a malfunction in a biological 
process, causing disease pathology (Teoh et al., 2011).  
Folding proteins are said to follow an energy landscape mechanism 
(Figure 1.4), whereby the unfolded protein at the top of the funnel samples 
many different folding conformations, selecting the one with the lowest free 
energy. This process of trial-by-error continues, forming more stable 
intermediates, as Van der Waals and hydrogen bonds stabilise the overall 
structure. Each stabilisation reduces the energy requirements, until the protein 





Figure 1.4 Energy landscape schematic indicating the newly synthesised, 
unfolded proteins entering the top of the funnel (red), the different folding routes 
a protein can take via intermediate folds (green), resulting in the final natively 
folded protein (blue). If a particular fold results in a conformation that does not 
allow further folding into the native structure, and cannot be recovered, the 
protein has misfolded (orange). Image taken from Radford (2000). 
 
In some circumstances, the intermediate conformation trialled is either 
less stable or an off-pathway intermediate, leading to the formation of a 
misfolded protein. This misfolded intermediate can usually be corrected with the 
help of chaperone proteins. Chaperone proteins allow the reversal of the free-
energy driven protein folding, allowing the previous intermediate to select 
another, more suitable conformation. In some cases, the misfolded intermediate 
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is too far off the native folding pathway and cannot be recovered, sometimes 
leading to their aggregation, which can act as precursors for amyloid formation 
(Dobson, 2003) as shown in Figure 1.5. 
 
 
Figure 1.5 Schematic of the protein-folding pathway. The newly synthesised 
polypeptide chains fold, via intermediates, into the native protein structure, 
which may be incorporated into larger protein complexes, highlighted by the 
green arrow pathway. Alternatively, both the unfolded protein and the 
intermediate folds may form disordered aggregates or prefibrillar species that 





1.3. Amyloid aggregation  
1.3.1. Destabilisation 
Amyloid fibres form via the misfolding of proteins into highly ordered β-sheet 
structures that do not match their native, most stable form, as shown in Figure 
1.5 (Dobson, 2003; Gillam and MacPhee, 2013; Serpell, Sunde, et al., 2000; Teoh 
et al., 2011). These misfolded proteins then have a higher propensity to 
aggregate, due to the exposure of aggregation prone regions, which self-assemble 
into amyloid structures. The aggregation into amyloid is not exclusive to the 
proteins listed above in Table 1, and it is theorised that, under the correct 
conditions, all proteins have the ability to misfold into an amyloid conformation 
(Madine et al., 2013; Guijarro et al., 1998). 
 
1.3.2. Nucleation dependent polymerisation 
Nucleation dependent aggregation is the leading theory detailing amyloid 
formation (Chiti and Dobson, 2006; Gillam and MacPhee, 2013). This mechanism 
is made up of four key stages: a lag phase, a nucleation point, rapid exponential 
growth, and finally, the accumulation of fully formed fibrils. Although the lag 
phase appears to have no aggregation kinetics, during this phase the individual 
protein monomers accumulate into a critical sized homogenous nucleus with a 
high β-sheet content. This process of aggregation is kinetically unfavourable and 
is dependent on various conditions, including protein concentration, pH and salt 
concentration. Once the nucleus has reached a critical state, it passes through the 
nucleation point and undergoes a thermodynamically favourable elongation 
process. During this period, protein monomers and oligomers are recruited to 
the elongating fibre, until the level of monomeric protein in solution is depleted 
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(Alies et al., 2013; Larsson et al., 2011; Naiki et al., 1997; Serio et al., 2000; 
Souillac et al., 2002). The most accurate way to measure amyloid formation is 
through the use of the benzothiazole salt dye, Thioflavin T (ThT). Upon binding 
to the grooves in the β-sheet structures of amyloid, the ThT molecule experiences 
a red shift in its fluorescence spectra, resulting in increased emission at 482 nm 
(LeVine, 1999; Wolfe et al., 2010). By following the increase in fluorescence, the 
aggregation of proteins into amyloid can be followed in real time, as well as 
allowing the calculation of the aggregation kinetics, as shown in Figure 1.6. 
 
Figure 1.6 Sigmoidal growth curve of amyloid fibrils, via a nucleation dependent 
polymerisation mechanism. The ThT fluorescence at 482nm depicts a lag phase, 
a nucleation point, an exponential growth then a plateau phase. From these 
values, a lag time (τlag) and a rate of aggregation (rmax) can be calculated from the 
gradient of the slope when it is at its steepest. Image taken from Gillam & 
MacPhee (2013).  
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1.3.3. Seeding 
The length of the lag phase in amyloid aggregation is highly variable between 
different amyloid species and conditions. The lag phase length can be reduced 
through seeding; a process that introduces pre-formed, homogenous aggregated 
protein fragments to the un-aggregated protein solution. These fragments act as 
the critical sized nucleus and promote the exponential growth of the fibril, hence 
reducing the lag phase, as shown in Figure 1.7 (Larsson et al., 2011; Paravastu et 













Figure 1.7 Model sigmoidal curve of amyloid formation, via nucleation 
dependent polymerisation. The blue solid line indicates the natural formation of 
amyloid, with the length of the lag phase shown above. The blue dotted line 
indicates the formation of amyloid after seeding (point shown), again with the 
lag time shown above.  
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1.3.4. Lipid induced amyloidosis 
Many of the proteins that misfold into amyloid species demonstrate increased 
aggregation upon interaction with lipids, micelles and membranes. For example, 
the anionic surface induced oligomerisation of α-synuclein in Parkinson’s disease 
(Necula et al., 2003), and islet amyloid polypeptide (IAPP) in diabetes mellitus. In 
the case of IAPP, the protein interacts with phospholipid membranes, which acts 
as a catalyst, resulting in the assembly of pre-amyloid structures. These 
structures can then induce nucleation dependent polymerisation, in a similar 
manner to seeding aggregation, reducing the lag time and increasing amyloidosis 
by up to 10 fold (Knight and Miranker, 2004).  
In Alzheimer's disease, Aβ peptides interact strongly with GM1-
ganglioside containing membranes, leading to the deformation of the C-terminus 
of Aβ and exposure of hydrophobic regions. These regions then lead to the 
oligomerisation of 2 Aβ peptides into a β-sheet structure, followed by growth of 
the fibril (Hoshino et al., 2013). The catalytic effect of membranes on the 
aggregation of amyloid prone proteins not only exacerbates the disease 
pathology through fibril formation but, during the interaction, the membranes 
normal function is often compromised, leading to additional cytotoxicity.  
 
1.3.5. Functional amyloid 
Not all amyloid species are inactive aggregates of previously native, functioning 
proteins. There are many cases where amyloid fibrils have essential functions in 
humans, bacteria, fungi, and invertebrates, highlighted in Table 1.2 (Fowler et 
al., 2007).  
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Bacteria utilise the high strength of amyloid fibrils, which in some cases 
have a strength yield similar to steel (Smith et al., 2006), and their immunity to 
protease degradation is an advantage to their function in mechanical processes 
within the cells. Escherichia Coli for example, contain machinery that actively 
promotes the formation of the curli amyloid fibril (Cherny et al., 2005), a 
structural protein used in surface adhesion, colony formation and the promotion 
of host inflammatory responses (Barnhart and Chapman, 2006; Chapman et al., 
2002). In insects and fish, the amyloid species of the chorion proteins are present 
in the shell of the eggs, protecting it from physical damage, protease degradation 
and microorganisms (Fowler et al., 2007; Podrabsky et al., 2001).  
In humans, a cleaved fragment of the Pmel 17 protein, referred to as Mα, 
forms amyloid fibrils that act as a template in the synthesis of melanin, 
accelerating the polymerisation of melanogenic precursors into melanin. Studies 
have shown that replacing the Mα amyloid with another species of amyloid fibril 
produces an equal increase in the production of melanin, suggesting that the 
amyloid structure, rather than the specific protein, is responsible for the 
enhanced melanin synthesis. Due to the risk of cytotoxic oligomer production as 
a by-product of these pathways, the formation of amyloid for functional reasons 






Table 1.2 Species of functional amyloid across bacterial, fungal and animal cell 
lines. The table was produced with data from Fowler et al. (2007) and Chiti & 
Dobson (2006). 
Species Protein Function 
Bacteria:  






Biofilm and Host Invasion 






















Non Stop Codon Read Through 
Poorly Understood 




Insects and Fish 
Nephila Clavipes 














Eggshell protective and support 
Structural, present in Spider silk 
Maintenance of synaptic changes in 
memory 




1.4. Amyloid characteristics 
1.4.1 Amyloid morphology 
Amyloid fibrils produce a very characteristic morphology, consisting of long, un-
branched fibrils, with a diameter of between 5 and 10 nm and a length of up to 
1600 nm when viewed via transmission electron or atomic force microscopy 
(Figure 1.8).  
 
Figure 1.8 Morphology of amyloid fibrils determined by TEM for (A) IAPP 
(Makin and Serpell, 2005) and (B) PLB (1-23) in the presence of heparin (Madine 
et al., 2013) and via AFM for (C) Aβ40 (Harper, Lieber, et al., 1997) and (D) apoA-
I (Ramella et al., 2011). 
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1.4.2. Amyloid structure 
With the development in molecular level biophysical analysis, common themes 
are being elucidated about amyloid fibrils, regardless of the protein sequence.  
There are three levels of structure in amyloid, as shown in Figure 1.9. The 
end product of fully formed fibrils can be visualised as networks of long, un-
branched fibres via electron and atomic force microscopy imaging. They have a 
diameter of approximately 60-120 Å and a length from 1000 to 16,000 Å.  
 These fibrils can be broken down into 5-8 proto-filaments (not to be 
confused with proto-fibrils, which represent partially fibrillar aggregates along 
the aggregation pathway), which arrange parallel to each other, extending in the 
direction of the fibre, with a diameter of roughly 25-35 Å. Each proto-filament 
contains an arrangement of β-sheet structural motifs, arranged perpendicular to 
the fibril axis in a cross-β conformation, typical of all amyloid species (Serpell, 
Blake, et al., 2000; Serpell, Sunde, et al., 2000; Serpell et al., 1997). 
Figure 1.9 Schematic diagram of the 3 levels of amyloid structure, from β-sheets 
in a cross-β structure, via proto-filaments, into full-length fibrils. 
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1.4.3. Cross-β structure 
Amyloid is highly distinguishable from other forms of insoluble protein 
aggregates, due to the high proportion of β-sheet secondary structures (Gillam 
and MacPhee, 2013), which run parallel to the fibril axis (Figure 1.10B). X-ray 
diffraction studies identify a core repeated region with a cross β conformation, 
containing sharp meridian reflections at 4.7-4.8 Å and less intense equatorial 
reflections at approximately 10 Å (Figure 1.10A). These reflections indicate the 
distance between the individual β-strands, running perpendicular to the fibril 
axis, and the multiple β-sheet layers, respectively (Figure 1.10 C) (Serpell et al., 
2000; Serpell et al., 1997; Jahn et al., 2010; Biancalana and Koide, 2010).  





Figure 1.10 (A) X-ray fibre diffraction pattern for un-orientated transthyretin 
(105-115), highlighting reflections at 4.7 Å and roughly 10 Å, consistent with β-
sheet spacings. Image taken from Gillam and MacPhee (2013). (B) Model of the β 
strand composition along the fibril axis forming a β-sheet structure in semi-
crystalline amyloid species, with the gap between each β strand labelled as 4.7 Å. 







1.4.4. Tertiary structure  
The individual β-sheets that form the cross β structure in Figure 1.10B are in an 
anti-parallel conformation. Nevertheless, they can also be orientated in a parallel 
form, as shown in Figure 1.11A. These β-strands are formed through backbone 
amide group interactions that are stabilised through hydrogen bonding. In the 
majority of amyloid structures, the β-sheet lie in-register, with the same side 
chains stacking on top of each other, a formation described as a steric zipper 
(Figure 1.11B). Other models including a β-helix conformation were originally 
proposed as the structure of amyloid, due to the high β-strand content measured 
by circular dichroism (CD) and morphology deduced by TEM. However, these 
were disproved when X-ray diffraction (XRD) patterns of amyloid lacked the 
required internal and external radii of 6 and 16 Å, respectively.  
Figure 1.11 (A) Models of β-sheets formed through the parallel and anti-parallel 
orientation of individual β-strands. (B) Steric zipper conformation in amyloid, 
where equivalent side chains stack vertically along the fibril axis. Image taken 
from (Nelson et al., 2005).  
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1.4.5. Quaternary structure of amyloid 
Despite the common structures mentioned above, which make up the amyloid 
fibre and are uniform across all thirty plus species of amyloidogenic proteins, 
variation in the protein sequence can lead to changes in the overall quaternary 
structure of the amyloid. Specific amino acid side chains extending out from the 
β-sheets can promote intra-molecular interactions, which lead to variation in the 
overall conformation of the many β-sheets in the amyloid (Petkova et al., 2002; 
Tycko, 2011).   
In some species of amyloid, different quaternary structures can be 
produced in vitro by the same protein precursor, depending on the conditions 
under which the proteins are studied. For example, the Aβ (1-40) peptide 
associated with Alzheimer’s disease has two well-defined quaternary structures 
for amyloid fibrils: 2A (striated ribbon) and 3Q (twisted pair) (Tycko, 2011). 
Despite their differences, both models share similar traits, including their overall 
U shape, caused by two parallel β-strands formed from residues 10-22 and 30-
40. Agitation promotes the formation of striated ribbon (2A) fibrils with a 
straight rod appearance and a diameter of 6nm, formed via lateral association.  
The proto-filaments of 2A fibrils contain two cross-β structures, in a twofold 
rotational symmetry along the fibril axis (Figure 1.12A), stabilised by a salt 
bridge between residues D23 and K28 (Petkova et al., 2006). However, when 
Aβ(1-40) is incubated in quiescent conditions, fibrils with a modulation in their 
diameter and an apparent lack of lateral association are formed. The proto-
filaments of 3Q fibrils contain three cross-β structures in a threefold rotational 




Figure 1.12 Aβ structures viewed along the fibrils axis formed under (A) 
agitated (2A)  (PDB 2LMN) and (B) quiescent (3Q) conditions (PDB 2LMP) 




1.5. Amyloid Therapies 
Despite the large amount of literature on amyloid associated diseases, there is 
currently no single cure. Available therapies are often invasive and focus around 
three main areas: targeting the source of the amyloid, inhibiting the toxic 
oligomeric phase and removing amyloid plaques (Figure 1.13 and 1.14).  
 
Figure 1.13 Therapeutic strategies to inhibit production, formation and stability 
of amyloid.  
 
1.5.1. Targeting the source 
Current therapies against systemic amyloidosis focus mainly on reducing the 
supply of precursor protein, in particular at the level of expression, so as to 
include both wild type and any cleaved amyloidogenic peptides. In AA 
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amyloidosis, patients are treated with anti-inflammatory drugs to reduce the 
production of the serum amyloid A (SAP) protein, the expression of which is 
increased during inflammation. In AL amyloidosis, targeting B-cell dyscrasia with 
chemotherapy regulates production of the monoclonal immunoglobulin light 
chain (Gillmore and Hawkins, 2006). In transthyretin (TTR) and Aα-chain 
amyloidosis, liver transplantation removes the abnormal genetic variant of the 
protein (Desai et al., 2010). In Alzheimer's disease, drugs targeting the β and γ-
secretase enzymes, which cause cleavage of the amyloidogenic Aβ (1-40/42) 
peptide from the amyloid precursor protein, are currently under investigation 
(Gillmore and Hawkins, 2006; Kumar et al., 2016). Furthermore, in Alzheimer's 
disease, hyper-phosphorylation of the tau protein can lead to its aggregation into 
amyloid-like structures (Sipe et al., 2014) and the production of neurofibrillary 
tangles (Kumar et al., 2016). Down regulation of glycogen synthase kinase (GSK-
3), the main protein involved in the phosphorylation of tau, has been considered 
as a potential therapy. Chemotherapy can also be used in the case of AL 
amyloidosis to eliminate the plasma cell clones responsible for the mutant AL 
secretion. This process involves removal of the patient’s own stem cells, followed 
by autologous stem cell transplantation (ASCT). This procedure can also be 
combined with heart transplantation (Dubrey et al., 2011).  
 
1.5.2. Stabilising the native fold 
Another method to inhibit amyloid formation is through stabilisation of the 
proteins native fold, since amyloidosis begins with destabilisation of the native 
fold. In TTR, it has been shown that small molecules can bind to the amyloid fibril 
precursors, stabilising their fold and reducing the propensity for them to 
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aggregate (Gillmore and Hawkins, 2006). One such drug in development, 
Tafamidis™, stabilises the protein in a dimer form, reducing the free monomeric 
protein, a requirement for amyloidosis (Bulawa et al., 2012). Similarly, the ZAβ3 
compound forms a dimer around the Aβ hairpin, inhibiting its self-assembly into 
amyloid (Hoyer et al., 2008).  
 
1.5.3. Inhibiting amyloidosis 
Targeting the amyloidosis step itself is another treatment method for amyloid 
associated diseases. This can be accomplished via small molecule interactions, or 
protein based β-sheet breakers.  
The development of small molecule inhibitors is most commonly derived 
from screening of large compound libraries for effects on amyloid formation. 
Comparing successful compounds can begin to highlight key structures or 
chemical groups required for effective amyloid inhibition (Pickhardt et al., 2005).  
The formation of amyloid is often linked to the inclusion of glycosaminoglycans, 
in particular heparin molecules (section 1.1.5), which promote or stabilise the 
change in structure from the proteins native fold to amyloid. N-
acetylglucosamine analogues, such as Fibrillex™, inhibit the binding of GAGs to 
the amyloid precursor protein and orally administered sulphated compounds 
have been shown to substantially reduce amyloid deposition of murine AA 
amyloid (Gillmore and Hawkins, 2006).  
Small peptides, or β-sheet breakers, have also been used as aggregation 
inhibitors. These can be designed according to the sequence of the target amyloid 
protein to increase specificity. These peptides arrange themselves against the 
aggregation “hot spots” of the amyloid precursor protein and inhibit self-
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association, which is required for the protein to undergo aggregation (Figure 
1.13). The selectivity of this treatment means peptides can be used to target a 
single disease (Gillmore and Hawkins, 2006; Soto et al., 1998). In the case of 
Alzheimer's disease, a 5-residue peptide iAβ5 (LPFFD) has been shown to not 
only inhibit amyloidosis, but also disassemble preformed fibrils in vitro (Hard 
and Lendel, 2012).  
Interfering with hydrogen bonds that stabilise the β-sheet structures is 
another way of inhibiting the formation of amyloid species. The self-recognition 
elements (SRE) in amyloidogenic proteins can be synthetically produced to 
include nitrogen methylation on one side. This allows binding of the synthetic 
SRE sequences to the target on one side, but the methylation on the alternative 
face inhibits further hydrogen bond interactions and elongation of the β-sheet 
(Figure 1.14). The 25-35 peptide of Aβ, incorporating residues GSNKGAIIGLM, 
readily forms aggregates typical of amyloid. Incubation of this peptide with N-
methylated derivatives leads to a reduction in aggregation and toxicity, since the 
methylated peptide binds to Aβ(25-35), but inhibits the interaction of additional 
monomers, thus reducing elongation (Hughes et al., 2000). This technique has 
also been used to inhibit the amyloidosis of Aβ(1-42) (Amijee et al., 2012). 
Finally, LMTX, a methylthinium chloride compound recently in phase 3 clinical 
trials, has been shown to inhibit the aggregation of tau proteins into amyloid-like 
structures involved with Alzheimer's disease (Kumar et al., 2016). 
 
1.5.4. Amyloid removal 
Given the delay in diagnosing amyloid associated diseases, large fibrillar deposits 
often accumulate within the organs or affected areas before treatment can begin. 
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As such, the final treatment area involves targeting amyloid’s removal. Due to the 
highly conserved structural characteristics of amyloid, anti-amyloid antibodies 
have been designed to enhance the removal of amyloid deposits. Antibodies 
raised against generic fibril epitopes promoted clearance of amyloid in mice with 
AA amyloidosis (Gillmore and Hawkins, 2006). Antibodies raised against serum 
amyloid P component, a glycoprotein associated with amyloid deposits, trigger a 
macrophage driven clearance of amyloid deposits, without adverse effects. 
Removal of a patients SAP, prior to treatment, allows specific targeting of the 
amyloid deposits (Bodin et al., 2010).  
 
Figure 1.14 Schematic of the various techniques that can be used to inhibit β-
sheet elongation or prevention of cytotoxic intermediates.  
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1.6 Conclusion 
This completes an extensive review of the background surrounding 
amyloidogenic proteins. A detailed list of the proteins known to misfold into 
amyloid species, along with the associated diseases, is given in Table 1.1, and 
includes the native structure of the amyloidogenic protein. How these aggregates 
induce a pathological disease state is described, with particular focus on the 
cytotoxic, intermediate, oligomeric species. Compounds known to localise with 
amyloid deposits, which can be involved in inducing aggregation, are also 
detailed.  
In order for a protein to aggregate into amyloid species, the native protein 
must first unfold, and thus, a brief overview of protein folding and unfolding is 
provided. Following unfolding, amyloid formation commonly follows a 
nucleation-dependent mechanism, which is outlined here, and this process can 
be monitored by the amyloid-specific dye ThT.  Also provided is a detailed 
characterisation of amyloid, including the secondary, tertiary and quaternary 
structures found across all amyloid species.  
Finally this introduction describes some of the current techniques utilised 
to inhibit the development of amyloid associated disease pathology. Chapter 6 of 
this thesis will go into more detail regarding the theory behind many of these 
techniques.  
Following on from this introduction, Chapter 2 will describe the structure 
and function of apoA-I, and how aggregation of apoA-I into amyloid-like material 
can be detrimental to cardiovascular health.   
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2. Cholesterol transport, atherosclerosis and apoA-I 
amyloidosis 
This introductory chapter will describe the human cholesterol transport 
mechanism, the involvement of apolipoprotein A-I (ApoA-I), and how 
deregulation of the cholesterol transport mechanism, including the inactivation 
of apoA-I through amyloidosis, results in atherosclerosis.  
 
2.1. Cholesterol  
Cells require cholesterol, and other sterol compounds, for strengthening cell 
membranes and as a precursor for the biosynthesis of hormones, bile and 
oxysterols. Since cholesterol is not uniformly distributed among cells and organs, 
it requires highly regulated transport (Prinz, 2007).  
The body acquires cholesterol via two methods, it is either synthesised in 
the intestine, via the mevalonate pathway, and regulated by the HMG CoA 
reductase enzyme, or acquired in the gut through dietary intake. These 2 systems 
are controlled by a feedback mechanism that self-regulates the production of 
endogenous cholesterol. In a high cholesterol state, such as after consuming a 
lipid rich meal, low-density lipoprotein (LDL), carrying exogenous cholesterol, 
binds to the LDL receptor (LDL-R) located on cell membranes. The whole 
LDL/LDL-R complex is then internalised into the cell, releasing the cholesterol 
into the cytoplasm (Olson, 1998). When inside the peripheral tissues, cholesterol 
has 4 main functions: (i) shut off the endogenous production of cholesterol, 
through inhibition of HMG CoA reductase; (ii) inhibit LDL-R synthesis, through 
down-regulating the sterol response element binding protein 1 (SREBP1); (iii) 
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promote acyl-CoA cholesterol acyltransferase (ACAT), and (iv) incorporation into 
lipid membranes (Wang et al., 1994; Ioannou, 2001).  
 
2.1.1. Mechanism of cholesterol transport 
The mechanism of cholesterol transport, via lipoprotein particles is described in 
Figure 2.1. Dietary fats from the gut become incorporated into chylomicron 
particles, containing 1% protein and 99% lipid content. These enter the 
bloodstream and lose 75% of their triglyceride content, following interaction 
with lipoprotein lipase, converting the chylomicrons into chylomicron remnants. 
The released triglycerides are taken up by adipose tissues for storage or used as 
a fuel source by cells, whilst the chylomicron remnants are taken up into 
hepatocytes via B100E receptors. Once inside the liver, the chylomicron 
remnants are broken down and the cholesterol content is either directly 
excreted, converted into bile salts or incorporated into very low-density 
lipoprotein (VLDL), consisting of 92 % lipid and only 8% protein. VLDL is 
secreted back into the bloodstream, where it is reduced by lipoprotein lipase into 
intermediate-density lipoprotein (IDL) releasing its triglyceride content. The IDL 
particle is either taken up by hepatocytes via B100E receptors, or further 
reduced by hepatic lipase into low-density lipoprotein (LDL). The LDL particle 
contains 21% protein and 79% lipid, of which only 11% is triglycerides. The LDL 
particle is transported in the bloodstream to the liver for cholesterol processing, 
or into peripheral tissues via interaction with the LDL-R. Any residual LDL that is 
not removed from the bloodstream, due to saturation of the LDL-R, continues 
circulating and increases the risk of atherosclerosis, following oxidation of the 
particle (Olson, 1998). LDL can remain in the bloodstream for up to 3 days.  
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Figure 2.1 Schematic of receptor mediated cholesterol transport mechanism via 
lipoprotein particles. The black arrows indicate exogenous cholesterol 
processing, the orange arrows depict the use/storage of triglycerides, and the red 
arrows show the reverse cholesterol transport mechanism.  
 
2.1.2. Reverse cholesterol transport 
In order to maintain a balance of arterial cholesterol, and to remove excess from 
peripheral tissues, a reverse cholesterol transport (RCT) mechanism is used to 
counteract the normal cholesterol movement. High-density lipoprotein (HDL), 
the main facilitator of RCT, consists of apolipoproteins AI (apoA-I), AII (apoA-II) 
and AIII (apoA-III), phospholipids and cholesterol. The lipoprotein particle is 
synthesised in the liver or intestine and released into the blood stream. HDL is 
often referred to as “good cholesterol”, due to its induction of monocyte adhesion 
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molecules, prevention of LDL modification, but primarily because of its role in 
the removal of excess cholesterol from the circulatory system, thus protecting 
against atherosclerosis (Stein and Stein, 1999; Fisher et al., 2012; Lewis, 2005).  
HDL, via the apoA-I protein, accepts cholesterol from cholesterol-laden cells, 
including macrophages and endothelial cells lining the arterial wall. This occurs 
in 4 ways: (i) apoA-I interacts with ATP-binding cassette transporter protein AI 
(ABCA1), which transfers cholesterol from the cell to the nascent HDL particle 
(Oram and Vaughan, 2006; Nagao et al., 2014; von Eckardstein et al., 2001), (ii) 
spontaneous desorption of cholesterol content from the lipid membranes to 
nascent HDL, (iii) ABCG1 mediates the flux of cholesterol from intracellular 
organelle to the plasma membrane, prior to desorption to nascent HDL, or, (iv) 
scavenger receptor BI (SR-B1) promotes a net movement of cholesterol, similar 
to aqueous diffusion, onto the HDL particle, requiring direct interaction (Annema 
and von Eckardstein, 2013).  
Upon binding to cholesterol, the apoA-I protein co-activates lecithin 
cholesterol acyltransferase (LCAT). This enzyme transfers fatty acids from 
lecithin to the cholesterol, forcing its internalisation into the hydrophobic core of 
the HDL particle. This allows the HDL particle to transfer its cholesterol content 
through the bloodstream. Upon reaching the liver, the cholesterol content is 
transferred from the HDL particle into the liver via an interaction between apoA-
I and the SR-B1 transporter protein, or endocytosis of the entire HDL-cholesterol 
particle into the liver, followed by activation of F0F1 ATPase. Alternatively, 
cholesterylester transfer protein (CETP) can promote the exchange of cholesterol 
for triglycerides with lipoproteins containing apo-B. Apo-B then removes the 
cholesterol, via LDL receptors on hepatic cells.  
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Cholesterol in the liver is then excreted as either free cholesterol, following its 
conversion into bile salts, or eliminated as faeces (Annema and von Eckardstein, 
2013). Poor regulation of the cholesterol transport, or the RCT pathway, can lead 
to an imbalance in the level of LDL within the circulatory system, with a potential 
to manifest itself into atherosclerotic plaques and pose a serious health risk. 
 
2.2. Atherosclerosis  
Atherosclerosis is the leading cause of heart attacks and is responsible for up to 
50% of deaths in the USA and Europe. It is caused by an excessive inflammatory 
response against accumulated fibrous and fibro-fatty plaques within the 
endothelium of arteries (Ross, 1993). There are many sources of injury to the 
endothelium that give rise to atherosclerosis. The most common is the 
endothelium interacting with excess LDL that has become oxidised, due to 
interaction with nitrous oxide, a product of endothelial cells normally used in the 
regulation of vascular tone (Matthys and Bult, 1997). Oxidised LDL leads to an 
inflammatory response, resulting in the recruitment of T-lymphocytes and 
macrophages. These white blood cells absorb the oxidised LDL, via scavenger 
receptors, converting the cells to lipid-rich foam cells. The lipid-rich 
macrophages and T-lymphocytes migrate to the intima, the inner layer of the 
arterial wall, and become deposited as “fatty streaks”. Over time, the fatty 
deposits develop into fibrous plaques, forming a core containing lipids and 
immune cell debris following necrosis, overlain with a fibrous cap of smooth 
muscle, collagen and connective tissue. These lesions increase in size, though cell 
proliferation and recruitment of macrophages and immune response cells, 
resulting in obstruction of blood flow in the lumen.  The fibrous caps can rupture, 
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causing a haemorrhage into the plaque area, or the formation of thrombi. 
Thrombi travel freely in the circulatory system, which can result in the blocking 
of arteries. This has the potential to lead to ischemia of the major organs 
including the heart and brain, manifesting itself as infarction (Ross, 1999a; Ross, 
1993; Ross, 1999b). The entire process is summarised in Figure 2.2. 
 
 
Figure 2.2 Progression of atherosclerosis in an arterial blood vessel. (A) 
Macrophages and leukocytes, having digested oxidised LDL, migrate to the sub 
endothelial space. (B) Formation of fatty steaks after the deposition of foam cells, 
activation of T-cells and invasion of smooth muscle cells. (C) Continued 
recruitment of macrophages. (D) Cracking of the fibrous cap leads to a plaque 
rupture and the formation of a thrombus. Alternatively, disruption of the plaque 
may lead to haemorrhaging from the artery. Modified image from Ross (1999a). 
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2.3. High-density lipoprotein (HDL) 
High-density lipoprotein (HDL) was the first of the cholesterol transport plasma 
proteins to be discovered, followed by low-density lipoprotein (LDL) and 
subsequently, the LDL receptor on peripheral tissues. This lead to the proposal of 
the receptor mediated lipid transport mechanism, via lipoprotein particles 
(Figure 2.1). Michael Macheboeuf isolated HDL particles in 1929 which were 
found to contain 59% protein and 41% lipid, of which 18% was cholesterol and 
23% was phospholipids (Olson, 1998). HDL is made up of several forms of 
apolipoproteins, including A-I, A-II, A-III and A-IV. However, with the exception 
of apoA-I, not all of these apolipoproteins are present on every HDL molecule. 
The specific combination of apolipoproteins on each HDL molecule gives them 
their individual subclass, each of which differs by size, shape, density and charge. 
HDL particles can include upwards of 80 proteins, 200 species of lipids and low 
copies of various micro-RNA molecules (Annema and von Eckardstein, 2013). 
The requirement for apoA-I on every HDL molecule further highlights its 
necessity in the RCT mechanism. 
 
2.3.1. HDL biogenesis 
Formation of the HDL molecule begins with the synthesis of apoA-I in the liver 
and intestine.  ApoA-I acquires cholesterol and phospholipids, the rate limiting 
step in HDL production, from either hepatic or peripheral cells, including 
macrophages. For this to occur, the lipid donor cells need to express the ATP-
binding cassette protein AI (ABCA1), an integral membrane transporter protein. 
This protein actively effluxes free cholesterol and phospholipids from cells, 
creating lipid-rich domains on the plasma membrane that apoA-I can interact 
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with (Oram and Vaughan, 2006). In this form, nascent HDL particles are disc 
shaped, due to the un-esterified cholesterol content. Once in circulation, the 
nascent HDL particle interacts with lecithin cholesterol acyltransferase (LCAT). 
LCAT esterifies the free cholesterol, producing cholesterol-esters, which migrate 
into the centre of the particle. This internalisation of the cholesterol produces the 
overall spherical shape of mature HDL (Fisher et al., 2012; Aguilar-Espinosa et 
al., 2013; Oram and Vaughan, 2006).  
 
2.3.2. Role of HDL as “good cholesterol” 
HDL is commonly referred to as “good cholesterol”, given its main role in the 
reverse cholesterol transport mechanism, described above in section 2.1.2. In 
addition to this function, HDL also has anti-oxidant and anti-inflammatory 
properties (Fisher et al., 2012), as well as acting as an inhibitor of monocyte 
adhesion molecules and LDL modifications (Stein and Stein, 1999). Although the 
role of HDL in the reverse cholesterol transport mechanism is only a small 
percentage of the overall cholesterol transport, efflux from the engulfed 
macrophages back to the liver for processing is most crucial, with regard to 
atherosclerosis (Lewis, 2005). Any reduction in the anti-atherosclerotic 
properties of HDL, whether it is a reduction in HDL production, its maturation, or 
its effectiveness in the cholesterol transport mechanism, would lead to an 
increase in atherosclerosis and enhanced health risk, hence the interest within 




2.4. Apolipoprotein AI 
Apo-AI, as mentioned previously, is the main constituent of HDL, making up 70-
75 % of the total protein content, and gives the lipoprotein its main cholesterol 
binding function (Oram and Vaughan, 2006). ApoA-I has a concentration in the 
plasma of approximately 0.2 mg/ml (Tate et al., 2006). 
 
2.4.1. ApoA-I sequence 
Prepro-apoA-I is a 267-residue peptide containing the 243-residue apoA-I, an 18-
residue signal sequence and a 6-residue linker region (Sharpe et al., 1984). 
Removal of the signal sequence releases pro-apoA-I and allows secretion into the 
plasma. The 6-residue linker sequence is cleaved by an unknown protease, 
forming apoA-I (McGuire et al., 1996). The native prepro-apoA-I sequence is 
shown in Figure 2.3, with a predicted mass of 28078 Da (Pankhurst et al., 2003).  
- 2 4     - 6  
MKAAVLTLAVLFLTGSQARHFWQQ  0  
DEPPQSPWDRVKDLATVYVDVLKDS  2 5  
GRDYVSQFEGSALGKQLNLKLLDNW   5 0  
DSVTSTFSKLREQLGPVTQEFWDNL  7 5  
EKETEGLRQEMSKDLEEVKAKVQPY   1 0 0  
LDDFQKKWQEEMELYRQKVEPLRAE   1 2 5  
LQEGARQKLHELQEKLSPLGEEMRD   1 5 0  
RARAHVDALRTHLAPYSDELRQRLA   1 7 5  
ARLEALKENGGARLAEYHAKATEHL   2 0 0  
STLSEKAKPALEDLRQGLLPVLESF   2 2 5  
KVSFLSALEEYTKKLNTQ    2 4 3  
 
Figure 2.3 Prepro apoA-I sequence containing the 18-residue signal peptide 
(green) a 6-residue linker (red) and the 243-residue apoA-I peptide (black). Hot 
spot regions 14-22, 53-58, 69-72 and 227-232 are underlined. 
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A modified plasmid vector allowing optimisation for bacterial expression has 
been produced by Oda (2001) and detailed in Ryan (2003). This plasmid will be 
utilised in Chapter 3 for the expression of recombinant apoA-I.  
 
2.4.2. Delipidation of apoA-I 
Dissociation of lipids from apoA-I, resulting in the lipid-free structure of apoA-I, 
is required for recycling of the HDL particle and subsequent interaction with ABC 
AI transporter proteins (Davidson and Thompson, 2007). Delipidation is also a 
key stage in the transition between the soluble native protein and its amyloid 
species (Obici et al., 2006). It has previously been shown that increased apoA-I 
expression coincides with increased levels of amyloidogenic apoA-I species 
deposited within atherosclerotic plaques. Despite apoA-I’s native role in 
reversing atherosclerosis, this suggests that when the lipid-free apoA-I 
concentration exceeds the level required for effective removal of cholesterol, it 
leads to a misassembled amyloid species (Mucchiano, et al., 2001). 
 
2.4.3. Structural studies of apoA-I  
ApoA-I exists in multiple native structures, due to its conversion between lipid-
free, partially lipidated and fully lipid associated forms (Ajees et al., 2006; Mei 
and Atkinson, 2011). The research collaboratory for structural bioinformatics 
protein data bank (RCSB PDB) website currently has 4 structural models, 
covering the majority of the apoA-I peptide sequence (Figure 2.4), and 5 
structural models for shorter segments of the peptide. 
A model produced by Ajees et al. (2006)(PDB 2A01) represents the crystal 
structure of full-length, lipid-free apoA-I at a resolution of 2.4 Å (Figure 2.4A). 
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However, this model has since been discredited by various authors, who present 
more accurate model structures (Tate et al., 2006). This model appears to show a 
high degree of similarity to the model for mouse apoA-I (PDB 2LEM). 
A crystal structure for the N-terminally truncated apoA-I (Δ 1-43), 
thought to be in its lipidated state, was proposed by Borhani et al (1997), 
consisting of a mainly α-helical structure in a looped belt conformation that 
facilitated lipid binding (Figure 2.4B).  
The most complete model for lipid-free apoA-I, described in detail below, 
comes from Mei and Atkinson (2011), deposited as PDB 3R2P. This structure of a 
C-terminally truncated apoA-I (Δ185-243) dimer was deduced via x-ray 
crystallography at a resolution of 2.2 Å (Figure 2.4C). The ability of this peptide 
to form functional HDL complexes, along with having strong similarities to the N-
terminally truncated, lipid-bound apoA-I (Δ1-43) described above, indicates that 
this model is a good representation of full-length apoA-I. It also contains many of 
the functional aspects in relation to lipid binding and the role of apoA-I in HDL.  
A model based on small angle neutron scattering for the full-length, lipid-
bound apoA-I in a reconstituted HDL nanoparticle, incorporating lipids and 
cholesterol, was presented by Wu et al., (2009). However, this had a much lower 
resolution compared to the other structures, due to the methods used (Figure 
2.4D). This is the structure that will be used throughout this thesis when 





Figure 2.4 Structural models of apoA-I deposited within the protein databank. 
(A) Lipid-free apoA-I (PDB 2A01) proposed by Ajees et al. (2006), (B) N-
terminally truncated apoA-I (Δ1-43) deduced by Borhani et al. (1997), (C) lipid-
free apoA-I (Δ185-243) proposed by Mei and Atkinson (2011),  (D) lipid-bound 
apoA-I in a HDL nanoparticle presented by Wu et al. (2009).  
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2.4.4. Lipid-free apoA-I  
ApoA-I is synthesised in its lipid-free form, and binds cholesterol and other lipids 
as part of its inclusion into a HDL particle. In vivo, given the strong affinity of 
apoA-I for lipids, the concentration of lipid-free apoA-I remains very low. In fact, 
less than 5 % of circulating apoA-I is lipid-free (Das et al., 2016). Lipid-free apoA-
I can be split into 3 regions: the N-terminus stabilises the protein structure, the 
central region offers flexibility, facilitating the conversion from monomer to 
dimers, whilst the C-terminus gives apoA-I its lipid binding ability. 
 
2.4.4.1. Lipid-free apoA-I structure  
The most complete, widely accepted structural model for lipid-free apoA-I comes 
from Mei and Atkinson (2011) and represents the C-terminally truncated (Δ185-
243) apoA-I peptide, with the structural model consisting of residues 3-182 
(Figure 2.5). This removes much of the lipid binding C-terminus, due to 
problems of self-association within this region, but retains the N-terminus. This 
region is of particular relevance in this study, due to its increased propensity to 
form amyloid-like structures.  
The (Δ185-243) apoA-I peptide contains 9 helical regions in total: two 
well defined helices and seven semi-continuous helices formed with conserved 
AB sequence repeats. The two well defined helices are located in the N-terminus: 
the major helix (residues 7-34) containing a valine kink at residue 21, and a 
minor helix (37-41) running parallel to the major helix. This minor helix forms a 
connecting turn into the first of the 11-residue repeated regions associated with 
H1. H1 consists of two 11-residue B repeats (residues 44-54 and 55-65) before 
termination by a proline kink at residue 66.  The A repeat of H2 produces a turn, 
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which extends into a second A repeat in H2 and, due to the lack of a proline, this 
helix continues into a B repeat of H3. The A/B repeat in H2/H3 is followed by 4 
consecutive A/B repeats (H4-H7), which form an almost continuous helix, with 
proline residues forming a kink at the start of each A segment of the next helix.  
 
2.4.4.1.1. Lipid-free apoA-I dimer 
Lipid-free apoA-I was shown to form a symmetrical homo-dimer in an 
approximate semi-circle, measuring roughly 17 Å in height and 110 Å in 
diameter, coinciding with the width of HDL particles (Mei and Atkinson, 2011).  
The backbone of the dimer contains 2 long antiparallel helices, one from each 
monomer, with an exact AB repeat pairing of the H5 region. At each end of the 
backbone, a 4 helical bundle is formed with 3 helices from the N-terminus of 1 
monomer and a single helix in the C-terminus from the second monomer, 
internalising the hydrophobic residues and stabilising the bundle (Figure 2.5A).  
 
2.4.4.1.2. Lipid-free apoA-I monomer 
The H5 helical region (residues 121-143) that holds the apoA-I dimer together 
via anti-parallel helices is the most flexible AB repeat, in particular residues 136-
141 which has little helical conformation, when in isolation. It is believed that in 
monomeric apoA-I this region acts as a hinge, with the final two AB repeats (H6 
and H7) folding back on the rest of the molecule to self-associate with its own N-
terminus rather than the N-terminus of its dimeric partner (Mei and Atkinson, 
2011; Gursky et al., 2012), as shown in Figure 2.5B. Therefore, the 4 helical 
bundle remains, but unlike the dimeric apoA-I, all 4 helices belong to the same 
molecule. It is predicted that the remaining peptide, residues 185-243, is largely 
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unstructured in the monomeric species (Gursky et al., 2012), suggesting that this  
model is a good representation of the full-length monomeric apoA-I.  
Figure 2.5A was produced using the PDB file 3R2D and generating 
symmetry mates within 6 Å, in order to produce the dimer interactions between 
the H5 regions, which are separated by approximately 5 Å (Mei and Atkinson, 
2011).  
Figure 2.5B was produced by Professor D. Middleton using the 
MODELLER programme and switching the residues 143-182 of H6 and H7 in the 
second molecule to the first molecule, before re-introducing residues 121- 143 of 
H5 in order to form the hinge region and link the domain swapped region to the 
rest of the apoA-I peptide.  
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Figure 2.5 Crystal structure of lipid-free apoA-I (Δ185-243) at 2.2 Å, deduced by 
Mei and Atkinson (2011). (A) Dimeric apoA-I linked via an anti-parallel H5-H5 
interaction (PDB 3R2D) and (B) Monomeric apoA-I model formed via domain 
swapping of the H6 and H7 regions and conversion of the H5 helix into a hinge, 
produced by D. Middleton. Hot spot regions are highlighted in green. 
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2.4.5. Lipid-bound apoA-I  
Lipid-bound apoA-I accounts for 90-95% of all circulating apoA-I, indicating 
apoA-I’s high affinity for cholesterol lipids (Ajees et al., 2006; Das et al., 2016; 
Tate et al., 2006).  
 
2.4.5.1. Lipid-bound apoA-I structure 
The structure of the lipid-free peptide is highly conserved upon binding lipids, 
with the sequence prediction for the 11 and 22 residue α-helical A and B repeats 
remaining the same (Gursky et al., 2012).   
It is proposed that upon lipid interaction, mediated by the C-terminus, the 
N-terminus of monomeric apoA-I unhinges, and opens itself to the formation of 
intermediate dimeric apoA-I. The N-terminus then continues to unfold, exposing 
hydrophobic interiors that then allow insertion of lipids. The N-terminus then 
interacts with the C-terminus of its opposing dimer, forming a double belt 
discoidal HDL particle. It is proposed that the N-terminal H1 and H2 repeat 
regions interact with the H8 and H9 of the C-terminus, regions that are not 
shown on the apoA-I (Δ185-243) model (Mei and Atkinson, 2011). This model 
agrees with the lipidated apoA-I (Δ1-43) structure of a figure of 8 bundle with 4 
helices deduced by Borhani et al. (1997) as shown in Figure 2.6A.  
The structure of reconstituted HDL associated full-length apoA-I is 
described in Wu et al. (2009) and shows similarities to the Borhani structure 
with the overall figure of 8 conformation and an anti-parallel helical dimer 
(Figure 2.6B), despite being deduced at a lower resolution. This structure is 
based on the apoA-I associated into the HDL complex, with cholesterol and POPC 
lipids at 10 and 100 times the molar concentration of apoA-I (Figure 2.6C). 
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Figure 2.6D gives better insight into the 3D structure of apoA-I dimer wrapped 
around a reconstituted HDL particle. Helices 1 and 10 show the highest affinity 
for cholesterol and phospholipids, whilst an 11-residue sequence in helix 9 is 
essential for ABC AI interaction, highlighting the importance of the C-terminus in 
the role of apoA-I (Oram and Vaughan, 2006). 
 
 
Figure 2.6 Structure of lipid-bound apoA-I. Figure of 8 dimer deduced by (A) 
Borhani et al. (1997) and (B) Wu et al. (2009). The Wu et al. structure was 
produced in the presence of 10 and 100-fold molar excess cholesterol and POPC 
lipid, compared to apoA-I (C), which gives a full 3D structure of apoA-I wrapped 






2.4.6. NMR studies of apoA-I 
Section 2.4.3 details the current models of apoA-I, based on either full-length 
apoA-I, or shortened peptides, such as the apoA-I (Δ1-43) and apoA-I (Δ185-
243). All 4 of these models were produced using data from X-ray crystallography 
studies, highlighting a lack of high-resolution solid-state NMR data in this area of 
study. This is due to issues with the insolubility of the aggregates, and the 
difficulty in assigning NMR residues of apoA-I. This arises because of the broad 
line widths, which are common in peptides with a flexible, open structure, such 
as apoA-I. NMR has been used to study the structure of small peptide sequences 
from the full-length apoA-I, including: residues 142-187 (PDB 1GW3/1GW3) 
(Wang et al., 1997), 166-185 (PDB 1ODP/1ODQ/1ODR) (Wang et al., 1996) and 
1-93 (Mangione et al., 2001). 
The 142-187 peptide studied by Wang (1997) in lipid environments, was 
found to include 2 amphipathic helical regions, consisting of residues 146-162 
and 168-182, which are believed to be involved in lipid binding. These 2 helices 
form a helix-hinge-helix confirmation, the formation of which is driven by lipid 
interaction. When compared to the full-length, lipid-bound structure of apoA-I in 
a reconstituted HDL particle, deduced by Wu et al. (2009), the 142-187 peptide 
shows a relatively high degree of similarity, in particular the presence of 2 helical 
regions, separated by an unstructured region (Figure 2.7A/B).  The 166-185 
peptide corresponds to the second helix of the aforementioned 142-187 peptide, 
and again matches the helix formed in the Wu et al. structure of lipid-bound, full 
–length apoA-I in a reconstituted HDL particle (Figure 2.7C/D).  
The 1-93 peptide studied by Mangione et al. (2001) is predicted to consist 
of primarily random coil structures, due to the C-terminus in this peptide driving 
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the formation of a coiled-coil conformation. This was confirmed with far UV 
circular dichroism that suggested 44 % of the peptide consisted of random coils, 
32 % β-sheets, 5 % α-helices and 19 % turns. However, both 1D and 2D solution 
NMR spectra failed to identify the random coiled structures. Instead, the 
resonances were clustered around statistically random chemical shifts, 
concluding that the apoA-I (1-93) peptide remained unfolded and highly flexible, 
under the conditions studied. The lack of a methodology for producing 13C and 
15N labelled apoA-I (1-93) hindered any further NMR analysis of this region. 
 
 
Figure 2.7 NMR derived structural models for (A) apoA-I (142-187) and (C) 
apoA-I (166-185) taken from PBD 1GW3 and 10DR, respectively. Figures B and D 
highlights the corresponding regions on the full-length, lipid-bound apoA-I 
structure deduced by Wu et al. (2009).  
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2.4.7. ApoA-I interactions  
ApoA-I interacts primarily with 3 proteins in its function within HDL: ABCA1 on 
peripheral tissues, for localising with free cholesterol; LCAT, to esterify and 
internalise the cholesterol into the HDL particle interior; and SR-B1 on hepatic 
cells, to transfer cholesterol to the liver for removal.  
 
2.4.7.1. ATP-binding cassette protein A1 
The ATP-binding cassette protein A1 (ABC A1), a member of the ABC 
superfamily, is a transporter protein that utilises ATP in order to transport 
cholesterol and phospholipids from cells, including macrophages, into the HDL 
reverse cholesterol transport pathway. Excess cholesterol in cells can lead to 
disruption of the membrane and eventually cell apoptosis, hence the 
requirement for its efficient removal. ABC A1, an integral membrane protein, 
forms a channel through the membrane that allows “flopping” of lipids from the 
inner to the outer surface of the membrane. Upon externalisation, the lipids can 
then associate with apoA-I (Oram and Vaughan, 2006). Lipidation of apoA-I via 
ABC A1 is the rate-limiting step in the production of HDL, and subsequently the 
entire reverse cholesterol transport mechanism. Despite, in theory, the 
overexpression of ABC A1 increasing reverse cholesterol transport, doing so can 
lead to cell viability issues, manifesting itself in unregulated release of 
cholesterol (Liu et al., 2014).  The interaction between ABCA1 and apoA-I is 
promoted by the apolipoprotein A-I binding protein (AIBP), which stabilises the 




2.4.7.2. Lecithin cholesterol acyltransferase 
LCAT is the primary enzyme responsible for esterification of cholesterol bound 
to nascent HDL, and hence, for the maturation of HDL. LCAT cleaves fatty acids 
from lecithin and transfers it onto serine 181 of LCAT, before releasing the fatty 
acid to the hydroxyl group of cholesterol through its acyltransferase activity.  
ApoA-I activates the LCAT enzyme in order to esterify its bound cholesterol and 
promote internalisation of the cholesterol-ester, resulting in HDL maturation 
(Ossoli et al., 2015). Residues 145-185 of apoA-I are believed to be involved with 
LCAT activation, since deletion of residues within this region resulted in reduced 
LCAT activity (Minnich et al., 1992).  
 
2.4.7.3. Scavenger receptor B1 
The scavenger receptor B1 (SR-B1) is a receptor for the HDL molecule, located on 
hepatic tissues (Acton et al., 1996). SR-B1 can bind to a host of ligands, including 
HDL, and selectively uptakes lipids into hepatic cells, with its highest affinity for 
cholesterol esters and free cholesterol, and a lower affinity for phospholipids and 
triglycerides. This process occurs via 2 definitive stages: the binding of HDL to 
the SR-B1 via the apoA-I protein, followed by the diffusion of lipid content into 
the plasma membrane. This all occurs without the breakdown of HDL, 
regenerating the lipid-free apoA-I, and reinitiating the RCT cycle (Lewis, 2005; 






2.4.8. ApoA-I amyloid 
ApoA-I, due to its lipid binding function, possesses a naturally high 
hydrophobicity and a low structural stability, in order to facilitate the binding of 
lipids, which induces a structural conversion. This also makes the protein 
susceptible to aggregation, in particular into β-sheet structures, bearing the 
hallmarks of amyloid (Figure 2.8).  
 
Figure 2.8 Congo red stained vocal fold biopsy of apoA-I amyloid (A), and 
visualised under cross polarised light (B), image from Hazenberg et al., (2009) 
  
ApoA-I associated amyloid deposition has been associated with two forms of 
human disease: (i) acquired amyloidosis, linked to the deposition of full-length 
apoA-I fibrils within atherosclerotic plaques (Das et al., 2016; Ramella et al., 
2012; Ramella et al., 2011; Mucchiano, Häggqvist, et al., 2001; Wong et al., 2010; 
Chan et al., 2015) and (ii) familial apoA-I amyloidosis (AApoAI), where N-
terminal fragments of mutant apoA-I species become deposited within major 
organs (Raimondi et al., 2011; Das et al., 2016; Andreola et al., 2003; Adachi et al., 
2014; Vigushin et al., 1994).  
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Natively folded apoA-I avoids aggregation into amyloid species by 
sequestering the aggregation hot spot region, residues 14-22, in the middle of the 
4-helix bundle. Mutations in the N-terminus, or cleavage of fragments consisting 
of residues 1-100, results in destabilisation of the helical bundle, allowing the 
formation of β-sheet structures in the 14-22 and 53-58 hot spot regions. It is 
proposed that these β-sheets organise into layers, with side chain interactions 
stabilising a “β-zipper” conformation (Figure 1.11B), propagating through the N 
terminus, or the full peptide (Das et al., 2016; Das et al., 2014).  However, the 
exact mechanism for the conversion of apoA-I into amyloid is unknown.  
 
2.4.8.1. Detrimental effects of apoA-I aggregation  
A reduction in the function of the HDL particle would result in a decrease in the 
reverse cholesterol transport mechanism and lead to an enhanced progression of 
atherosclerosis. Therefore, any change in the activity of apoA-I that could affect 
the formation of the HDL particle, or the effectiveness of its reverse cholesterol 
transport function, would also be detrimental to health.  
Aggregation of apoA-I into amyloid species leads to the inactivation of the 
HDL molecule, in particular its ability to interact with ABCA1, LCAT, SRB1 and 
lipids. Amyloidosis of apoA-I manifests itself as three driving forces for 
atherosclerosis: (i) a reduction in reverse cholesterol transport, (ii) deposition of 
the aggregated apoA-I or inactive HDL molecules within vessels, leading to 
increased plaque loading, and (iii) cytotoxicity of the apoA-I aggregates, or 
aggregation intermediates on endothelial tissue, thus enhancing the 
inflammatory response (Stein and Stein, 1999; Annema and von Eckardstein, 
2013; Baglioni et al., 2006). An increase in apoA-I expression, and a subsequent 
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increase in vascular HDL concentration, results in a reduction in free cholesterol 
and the associated risk of plaque formation, in addition to the removal of 
cholesterol that has already been deposited within plaques (Annema and von 
Eckardstein, 2013).  
Oxidation of apoA-I, via myeloperoxidase, particularly on residue W72, 
leads to an inhibition of the apoA-I’s ability to bind to ABCAI, thus reducing the 
cholesterol absorption ability of the protein, halting the maturation of HDL. 
ApoA-I with the oxidised tryptophan residue is present in only low 
concentrations within the plasma, but accounts for 20% of all apoA-I in vessels 
with atherosclerotic plaques (Huang et al., 2014).  
 
2.4.9. ApoA-I mutants 
ApoA-I is known to have many naturally occurring mutants. Most of the research 
focuses on the atheroprotective R173C “Milano” mutant (Mahley et al., 1983) or 
the amyloidogenic mutants that lead to the release of the apoA-I N terminus, 
resulting in familial apoA-I amyloidosis (Gursky et al., 2012). These include 
G26R, W50R, L60R, L64P, L75P, and L90P (Raimondi et al., 2011).  
 
2.4.9.1. Aggregation inducing mutants  
Raimondi (2011) studied a range of mutations (G26R, W50R, L60R, L64P, L75P 
and L90P) within the N-terminus of apoA-I. Reduction in pH resulted in 
aggregation of all mutants into amyloid species. Fourier transformed infrared 
spectroscopy (FTIR) showed a conversion from primarily unstructured regions, 
to β-sheet structures, characteristic of amyloid. The L90P mutant showed the 
largest increase in amyloidosis, followed by the W50R and L75P mutants, 
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whereas the G26R and L60R had no significant difference in the aggregation 
propensity, compared to the wild type apoA-I (1-93) peptide. Despite this, the 
full-length apoA-I G26R mutant and the N-terminus of the L90P mutant (Soutar, 
1992) have been detected as amyloid deposits within arterial plaques. The 
naturally occurring Iowa G26R mutant is thought to induce amyloidosis of apoA-I 
via destabilisation of the N-terminal region. 
As well as mutations within the 1-93 N-terminus, mutations outside of the 
N-terminus region can lead to increased cleavage and release of the 1-93 peptide, 
which then has an increased propensity to aggregate (Gursky et al., 2012).  
 
2.4.9.2. Atheroprotective mutants  
The R173C “Milano” mutant was the first known natural apoA-I mutant, which 
introduces a cysteine into the native sequence, allowing the increased formation 
of apoA-I homo and heterodimers. Individuals with the Milano variant of apoA-I 
have decreased expression of apoA-I, and subsequent HDL, which normally 
coincides with increased risk of cardiovascular disease. However, the inverse is 
observed, whereby apoA-I Milano has an additional atheroprotective function. It 
is thought that this function is caused by a change in the structure of apoA-I 
Milano compared to the wild type. Removal of the positively charged arginine 
from position 173, and replacement with a cysteine inhibits the salt bridge 
formation between residues 173 and 169, leading to decreased stability of the 
monomeric apoA-I Milano. These changes to the apoA-I Milano structure affect 
its ability to bind lipids, resulting in a lower concentration of the cholesterol-
bound HDL complexes in the plasma. How this results in better cardiac health is 
still unknown (Alexander et al., 2009). 
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2.5. Aims 
The aims of this work were to understand the biophysical and structural changes 
that apoA-I undergoes when aggregating into amyloid species. Secondly, the 
work aims to identify modulators of aggregation as potential therapies. The 
objectives were to: 
 Establish a working protocol for the large-scale production of apoA-I, with 
the ability to modify the expression system to facilitate the production of 13C 
and 15N isotopically labelled apoA-I for analysis by solid-state NMR (SSNMR), 
and insertion of single amino acid mutations. This will be described in 
Chapter 3.  
 Establish suitable conditions for promoting the aggregation of apoA-I into 
amyloid species. This will focus on the effects of pH, heparin and methionine 
oxidation. It will be essential to confirm that scaling up of amyloid 
production can facilitate structural studies of apoA-I aggregates using 
circular dichroism, X-ray diffraction and SSNMR. This will be described in 
Chapter 4. 
 Use biophysical techniques (CD, X-ray diffraction and SSNMR) to propose a 
detailed model for apoA-I aggregation into amyloid species. This will be 
discussed in Chapter 5. 
 Examine the effect of green tea polyphenols on apoA-I aggregation. In 
particular, epigallocatechin gallate (EGCG), which has been shown to inhibit 
aggregation of other amyloidogenic proteins. This will be discussed in 
Chapter 6.  
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3. Recombinant expression of apoA-I and apoA-I 
mutants 
3.1. Introduction 
3.1.1. Protein expression 
Throughout the duration of this study, apoA-I was required in large quantities for 
use in a range of measurements to determine suitable conditions that promote 
its aggregation, and for structural studies, including SSNMR, to study the 
structure of the aggregated material. SSNMR analysis additionally required the 
production of uniformly labelled 13C and 15N apoA-I. Furthermore, the production 
of natural mutants of apoA-I, and mutants that included the introduction of a 
novel cysteine residue into the sequence for fluorescence tagging purposes were 
investigated. Recombinant expression of apoA-I in Escherichia Coli (E.Coli) was 
carried out in order to facilitate these requirements. The size of apoA-I, at 243 
residues, meant that purchasing synthetic protein in the quantities required 
would not be feasible. The cost of labelling the synthetically produced peptide 
would also rule out SSNMR analysis of the protein, due to the cost implications.  
The objectives of this section were to establish a suitable recombinant 
expression and purification system for apoA-I, which would also facilitate site-
directed ligase independent mutagenesis (SLIM) (Chiu, 2004) and expression of 
13C and 15N labelled apoA-I . 
An N-terminally hexa-histidine tagged recombinant protein construct for 
apoA-I, including an E2D mutation, facilitating formic acid cleavage of the his-tag 
via the introduction of a novel acid labile Asp-Pro peptide bond, has been 
successfully expressed in E.Coli cells (Oda et al., 2001). This methodology 
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produced a suitably high yield of apoA-I (3-243) protein, which is referred to as 
apoA-I, or wild type apoA-I to distinguish it from the mutant apoA-I proteins 
throughout the remainder of this thesis. This protocol forms the basis of the 
expression methods used throughout this work and uses the plasmid construct 
kindly provided by Dr. M. Oda (Oakland Children’s Hospital Research Institute). A 
plasmid map is supplied in Appendix 1. Given the success of this methodology, it 
was utilised not only for the production of the apoA-I (3-243) wild type, but also 
the production of mutant apoA-I (3-234) species via SLIM based PCR methods, 
and modified to allow isotopic labelling of the wild type protein.  
 
3.1.2. Labelled protein production 
Recombinant protein expression allows the inclusion of stable isotope labels, in 
particular, 13C and 15N, uniformly or sparsely distributed through the protein 
sequence. These are essential for SSNMR studies, as they allow an increase in 
sensitivity and resolution and can simplify the complexities of the spectra. There 
are several ways to label proteins, depending on the information that is required 
from the solid-state NMR experiments. Selectively labelling individual amino 
acids, such as Ile, Leu and Val, gives insight into the proteins global fold, due to 
their location within hydrophobic cores. However, this requires the purchasing 
of synthetic protein, which was too costly due to the size of apoA-I, or acquiring 
one of the auxotrophic strains of E.Coli. Uniform labelling of apoA-I with 13C and 
15N is more cost effective and a good starting point to assess the resolution 
achieved. Uniform labelling also increases the accuracy of residue assignment, 
when facilitated by multi-dimensional triple resonance experiments (Lian and 
Middleton, 2001).  
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3.1.3. ApoA-I mutants 
The production of mutant apoA-I proteins was investigated for two reasons: (i) 
the comparison of aggregation kinetics of naturally occuring mutant apoA-I to 
native apoA-I, and (ii) to introduce a novel cysteine residue into the apoA-I 
sequence. This cysteine residue will facilitate fluorescently labelled tagging of the 
protein, in order to allow the visualisation of apoA-I uptake and distribution 
within human endothelial cells. Four single amino acid mutations have been 
selected and will be produced via SLIM.  
1. A naturally occurring mutant, apoA-I Iowa, substitutes the glycine in position 
26 with an arginine, and has been found deposited as amyloid aggregates 
within arterial plaques. The mutant also increases the formation of amyloid-
like species in apoA-I (1-83), albeit at a slower rate (Adachi et al., 2012). This 
is thought to be caused by destabilisation of the N-terminus region (Adachi et 
al., 2014). The destabilising effects of G26R on full-length apoA-I correspond 
to its location within the major helix of the N-terminus (Figure 3.1A). It is 
proposed that the introduction of basic charge, carried by the arginine, into 
the hydrophobic face of the helix, increases the solvent exposure of the helix 
bundle, leading to its destabilisation (Adachi et al., 2012).  
2. A mutant corresponding to the replacement of the leucine in position 90 with 
a proline residue, has been shown to enhance the rate of aggregation of the 
apoA-I (1-93) peptide into insoluble material, characteristic of amyloid 
(Raimondi et al., 2011; Monti et al., 2011). This mutation is located within the 
N-terminal 1-100 residues (Figure 3.1B), and its increased propensity to 
aggregate could be linked to destabilisation of the N-terminus, as with the 
G26R mutant.  
 63 
3. A mutant with leucine 44 replaced by a stop codon should facilitate the 
production of apoA-I (3-43). The N-terminal 1-80/100 residues of apoA-I 
have a strong propensity to form amyloid when isolated from the remaining 
apoA-I sequence. Proteolytic cleavage and release of N-terminal fragments 
occurs naturally, leading to increased deposition of these short peptides as 
amyloid species. A peptide corresponding to residues 1-43 has been shown to 
readily form amyloid-like species in isolation (Adachi et al., 2014).  
4. Two cysteine mutants were produced in order to facilitate tagging of the free 
thiol group on the cysteine residue with luminescent tags, since apoA-I lacks 
native cysteine residues. Lysine and arginine in positions 96 and 173, 
respectively, were each replaced with a cysteine residue, producing the K96C 
and R173C mutant (Figure 3.1 C and D, respectively). The R173C mutant is 
the naturally occurring apoA-I Milano mutant, which is of increasing 
significance in the study of lipid-bound apoA-I, due to its reduced 
concentration in carriers of the R173C gene, despite having lower incidence 
of atherosclerosis and associated cardiac disease (Alexander et al., 2009). 
Both of these cysteine mutants have previously been produced, using the 
same expression and purification methods as the wild type protein (Oda et al., 
2001). The K96C mutant is located in the extended helix repeats along 
domain 4/5 but appears internally located, meaning that its ability to be 
tagged is reduced (Figure 3.1C). However, the cysteine introduced into 
position R173C, lies in the domain swapped C-terminus and is exposed to the 
exterior of the protein (Figure 3.1D).  This C-terminal region is involved in 
dimerisation, and introduction of a free thiol group into this region could lead 
to the formation of more stable apoA-I dimers via disulfide cross bridges. 
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Figure 3.1 Structure of monomeric apoA-I (Δ185-243) highlighting the native 
residue to be removed for the apoA-I mutants (A) G26R in red, (B) L90P in 
purple, (C) K96C in green and (D) R173C in orange.  
 
3.1.4. SLIM PCR mutagenesis 
Site-directed ligase independent mutagenesis (SLIM) is a PCR based mutagenesis 
method that allows the rapid insertion, deletion or substitution of single amino 
acids (Chiu, 2004). This method utilises an inverse PCR amplification of the 
template sequence by 4 primers: 2 long-tailed primers, containing the desired 




3.1.5. Formic acid cleavage  
The Asp-X bond is readily hydrolysed under acidic conditions. The nucleophilic 
attack of the ionised carboxylate of the aspartic acid side chain on the peptide 
carbonyl group releases the Asp-C-terminal peptide. The reactive N-terminal 
aspartic anhydride is then hydrolysed, releasing the N-terminal peptide, ending 
with aspartic acid residue ta its C-terminus (Figure 3.2).  
 
Figure 3.2 Peptide hydrolysis following incubation of the asp-X peptide bond in 
acidic conditions.  
 
3.1.6. Aims 
The main aim of this chapter of research was to establish a working protocol for 
the large-scale production of apoA-I. This expression system must have the 
ability to be modified, in order to allow expression of 13C and 15N uniformly 
labelled apoA-I for analysis by solid-state NMR. Finally, the procedure should be 
able to facilitate the expression and purification of the apoA-I mutants listed in 
section 3.1.3, following mutagenesis of the apoA-I DNA.  
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3.2. Materials and methods 
3.2.1. Construct design 
3.2.1.1. ApoA-I E2D Construct  
A pNFXex expression vector containing the E2D mutated and codon optimised 
human apoA-I gene with an N-terminal hexa-histidine tag, was kindly provided 
by Dr M. Oda of Oakland Research Institute, USA. Also provided were expression 
vectors for the human apoA-I (G26R) mutant. 
Oda et al. (2001) and Ryan et al. (2003) conducted studies on apoA-I that 
required expression of recombinant apoA-I, and started with a pBluescript K+ 
plasmid, containing the gene for apoA-I (Figure 2.3).  The cDNA of human apoA-I 
has a distinctive lack of useful restriction endonuclease sites, required for sub-
cloning and DNA manipulation. As such, several silent mutations were 
introduced into the apoA-I DNA to produce 13 new restriction endonuclease sites 
(Table 3.1). The pBluescript K+ plasmid is suitable for the manipulation of DNA 
and is commonly used for sub-cloning, sequencing and site-directed mutagenesis 
(Mayer, 1995). In the work by Oda et al. and Ryan et al., the plasmid allowed (i) 
attachment of a hexa-histidine tag to the N-terminus of apoA-I (ii) insertion of 
the E2D mutation into the apoA-I sequence, creating an Asp-Pro acid labile bond 
to facilitate formic acid cleavage of the N-terminal histidine-tag and linker region, 
and (iii) 18 individual codon optimisations (Table 3.2), which removed codons 
that utilise tRNA molecules of low abundance in E.coli. Changing the codons in 
the human apoA-I DNA sequence to those corresponding to the same residue, but 
with increased use in bacterial cells, leads to a 5-fold increase in protein yield. 
This recombinant gene was then sub-cloned into the highly expressive pET20b+ 
plasmid, producing the expression vector pNFXex, containing the sequence 
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shown in Figure 3.3, and a gene corresponding to ampicillin resistance (Ryan et 
al., 2003). 
 
Table 3.1 Codon changes made in apoA-I cDNA to introduce 13 new endonuclease 
sites (Ryan et al., 2003).  
 
Amino acid  Codon change  Restriction site 
Asp 1 GAT to GAC ClaI 
Pro 7 CCC to CCA Nco 
Gyl 35 GGC to GGA BamHI 
Gln 41 CAG to CAA MfeI 
Leu 42 CTA to TTG  
Leu 44 CTA to CTT AflII 
Thr 54 ACC to ACG AatII 
Glu 70 GAG to GAA EcoRI 
Leu 126 CTC to CTG PstI 
Gln 127 CAA to CAG  
Val 156 GTG to GTC SalI 
Ala 164 GCC to GCG KasI/NarI 
Ala 175 GCC to GCG AscI 
Gly 186 GGC to GGG  
Arg 188 AGA to CGG ApaI 
Glu 234 GAG to GAA DXhoI 
Leu 240 CTC to CTT HindIII 
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Table 3.2 Codon optimisations made in human apoA-I cDNA, and the codon 
frequency per 1000 in E.coli cells. Red letters indicate the altered nucleotide. 
Information taken from Ryan et al, (2003). 
 








Pro 3 CCC 5.4 CCG 22.3 
Pro 4 CCC 5.4 CCG 22.3 
Pro 7 CCC 5.4 CCA 8.5 
Pro 99 CCC 5.4 CCG 22.3 
Pro 165 CCC 5.4 CCG 22.3 
Pro 209 CCC 5.4 CCG 22.3 
Pro 220 CCC 5.4 CCG 22.3 
Arg 10 CGA 3.7 CGC 21.1 
Arg 83 AGG 1.6 CGC 21.1 
Arg 188 AGA 2.7 CGC 21.1 
Leu 42 CTA 4.0 TTG 11.3 
Leu 44 CTA 4.0 CTT 11.3 
Leu 46 CTC 10.6 CTG 50.9 
Leu 47 CTT 11.3   CTG 50.9 
Leu 126 CTC 10.6 CTG 50.9 
Leu 214 CTC 10.6 CTG 50.9 
Leu 233 CTC 10.6 CTG 50.9 









Figure 3.3. N-terminally his-tagged apoA-I (E2D) sequence in the pNFXex 
expression vector. The red lowercase letters represent the nucleotides that were 
altered in the codon optimisation step (listed in Table 3.2). The sequences 
highlighted in blue, orange and red are the hexa-histidine tag, thrombin cleavage 
site and formic acid cleavage site, respectively. 
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3.2.1.2. Production of mutant constructs via SLIM PCR 
As described in Section 3.1.4, the SLIM PCR method of mutagenesis utilises 4 
primers to amplify the template DNA: 2 long tailed primers, containing the 
desired mutation; and 2 short primers. These are detailed in Appendix 2. 
Amplification of the template DNA by the 4 primers in complementary pairs 
result in the formation of 4 PCR products. Following denaturation and 
subsequent re-hybridisation, 16 hybrid products are formed, 2 of which able to 
form plasmids spontaneously. The entire procedure is simplified in Figure 3.4. 
 
Figure 3.4 Schematic of the SLIM PCR protocol adapted from Chiu et al., (2004). 
This example includes the primers used to create the K96C mutation in apoA-I. 
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SLIM PCR mutagenesis followed the same procedure for all 4 mutants, utilising 
the Novagen KOD Hot Start DNA Polymerase Kit.  
To each of the 3 PCR tubes: reaction 1, reaction 2 and the control sample, 
12.5 μL water, 5 μL Phusion HF buffer (ThermoFisher), 2.5 μL DTNPs (Novagen), 
2.5 μL betamine, 0.5 μL Phusion Hot Start II DNa Polymerase (ThermoFisher) 
and 1 μL of template apoA-I E2D DNA were added. 0.5 μL of the forward-long and 
0.5 μL of reverse-short primers were added to reaction 1, whilst 0.5 μL of 
forward-short and 0.5 μL of reverse-long primers were added to reaction 2. No 
primers were added to the control sample.  
After pre-warming all 3 samples at 98 °C for 2 minutes, each reaction 
underwent the first round of PCR. This consisted of 30 cycles of: 95 °C for 30 
seconds, 50 °C for 30 seconds and 68 °C for 8 minutes, prior to holding at 4 °C.   
Samples of 5 μL were removed from each reaction for analysis by agarose 
gel electrophoresis, in order to determine whether the DNA had been amplified. 
The control reaction was then discarded following the gel electrophoresis stage.  
To degrade the original methylated template DNA, 1 μL of Dpn1 restriction 
enzyme (New England BioLabs) was added to reactions 1 and 2 and incubated at 
37 °C for 1 hour. 30 μL of hybridisation buffer was added to each reaction, prior 
to combining the two. After denaturing the DNA at 98 °C for 3 minutes, the 
combined reactions underwent a second round of PCR. This involved 2 cycles of 
heating to 65 °C for 5 minutes and then cooling to 30 °C for 15 minutes. After 





3.2.1.3. Confirmation of PCR products via agarose gel 
After the first round of PCR, 5 μL samples of DNA taken from reactions 1, 2 and 
the control to confirm the amplification of DNA on a 0.8 % agarose gel.  
0.8 g of agarose was dissolved in 100 mL Tris acetate EDTA (TAE) buffer, 
along with 10 μL SYBR Safe DNA Gel Stain (Invotrogen). The gel solution was 
poured into a gel cast and allowed to set.  
5 μL of each of sample (reaction1, reaction 2 and the control sample) were 
combined with 1 μL of Gel Loading Buffer (ThermoFisher) and loaded onto the 
gel, along with 6 μL Quick Load 1Kb DNA Ladder (New England BioLabs). The gel 
was run at 100V for 60 minutes, before imaging under UV light using a Chemidoc 
XRS+ imaging system, running the Image Lab 4 programme. The pre-set 
programme for SYBR Safe stain, and automatic exposure were selected, to detect 
the highest intensity bands. 
 
3.2.2. Transformation into E.coli 
Transformation involves the incorporation of an engineered plasmid vector into 
the genomes of competent cells. For this study, 2 separate E.coli cell lines were 
used, XL1Blue and BL21 (DE3), to allow plasmid vector storage and recombinant 
expression, respectively. 
 
3.2.2.1. Transformation into XL1Blue cells 
DNA from each of the apoA-I species, apoA-I E2D, G26R, L90P, K96C, R173C and 
L44Stop, required transformation into an E.coli XL1Blue strain for long-term 
storage.  
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50 μL of E.coli XL1Blue cells (Agilent Technologies) for each of the 6 apoA-I 
species (apoA-I E2D, G26R, L90P, K96C R173C and L44Stop) were thawed on ice, 
prior to the addition of 1.7 μL of β-mercaptoethanol (BioRad). After 10 minutes, 
5 μL of plasmid DNA (provided by Oda or produced via SLIM PCR, as described in 
section 3.2.1.2) was added, gently mixed, and left on ice for 30 minutes.  The 
cells were then heat-shocked at 45 °C for 45 seconds before returning to ice for 2 
minutes. 900 μL of SOB media was slowly added and incubated for 1 hour at 37 
°C with shaking.  
Following incubation, 200 μL of culture was plated out on LB agar plates, 
containing 200 μM ampicillin. The plates were then returned to incubation at 
37°C overnight. Growth on the plates, in the presence of ampicillin, indicated that 
the cells had taken up the plasmid vector containing the gene for ampicillin 
resistance and the apoA-I fusion peptide. Individual colonies were selected and 
grown in overnight cultures of LB media containing 200 μM ampicillin at 37 °C. 
Overnight cultures were used to create 50 % glycerol stocks and frozen at -80 °C. 
 
3.2.2.2. Transformation into E.coli Bl21 (DE3) cells 
In addition to the long-term storage of the plasmid vectors in the E.coli XL1Blue 
cell line, the vectors were also transformed into an E.coli BL21 (DE3) expressing 
cell line (Agilent Technologies) to increase protein expression yields. This allows 
the formation of expressing cell line glycerol stocks, meaning that repeated DNA 
isolation from the XL1Blue cell line and transformation into the BL21 (DE3) cell 
line, prior to protein expression, can be avoided.  
The method for the transformation of DNA into BL21 (DE3) cells was 
identical to the transformation into the XL1Blue cell line (Section 3.2.2.1).  
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3.2.3. Production of apoA-I 
3.2.3.1. Recombinant protein expression 
Small overnight cultures of E.coli BL21 (DE3) cells, containing each of the apoA-I 
mutant plasmids, were prepared in LB media, containing 0.1 % ampicillin 
(Melford Biolabs), from the glycerol stocks produced in Section 3.2.2.2. The 
cultures were incubated at 37 °C overnight, with shaking. These cultures were 
then used to inoculate 2 L of LB media.  
The 2L cell culture was incubated at 37 °C until an OD600 of 0.6 had been 
reached. Once the OD600 was sufficient, a 1 mL sample of culture was removed, 
for analysis by gel electrophoresis.  
Protein expression was induced by addition of 1mM isopropyl β-D-
thiogalactoside (IPTG) (Melford Biolabs). Incubation continued at 37 °C, with 
shaking, for a further 5 hours following induction. Samples of the induced cells 
were taken every hour from the second hour-point for gel electrophoresis. 
 
3.2.3.2. Minimal media growth 
Transformed cells were also induced in minimal media, enriched with labelled 
glucose and ammonium chloride (CortecNet), as the sole 13C and 15N sources. The 
cells were grown as previously described in Section 3.2.3.1. Briefly, overnight 
cultures of the BL21 (DE3) cells, containing the desired apoA-I plasmid were 
prepared and used to inoculate 2 L of LB media, which was grown at 37 °C until 
an OD600 of 0.6 was reached.   
The cells were then pelleted by centrifugation at 5000 g and re-suspended 
in 1 L pre-warmed minimal media (88 mM Na2PO4, 55 mM KH2PO4, 1 mM MgSO4, 
0.3 mM ampicillin, 0.1 mM CaCl2, 0.03 mM thiamine HCl, 22 mM glucose, 19 mM 
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NH4Cl). The cells were left to adjust to the new media for 30 minutes, before 
induction with 1mM IPTG. Cells were incubated for a further 5 hours, to allow 
protein expression. 
 
3.2.3.3. Cell harvest and lysis 
Following the 5-hour induction, cells were harvested through centrifugation at 
5,000 g for 20 minutes. The cells were then re-suspended in 6 M guanidine 
hydrochloride cell lysis buffer (6 M GnHCl, 20 mM NaPO4 pH 7.4) and frozen at     
-20°C to aid lysis. The re-suspended cells were further lysed through sonication 
at 20 microns of power, for 5 cycles of 15 seconds on, 45 seconds off. The cells 
were kept on ice during this time to avoid overheating. Cell debris was removed 
through centrifugation at 43,000 g for 30 minutes, and the supernatant was 
collected.   
 
3.2.3.4. Immobilised metal ion affinity chromatography (IMAC) 
The fusion protein, containing the apoA-I (E2D) gene and the hexa-histidine tag, 
can be isolated from the other cell proteins via immobilised metal ion affinity 
chromatography (IMAC). The hexa-histidine tag binds with high affinity to a 
nickel sepharose resin, whilst the remaining cell proteins pass through the 
column in the flow-through. The his-tagged protein can then be washed and 
eluted with increasing concentrations of imidazole, which out-competes the 
hexa-histidine tag for nickel binding. 
A 20 mL HisTrap FF™ pre-packed Nickel Sepharose column (GE 
Healthcare) was set up on an AKTA Start system (GE Healthcare) running the 
UNICORN control software. The column was equilibrated with guanidine lysis 
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buffer until the conductivity and UV readings were constant, which was roughly 
5 column volumes.  
The cell lysis supernatant was loaded onto the column at a flow rate of 1 
mL/min and the flow-through was collected. The column was sequentially 
washed with (I) guanidine lysis buffer (II) 20mM NaPO4, 0.5M NaCl, pH 7.5 (III) 
20mM NaPO4, 0.5M NaCl, 25mM imidazole, pH 7.5 (IV) 20mM NaPO4 0.5M NaCl, 
50mM imidazole, pH 7.5, each at a flow rate of 5 mL/min, until the UV remained 
constant, roughly 3-4 column volumes of each. 10 mL fractions were collected at 
each stage for analysis by SDS-PAGE. The fusion protein was then eluted with 
20mM NaPO4, 0.5M NaCl 0.5M imidazole pH 7.5, running at 1 mL/min with 1 mL 
fractions collected. 
The concentration of elution fractions were measured using a Nanodrop 2000 
(Thermo Scientific) and those with high UV absorbance and protein 
concentration were pooled. A 50 μL sample of the eluted fractions was taken for 
analysis by gel electrophoresis.  
 
3.2.3.5. Dialysis and cleavage  
The elution fractions with the highest UV and concentrations were pooled in a 
cellulose dialysis membrane and dialysed against 50 mM Tris HCl, 1 mM 
benzamidine, 1 mM EDTA, pH 7.4 at 4 °C overnight.  
The dialysed protein was then filtered through a 0.2 μm syringe filter 
(Corning) to remove a white precipitate that had developed during dialysis. The 
filtered protein was then incubated in 45 % v/v formic acid (Sigma) at 55 °C for 5 
hours to cleave the hexa-histidine tag from the apoA-I, via the acid labile Asp-Pro 
sequence, introduced with the E2D mutation.  
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Following cleavage with formic acid, the protein was dialysed a further 2 
times into 50 mM Tris HCl, 1 mM benzamidine, 1 mM EDTA pH 7.4 at 4 °C for 16 
hours to remove the residual formic acid. A second filtration through a 0.2 μm 
membrane removed any precipitate that formed during the dialysis. Finally, the 
protein was dialysed into McIlvaine buffer (165 mM Na2HPO4, 17.6 mM citrate, at 
pH 7.0) overnight. This step was incorporated to enable apoA-I aggregation to be 
monitored over a large pH range (pH 2.2-8). The final protein product was then 
frozen at -20 °C.  
 
3.2.4. Characterisation of recombinant apoA-I 
3.2.4.1. SDS poly-acrylamide gel electrophoresis (PAGE) 
SDS-PAGE gels were run in order to determine the expression level and purity of 
apoA-I at various stages of the procedure. The proteins were separated using a 
15 or 17.5 % polyacrylamide gel in a Bio-Rad gel electrophoresis system. 18 μL of 
protein samples were added to 2 μL of 10x sample buffer (20 % 1 M Tris HCl, 40 
% glycerol, 2 % mercaptoethanol, 5 % 0.5 M EDTA, 4 % SDS and 29 % water). 
The samples were heated at 95 °C to aid denaturing, and loaded into a 5 % 
stacking gel, along with 5 μL of PageRuler™ Low Range Unstained Protein Ladder 
(Thermo Scientific). All gels were run at 200 V for roughly 60 minutes, prior to 
fixing with 25 % isopropanol and 10 % acetic acid in water. Gels were then 
stained with 10 % acetic acid and 6 % Coomassie Brilliant Blue G-250 overnight. 
The excess stain was removed with 10 % acetic acid. 
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3.2.4.2. Native poly-acrylamide gel electrophoresis (PAGE) 
Native PAGE gels were run in order to determine the native fold of apoA-I, in 
particular the oligomeric state of the wild type and cysteine mutants (K96C and 
R173C) in non-reducing conditions. The introduction of the cysteine residue into 
the apoA-I sequence gives rise to a free thiol group, which has the ability to form 
apoA-I dimers via disulphide cross links.  
The proteins were run on a NativePAGE™ 4-16% Bis-Tris gel (Life 
Technologies) with the NativePAGE gel running system.  Protein samples of 7.5 
μL were added to 2.5 μL of NativePAGE™ sample buffer and loaded onto the gel. 
The gel was run using NativePAGE™ Anode Buffer and NativePAGE™ Dark Blue 
Cathode Buffer at 150 V for 120 minutes with a NativeMark Unstained Protein 
Standard (Thermo Fisher).  
 
3.2.4.3. Mass spectrometry 
Electrospray ionisation mass spectrometry of apoA-I and apoA-I mutants was 
carried out in order to determine the identity of the proteins. This analysis was 
undertaken at the Institute of Integrative Biology at Liverpool University, 
assisted by Mr Mark Prescott. ApoA-I samples, in 30 % acetonitrile, were loaded 
into the nano-electrospray source of the mass spectrometer (Waters Q-ToF 
micro) at a rate of 250 μL/hour, via syringe.  The positive ion mass spectrum was 
collected, containing multiply-charged ions, and analysed by applying MaxEnt to 
the data, in order to determine a single mass for the peptide.  
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3.2.4.4. Gene sequencing  
Following transformation of the plasmid into E.coli XL1Blue cells for long-term 
storage, as described in section 3.2.2.1, it was necessary to isolate the DNA from 
the cells in order to sequence the plasmid. This was done using the GenElute™ 
Plasmid DNA Mini-Prep system (Sigma Aldrich). Overnight cultures of 5 mL were 
spun down at 12,000 g into a pellet. The pellet was then re-suspended in 200 μL 
re-suspension solution, prior to lysing the cells, using 200 μL of the GenElute 
alkaline-SDS based lysis solution. This was gently mixed before the lysis was 
stopped with 350 μL neutralisation solution. The solution was mixed again 
before centrifugation at 12,000 g for 10 minutes to pellet the cell debris. The cell 
lysis was then loaded onto a GenElute MiniPrep Binding Column and centrifuged 
at 12,000 g for 1 minute to remove any non-DNA material in the flow-through. 
The DNA bound to the column was washed with 750 μL of the diluted wash 
solution, prior to another centrifugation at 12,000 g. This removed any residual 
salts and other contaminants. Excess ethanol from the lysis buffer was removed 
by repeating the centrifugation step. DNA was eluted with 100 μL of molecular 
biology reagent water by centrifugation at 12,000 g. DNA samples were sent to 
Source-Bioscience for sequencing, followed by translation into amino acid 
sequence using the ExPASy Translate online server. The sequences for each of 




3.3. Results  
3.3.1. SLIM PCR mutagenesis  
3.3.1.1. PCR amplification of the DNA by the mutated primers  
SLIM PCR was used to introduce a series of single amino acid mutations into the 
apoA-I E2D sequence: G26R, L44Stop, L90P, K96C and R173C. Following the 
incubation of the paired primers in two separate reactions, and the first round of 
the PCR amplification, DNA samples of the two separate reactions for each 
mutant were taken.  
Agarose gel electrophoresis confirmed the PCR amplification of the DNA 
for the L44Stop, L90P and R173C in both reactions, as seen in Figure 3.5. The 
K96C mutant samples show amplification of the DNA in reaction 1, but not in 
reaction 2. The two reaction samples were combined, regardless of the lack of 
PCR product in reaction 2, and taken forward into transformations and 
subsequent DNA sequencing. This was due to the successful amplification of the 
other 3 mutants and presence of a band in reaction 1.   
 
3.3.1.2. Confirmation of mutation by gene sequencing 
Sequencing of the DNA from all apoA-I species was performed by Source-
Bioscience (Nottingham, UK), the sequences determined are shown in Appendix 
3. The sequence for apoA-I E2D, L44Stop, K96C and R173C came back as 
expected, confirming successful substitution of the desired nucleotides. However, 
the G26R and L90P mutant contained undistinguishable nucleotides, resulting in 
an incomplete amino acid conversion (Appendix 3, blue X). However, these 
indistinguishable codons are away from site of mutation, suggesting that the 
cause is due to a sequencing error, rather than an issue with the mutation. 
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Moreover, the G26R sequence contained codons that could not be distinguished 
in the linker region between the his-tag and the formic acid cleavage site, in 
particular, the Glu 2 residue that should have been mutated into an Asp residue 
to facilitate the formic acid cleavage.  
 
Figure 3.5 Agarose gel electrophoresis of apoA-I (A) L90P, K96C, R173C and (B) 
L44Stop DNA, after the first round of SLIM PCR. 
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3.3.2. ApoA-I expression and purification 
3.3.2.1. Expression of apoA-I 
Once the pNFX expression plasmid, containing the apoA-I E2D gene, had been 
successfully transformed into the E.coli BL21 (DE3) expressing cell line, the next 
stage involved large-scale expression in LB media, enriched with ampicillin. The 
methods outlined in Oda et al., (2001) and Ryan et al., (2003) had already been 
optimised to produce yields of up to 100 mg/L culture, which used an incubation 
temperature of 37 °C, and induction with 1mM IPTG at an OD600 of 0.6, for 3 
hours.  
Incubation times from 2 to 5 hours were monitored to determine if longer 
incubation after induction would lead to a further increase in apoA-I yield. This   
enhancement may be required when it comes to expressing apoA-I in minimal 
media. A sample of the cell culture taken prior to induction with IPTG (pre-
induction) and was run on an SDS PAGE gel to highlight the low level of apoA-I 
expression (Figure 3.6). This is essential as it confirms that cell growth can be 
carried out in LB media without expressing apoA-I fusion protein, prior to 
transfer into minimal media for induction of labelled protein expression. This 
will result in a negligible amount of unlabelled apoA-I being produced, whilst 
simultaneously maximising labelled apoA-I expression. 
The gel in Figure 3.6 also included samples of the cell culture taken at 
various time points after induction with IPTG and activation of the T7 promoter, 
controlling the expression of the apoA-I fusion peptide. Expression of a protein 
that migrates to the 25-30 kDa region of the gel, and consistent with the apoA-I 
fusion peptide (29642 Da), is dramatically increased after 2, 3, 4 and 5 hours of 
induction. The yield of apoA-I fusion peptide was sufficient for further work after 
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induction for 3 hours. However, induction for 5 hours led to a slightly denser 
band in the apoA-I fusion peptide region, suggesting an increase in yield, without 
increasing the expression of cellular proteins not under the LAC operon control. 
As such, it was decided that expression would continue with incubation for 5 
hours after induction.  
 
Figure 3.6 15% SDS PAGE gel of apoA-I fusion peptide expression prior to, and 
after induction for 2, 3, 4 and 5 hours with 1 mM IPTG.  
 
Following optimisation of the length of induction, expression of apoA-I was 
trialled using a range of IPTG concentrations, and at a reduced temperature. 
Figure 3.7 shows that at 30 °C, the lowest maintainable incubator temperature 
available in the lab, expression of apoA-I was still accomplished, albeit at a 
reduced level, compared to expression at 37 °C, across all IPTG concentrations 
and regardless of the induction time. This concluded that, if necessary, induction 
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of apoA-I expression could be carried out at a lower temperature but would 
result in a decreased yield. At 37 °C, the concentration of IPTG added made no 
difference to the protein yield.  
 
Figure 3.7 15 % SDS PAGE gel of the expression tests for apoA-I at 37 °C (A-C) 
and 30 °C (D-F) following induction with 0.1 mM (A/D), 0.5 mM (B/E) or 1 mM 
(C/E) IPTG and left to express protein for up to 5 hours.  
 
Next, expression of apoA-I in minimal media was investigated. Expression was 
induced at 37 °C with 0.5 or 1 mM IPTG. Expression was monitored overnight, in 
order to deduce whether leaving cells in minimal media overnight would affect 
the protein yield. Due to the slow growth of E.coli cells in labelled media, it is 
often common to leave expressing cells to grow overnight at reduced 
temperatures. Figure 3.8 shows the expression of apoA-I is induced with both 
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0.5 and 1 mM IPTG, independent of the concentration. As with Figure 3.6, 
incubation for 5 hours or longer resulted in a slightly higher concentration of 
protein expressed. This gel also confirms that if need be, cells can be induced in 
minimal media overnight without effecting the protein yield, or resulting in 
protein fragmentation.  
 
 
Figure 3.8 15 % SDS PAGE gel of the expression tests for apoA-I production in 
minimal media at 37 °C, monitored overnight following induction of protein 





3.3.2.2. Expression of apoA-I mutants  
The methodology for the apoA-I mutant fusion peptide expression, followed that 
of the apoA-I E2D procedure outlined in Oda et al., (2001) and Ryan et al., (2003), 
with an increased induction time of 5 hours. 
Upon induction with IPTG, the L90P, K96C and R173C mutants all 
experienced increased expression of a protein, which migrated to the expected 
regions on an SDS gel for the mutated apoA-I fusion peptide, (Figure 3.9). 
However, the expression level of the mutants was considerably less compared to 
the native protein.  
No increase in expression of a protein corresponding to the apoA-I 
L44Stop was observed following induction (Figure 3.9 lanes 2/3). This could 
have been due to the small size of the apoA-I (1-43) fusion peptide (roughly 
7,300 Da), running poorly on the 15 % gel, or a poor staining result, again due to 
its small size in comparison to the remainder of the proteins stained in the gel. 
Figure 3.9 shows that any proteins running below 10 kDa, including the protein 
marker, are poorly resolved. Expression of this mutant did not go any further, 
due to time restraints on the project. However, if this were to continue, a full 
expression test would be required to determine suitable conditions for 




Figure 3.9 15% SDS PAGE of apoA-I L44Stop, L90P, K96C and R173C mutants 
prior to induction and after 5 hours incubation, following induction with 1 mM 
IPTG.  
 
3.3.2.3. Immobilised metal ion affinity chromatography 
Following expression, cell harvesting, lysis and the removal of cell debris, the 
lysis supernatant was loaded onto a hisTrap column, using an AKTA StartTM 
purification system. This system allows the UV monitoring of the material leaving 
the column at 280 nm, which is roughly proportional to the protein 
concentration. 
After collecting the flow-through, which produced a high UV absorbance, 
consistent with the elution of large quantities of non-binding cellular proteins 
(Figure 3.10: Flow-through), an initial wash stage with the guanidine lysis 
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buffer removed a large concentration of impurities (Figure 3.10: Wash 1). The 
subsequent wash stages with sodium phosphate buffer, containing 0 %, 5 % and 
10 % of a 500mM imidazole buffer (0, 25 and 55 mM, respectively), removed 
additional non-specific binding proteins, shown by peaks in the UV absorbance 
(Figure 3.10: Wash 2, 3 and 4). 
Elution with 500 mM imidazole buffer resulted in a large spike in UV, 
consistent with the elution of the his-tagged apoA-I (Figure 3.10 Elution). This 
was collected in 1 mL fractions and the fractions containing the highest protein 
concentration were pooled. Combined fractions underwent dialysis into Tris 
buffer, in order to remove the imidazole. 
Samples of fractions 3, 5, 10, 17 and 22 coinciding with the flow-through, 
wash 1, wash 2, wash 3 and wash 4, were taken and underwent ethanol 




Figure 3.10 Chromatograph of the labelled apoA-I fusion peptide purification 
using a nickel IMAC his-trap column. The UV absorbance (blue), 500mM 
imidazole buffer ratio (pink), and fraction numbers (red) are included in this 
diagram, along with a description of each step.  
 
Samples of the flow-through and various wash stages for the labelled apoA-I 
purification were run on SDS PAGE gel electrophoresis to determine what 
protein content was being removed from the column at each step.  
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Figure 3.11 indicates a high level of impurities present in the flow-through, as 
expected, due to the high UV absorbance seen in Figure 3.10. Wash 1, with 
guanidine, removes non-specifically binding proteins, associated with the apoA-I 
fusion protein, whilst wash 3 and 4, containing low concentrations of imidazole, 
remove proteins that are bound weakly to the column, presumably via the 




Figure 3.11 15% SDS PAGE of samples from each of the stages of the his-Trap 
purification of labelled apoA-I. Samples of the lysis, flow-through, wash 1, wash 2, 




3.3.2.4. Cleavage of the fusion peptide 
Following incubation with formic acid for 3 hours, gels of the cleavage products 
identified 2 bands in close proximity (gel not shown), similar to that shown in 
Figure 3.12 for the 2.5 hour sample. These 2 species were believed to be the 
isolated apoA-I (2-243) product, and the fusion peptide that has not undergone 
cleavage of the his-tag. It was unclear at this time whether the formic acid 
concentration, incubation time or temperature was leading to incomplete 
cleavage. Initially, samples were incubated in 45 % formic acid at 55 °C 
overnight, with samples taken at various time points. This experiment confirmed 
that the length of the incubation period was the cause of the incomplete cleavge. 
3 hours was shown not sufficient to cleave all of the fusion peptide. After 2.5 
hours, 2 species of protein are detected, presumed to be the fusion peptide and 
cleaved apoA-I. However, beyond 5 hours, only a single product with the smaller 
molecular weight is detected without any additional protein degradation. As 
such, all future formic acid treatment steps were carried out for 5 hours.   
 
Figure 3.12 15 % SDS PAGE of samples taken at various time points, during the 
incubation of the apoA-I fusion peptide in 45 % formic acid.  
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3.3.3. ApoA-I characterisation 
Incubation of proteins in 45 % formic acid leads to the cleavage of peptides 
following aspartic acid residues, in particular, between the aspartic acid and 
proline residues, introduced into the apoA-I N-terminus via the E2D mutation. 
This results in the release of the hexa-histidine tag connected to the linker region 
and the apoA-I peptide, minus the first 2 residues. The sequence apoA-I (3-243) 
will be referred to as apoA-I or the wild type protein for the remainder of this 
thesis, unless stated otherwise. All additional mutants produced, such as G26R, 
L44Stop, L90P, K96C and R173C all carried the same E2D mutation to promote 
formic acid cleavage.  
 
3.3.3.1. SDS PAGE  
SDS PAGE analysis of the purified apoA-I, labelled apoA-I, apoA-I K96C and apoA-
I R173C mutants confirmed a single protein product for each mutant, which 
migrated to a region on the gel with a molecular weight of approximately 25 kDa 
(Figure 3.13). This is in agreement with the predicted molecular weight of 
27834 Da, 27809 Da and 27781 Da for the wild type apoA-I, the K96C and R173C 
mutants, respectively.  The gel appears to show multiple faint bands for each 
protein product. However, since the same occurs for the protein marker, and 
individual gels confirm the purity of each species, this increased bandwidth is 
presumed to be caused by uneven running of the gel, or poor staining.  
The apoA-I L90P mutant was also run on an SDS PAGE gel as shown in 
Figure 3.14. The apoA-I (L90P) mutant produced a band in the 25 kDa region 
corresponding to full-length apoA-I, consistent with the predicted mass of the 
peptide (27817 Da). However, unlike the other mutants, apoA-I L90P also 
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produced two additional bands in the 15 and 10 kDa regions (Figure 3.14). At 
this point, it was noticed that the introduction of the L90P mutation produced a 
second Asp-Pro acid labile bond. Upon incubation with formic acid to cleave the 
N-terminal his-tag, an additional cleavage of the peptide between residues Asp 
89 and Pro 90 would result in the production of 2 apoA-I fragments, 3-89 and 90-
243, with masses of 10005 and 17847, respectively, corresponding to the 2 
additional bands on the apoA-I L90P gel. Despite the interest in the N-terminal 
region of apoA-I, the purification of the apoA-I (3-89) peptide was not continued, 
due to time restraints on the project.  
 
 
Figure 3.13 SDS PAGE analysis of apoA-I and apoA-I mutants, showing the 
protein purity following immobilised metal-ion chromatography and cleavage of 














Figure 3.14 17.5 % SDS PAGE of apoA-I (L90P), highlighting the region 
associated with full-length apoA-I L90P, and fragments in the 15 and 10 kDa 
regions corresponding to apoA-I (3-89) and (90-243).   
 
3.3.3.2. Native PAGE 
Native PAGE gels of apoA-I, and the cysteine K96C and R173C mutants were run 
in order to determine the oligomeric state of the proteins. Native apoA-I 
produces a single band in the 25-30 kDa region, confirming the protein is in its 
monomeric state (Figure 3.15). Introducing a novel cysteine residue into the 
apoA-I sequence could lead to the formation of apoA-I disulphide-linked homo-
dimers. ApoA-I K96C appears to remain monomeric, showing a similar banding 
pattern to wild type apoA-I. In the apoA-I R173C sample, a main band in the 25-
30 kDa region is present and suggests that the majority of the protein is in the 
monomeric state. However, unlike the wild type and apoA-I K96C species, the 
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R173C mutant also produces an additional band in the 66 kDa region, which is 












Figure 3.15 4-16 % Native PAGE gel of wild type apoA-I and the apoA-I K96C 
and R173C cysteine mutants. 
 
3.3.3.3. Mass spectrometry 
In order to confirm the identity of the purified product as apoA-I, samples were 
analysed by electrospray ionising mass spectrometry. ApoA-I (2-243) has a 
predicted intact mass of 27834 Da. Figure 3.16 shows an intact peak of 27837 
Da for apoA-I, in concurrence with the predicted masses and sufficient to confirm 
the identity of the protein as apoA-I. Despite not matching with the predicted 








Although the gene sequence of the mutant apoA-I species confirmed successful 
mutation, none of the mutant plasmids produced here could be expressed as 
proteins corresponding with the intact predicted masses, according to 
electrospray ionisation mass spectrometry. ApoA-I G26R has a predicted mass of 
27933 Da, but the mass spectrometry detected a peak mass of 28557 Da (Figure 
3.17). The gene sequencing for this mutant did highlight 6 codons that it could 
not detect as amino acids, due to missed nucleotides, 5 of which would be 
present in the cleaved 3-243 residue peptide. It is possible that these 
undistinguishable amino acids do not match up to the native sequence, and as 
such have resulted in a mass higher than predicted.     
ApoA-I K96C peptide has a predicted mass of 27809 Da. However, the 
mass spectrometry detected a main peak at 27888 Da (Figure 3.18). ApoA-I 
R173C has a predicted average mass of 27781 Da, but the mass spectrometry 
returned a peak mass of 18207 Da (Figure 3.19). Despite a much lower mass 
than expected, there is no reason to suggest that cleavage of the apoA-I (R173C) 
peptide occurred. Both the K96C and R173C mutant plasmid DNA returned a 
gene sequence consistent with only the intended single amino acid mutation into 
the native apoA-I species.   
ApoA-I L90P has a predicted mass of 27818 Da for the intact peptide, but 
as discussed in section 3.3.3.1, this mutation leads to the cleavage of the peptide 
into fragments 3-89 and 90-243. These fragments have intact masses of 10005 
Da and 17847 Da, respectively. The smaller of these fragments was detected via 
mass spectrometry as a major peak (10005 Da), whilst only a small contribution 
came from a mass of 17849 Da (Figure 3.20). Cleavage of the apoA-I L90P would 
result in equal ratios of the 3-89 and 90-243 peptide present in solution. 
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However, despite a band appearing on the SDS gel, the low intensity of the peak 
corresponding to the apoA-I (90-243) peptide suggests that the majority of the 
peptide is no longer in solution. 
 
3.3.3.4. Detection of labelled apoA-I. 
Uniformly labelled apoA-I was produced to enable solid-state NMR analysis of 
the structure of apoA-I. The expression of a peptide consistent with apoA-I was 
successful, as shown in Figure 3.16, although the only way to determine the 
protein produced had incorporated the 13C was to run a 1D spectrum of the 
lyophilised labelled apoA-I at pH 7. Figure 3.21 confirms the intensity of the 13C 
signal is sufficient to allow structural studies to be carried out, thus confirming 



























Figure 3.21 Preliminary 1D 13C DP MAS spectrum of labelled apoA-I, confirming 
the expression of apoA-I in minimal media enriched with 13C glucose produced a 
uniformly labelled protein.  
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3.4. Discussion 
The research carried out in this thesis required large quantities of apoA-I in 
order to allow characterisation of conditions that promoted the aggregation of 
apoA-I into insoluble, amyloid-like aggregates. Isotopically labelled apoA-I was 
also required for structural studies by SSNMR. There is also evidence to suggest 
that chemically synthesised proteins can behave differently to those produced 
via recombinant expression methods, in particular in their aggregation potential 
(Finder et al., 2010). As such, expression of apoA-I, adapting the previously 
published methods of Oda et al., (2001) and Ryan et al., (2003) was utilised and 
modified to allow production of 13C and 15N uniformly labelled apoA-I.  
This chapter aimed to ensure that sufficient apoA-I could be produced via 
a bacterial expression system to enable large-scale production of apoA-I. Figure 
3.13 confirms the purity of the final apoA-I product that was produced with a 
yield of roughly 80 mg per litre of culture. This system was successfully modified 
to incorporate protein induction in minimal media solution, containing 13C 
glucose and 15N ammonium chloride as sole carbon and nitrogen sources. This 
resulted in the production of uniformly labelled 13C and 15N apoA-I with a yield of 
22 and 29 mg per litre of culture respectively, which is suitable for NMR studies.  
Manipulation of the gene DNA, through SLIM PCR meant that mutant plasmids 
corresponding to L44Stop, L90P, K96C and R173C could be produced and used 
for protein expression. Despite all mutants forming plasmids with the correct 
amino acid sequence (Appendix 3), only the apoA-I G26R, L90P, K96C and 
R173C were expressed under the same experimental procedure as the wild type 
apoA-I. From those that were expressed, only the G26R, K96C and R173C mutant 
were able to be isolated as pure protein. The introduction of the L90P mutant 
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produces an Asp-Pro sequence at residues 89-90, which is acid labile. The use of 
formic acid cleavage, in order to cleave the apoA-I mutant protein from the 
bound his-tag, degrades the apoA-I L90P protein into fragments, corresponding 
to residues 2-89 and 90-243. These fragments were detectable in a 17.5 % SDS 
PAGE gel (Figure 3.14) and a peptide with a mass corresponding to residues 3-
89 was detected in the mass spectrometry.  
Despite the apoA-I G26R, K96C and R173C mutant plasmids containing 
the correct DNA sequence, and the expression of a protein, which migrated to the 
area associated with apoA-I on an SDS page gel, mass spectrometry failed to 
identify any of the mutant apoA-I species by their mass. The use of the apoA-I 
mutants in the remainder of this project was limited, with only their aggregation 
propensities compared to the wild type protein, and structural characterisation 
was not attempted, due to a lack of time.  
Future work would need to focus on modifying the expression and 
purification procedure, in order to facilitate the production of the mutants listed. 
SLIM PCR successfully produced the mutant plasmids, as determined by DNA 
sequencing, and uptake of the plasmids into E.Coli cells was confirmed, via 
selection of colonies that were resistant to ampicillin. This implies that 
somewhere between the expression procedure and the final dialysis of the 
purified and cleaved apoA-I mutants into McIlvaine buffer, there has been an 
error that did not occur in expression of the wild type apoA-I and labelled apoA-I.  
 
3.4.1. Production of N-terminal apoA-I peptides 
For the N-terminal 1-43 peptide, expression of the full-length peptide with a 
cleavage site mutated into the sequence may be more successful than introducing 
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a stop codon into the apoA-I sequence. Given the serendipitous observation that 
the introduction of the proline residue in position 90 lead to the cleavage of the 
intended L90P mutant peptide into apoA-I (3- 89) and (90-243), the arginine in 
position 49 could be mutated into a proline residue, creating an Asp-Pro formic 
acid cleavage site at residues 48-49. After treatment with formic acid, a step that 
would still be necessary to remove the his-tag, apoA-I peptides corresponding to 
residues 3-48 and 49-243 would be produced. The apoA-I (3-48) peptide could 
then be separated from the his-tag and the remainder of the apoA-I 90-243 
sequence by size exclusion chromatography, avoiding the loss of the short 
peptide through the dialysis membrane, which has a molecular weight cut-off of 
14 kDa.  
Following on from the L90P mutant, looking into the ability of the apoA-I 
(3-89) peptide to form amyloid and its structure upon aggregation would be 
interesting, given the increased propensity of the first 100 residues in the N-
terminus to aggregate into amyloid species. Here is presented a method by which 
a peptide corresponding to the majority of the apoA-I N-terminus can easily be 
produced, in an expression system that can be modified to produce uniformly 
labelled protein. Alternatively, cleavage of the N-terminal tag could be carried 
out with thrombin protease, in order to avoid the addition of formic acid, since 
the apoA-I pNFX plasmid also contains a thrombin cleavage sequence. This would 
also result in the production of the entire apoA-I (1-243) peptide, rather than the 
3-243 sequence.  
Successful expression and purification of apoA-I facilitated the analysis of 
apoA-I aggregation in chapter 3, the structural studies of the amyloid-like 
material in chapter 4 and preliminary inhibition experiments in chapter 5.  
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4. Determination of the factors responsible for apoA-I 
aggregation 
4.1. Introduction 
4.1.1. ApoA-I amyloid 
Current understanding of the aggregation of apoA-I into amyloid is that the 
protein can become deposited within human arteries as either N-terminal 
fragments of apoA-I, or as the full-length protein. Familial apoA-I amyloidosis is 
associated with N-terminal fragments of mutant apoA-I, which become deposited 
within major organs (Ramella et al., 2012; Das et al., 2016; Rosú et al., 2015; Sipe 
et al., 2014; Monti et al., 2011; Chan et al., 2015). Alternatively, acquired 
amyloidosis is linked to the deposition of full-length protein as amyloid within 
atherosclerotic plaques (Ramella et al., 2011; Chan et al., 2015; Mucchiano, 
Häggqvist, et al., 2001). Deposition of full-length apoA-I as insoluble aggregates 
reduces its ability to form functioning HDL, leading to a reduced atheroprotective 
function and a potential increased pathogenic fibril load (Ramella et al., 2011). 
Cleavage of the N-terminus of apoA-I can occur when the protein undergoes a 
transition from its lipid-bound to lipid-free structure (Mucchiano, Jonasson, et al., 
2001), but may also occur after the deposition of full-length protein.  
The presence of myeloperoxidase-oxidised lipid-free, full-length apoA-I in 
atherosclerotic plaques has been reported (Chan et al., 2015; Sigalov and Stern, 
2001). This may be significant because oxidation of methionine residues, in 
particular Met-86 and Met-148, promotes the aggregation of lipid-free apoA-I 
into amyloid. In serum, oxidised apoA-I can account for up to 25 % of circulating 
apoA-I, although the extent of oxidation of each individual protein can vary from 
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1 to all 3 methionine residues (Wong et al., 2010). Even though oxidative 
cleavage of apoA-I has been reported, the chemical oxidation methods described 
by Chan et al. (2015) and Sigalov and Stern (2001) avoid oxidative cleavage.  
Amyloid formation by apoA-I in vitro occurs under conditions that reflect 
environments experienced by lipid-free apoA-I at the pro-inflammatory sites of 
atherosclerotic plaques (Ramella et al., 2012). Such conditions include oxidation, 
either chemically or enzymatically (Chan et al., 2015); interaction with GAGs, in 
particular heparin in the circulatory system, as discussed in section 1.1.5.1 
(Ramella et al., 2012; Madine et al., 2013); and acidic pH (Ramella et al., 2011; 
Raimondi et al., 2011), caused by the release of arachidonic acid during platelet 
activation in an immune response against atherosclerotic plaques (Ross, 1999a). 
The aim here is to produce a more detailed description of the factors that 
influence apoA-I aggregation than work previously published, and to identify 
suitable conditions to produce aggregates for structural analysis in Chapter 5. 
Here follows a brief description of the techniques used in this study, also 
summarised in Table 4.1 for each of the amyloid structures.   
 







Protofibril Amyloid Fibril 
Atomic Structure Solution-state NMR   Solid-state NMR 
  Circular Dichroism Thin Film CD 
Secondary     X-ray Fibre Diffraction  
Structure     Thioflavin T Assay 
    Transmission Electron Microscopy 
Fibril   Atomic Force Microscopy  
Morphology  Intrinsic Fluorescence   
  Gel electrophoresis     
Assembly Size Dynamic Light Scattering   
  Mass spectrometry      
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4.1.2. Biophysical Techniques 
4.1.2.1. Thioflavin T 
A technique widely used to study the aggregation of proteins into amyloid 
species in vitro is Thioflavin T (ThT) fluorescence. ThT is a benzothiazole salt dye 
that selectively stains amyloid fibrils, due to its high affinity binding to cross-β 
strand ladders, the solvent exposed grooves between parallel β-sheet structures 
(Biancalana and Koide, 2010; Coelho-Cerqueira et al., 2014; Nelson et al., 2005).  
The restricted oscillations of the benzothiazole and aminobenzoyl rings, upon 
binding to consecutive β-strands, causes rotation of the bond outlined in Figure 
4.1 (Girych et al., 2014; Chan et al., 2015). This causes a red shift in the 
fluorescent properties of the molecule with increased emission at 482 nm, when 
excited at 450 nm (Wolfe et al., 2010; LeVine, 1999; Girych et al., 2014). This 
allows quantification of the extent of amyloid formation, and measurement of 







Figure 4.1 Chemical structure of Thioflavin T, highlighting the bond that rotates 
upon binding to β-sheet structures (red), causing a red shift in the compound’s 
fluorescent properties, with enhanced emission at 482nm when excited at 
450nm.  
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Figure 4.2 gives a typical ThT fluorescence curve in the presence of amyloid 
forming peptides, derived from incubation of ThT with the amyloidogenic N-
terminal apoA-I G26R mutant (Girych et al., 2014). This curve shows the main 
stages in the nucleation-dependent polymerisation mechanism, which is common 
among most amyloid species. The process shown below does not include any 
secondary nucleation stages, which would produce an additional increase, 
similar to the elongation phase (Cohen et al., 2013).  
 
Figure 4.2 ThT fluorescence increase upon incubation with amyloidogenic apoA-
I 1-83 (G26R) at 0.9 μM. Image modified from Girych (2014) to highlight the 
nucleation-dependent growth mechanism.  
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Using ThT does have its disadvantages, including its reduced binding to β-sheets 
at acidic pH (Li et al., 2009) and the ability to promote the aggregation of amyloid 
species, as shown for α-synuclein (Coelho-Cerqueira et al., 2014). As such, 
studies of apoA-I incubated in the presence of ThT, allowing real-time changes in 
the ThT fluorescence to be monitored, may not be reliable and should be 
complemented with single point measurements. In single point experiments ThT 
is added after the aggregation end point, so as not to interfere with the 
aggregation process. Doing so will also allow assays with longer incubation 
periods to be measured, as real-time measurements are limited to approximately 
6-7 hours at 37 °C, before solvent evaporation affects the fluorescence signal.  
 
4.1.2.2. Congo red 
Congo red is a dye which selectively binds to the β-sheets of amyloid species 
(Puchtler et al., 1962) with high affinity. The exact interaction between Congo 
red and amyloid is currently unknown. Nevertheless, it is assumed that the dye 
binds to the cross-β structures, similar to how ThT interacts with amyloid.  Upon 
binding to amyloid, Congo red’s absorbance spectrum changes, with a shift in the 
maximum absorbance from 490 nm to 540 nm, causing the amyloid species to be 
stained red when visualised under a microscope. This can be measured both 
qualitatively, for determining the presence of amyloid in tissue samples; and 
quantitatively, in order to determine the amount of amyloid formed using in vitro 
experiments (Klunk et al., 1999b; Li et al., 2009). Upon cross-polarisation of 
microscope lenses, the Congo red stained amyloid exhibits a green birefringence, 



















Figure 4.3 Methionine oxidized apoA-I aggregates stained with congo red and 
visualised with an uncrossed polariser  (A) and after crossing by 90 ° Image 
taken from Wong et al., (Wong et al., 2010)wong.  
 
4.1.2.3. Intrinsic Fluorescence  
 Intrinsic fluorescence of specific amino acids within a protein, namely 
tryptophan, phenylalanine, and tyrosine, have been used to determine whether 
or not a change in the environment of these residues occurs during self-assembly 
of the peptide (Vivian and Callis, 2001; Andrews and Forster, 1972). 
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Internalisation of residues to a less polar environment within the β-sheet 
structures of amyloid can give rise to a blue shift in the spectrum, whereas the 
inverse results in a red shift. Fluorescence excitation of tryptophan residues at 
280 nm gives rise to emission maximum at around 355 and 335 nm for solvent 
exposed and hydrophobic environments, respectively (Das et al., 2016; 
Touchette et al., 2010). The location of tryptophan residues, in close proximity to 
either acidic or basic residues, can also alter the maximum emission wavelength. 
An acidic residue near the pyrrole end or a basic residue near the benzene end of 
tryptophan will result in a red shift of the fluorescence spectrum, with the 
inverse configuration producing a blue shift (Vivian and Callis, 2001). Acidic and 
basic residues surrounding tryptophan residues can also result in the quenching 
of fluorescence signals.  
 
4.1.2.4. Morphology of amyloid 
Amyloid fibrils have a highly characteristic morphology on the nano-scale, 
consisting of networks of long un-branched fibrils, roughly 10 nm in diameter 
(Serpell, 2000; Serpell, Sunde, et al., 2000), described in detail in section 1.4.1. 
TEM is the most commonly used microscopic technique for studying the 
morphology of amyloid fibrils and intermediate oligomeric species. In addition, 
AFM is unique in its ability to detect and measure dimensions of substrates 
adsorbed onto mica surfaces. By detecting how far the cantilever deflects as it is 
traced across the surface, the height of the sample from the mica surface can be 
measured, and the topography determined (Harper, Wong, et al., 1997). A 
combination of these techniques can be used to determine the morphology of 
insoluble protein aggregates, including their length, width and height. 
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4.1.2.5. X-ray diffraction 
X-ray diffraction patterns can be used to study the secondary structural content 
of amyloid deposits, without the requirement for high-quality crystal structures 
that can make x-ray crystallography difficult. All X-ray diffraction patterns of 
amyloid contain broad reflections at roughly 10 Å for the equatorial region and 5 
Å for the meridional reflections. These values are characteristic of the spacing 
between the β-sheet layers (Figure 1.11B) and individual β-sheet motifs (Figure 
1.11A), respectively, as discussed in Section 1.4.3 and shown in Figure 1.10. 
These values can vary, depending on the protein sequence, due to the side chain 




The main aim of this chapter of research was to establish suitable conditions for 
promoting the aggregation of apoA-I into amyloid species, focusing on the effects 
of pH, heparin, and methionine oxidation.  
Previous reports have observed that acidification of full-length apoA-I 
induces amyloid formation, which is enhanced in the presence of heparin, as well 
as noting the aggregation-inducing effects of methionine oxidation on apoA-I. 
Here, these conditions are examined in further detail, with the aim to determine 
whether any differences can be detected between the aggregates formed in the 
absence and presence of heparin. Upon confirmation of amyloid formation under 
these conditions, it will be essential to confirm that scaling up of the amyloid 
formation can be achieved, allowing structural studies using circular dichroism 
and solid-state NMR.  
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4.2. Methods  
Unless otherwise stated, all samples are solubilised in a phosphate/citrate 
(McIlvaine) buffer, containing 165 mM Na2HPO4 and 17.6 mM citrate and 
adjusted to the correct pH, using concentrated HCl (37%) or 5M NaOH, giving a 
buffer range of pH 2.2 to pH 8.0 (McIlvaine, 1921). This buffer was used by 
Ramella (2011) in the study of apoA-I across a pH range of 4 to 8. This work 
showed that, when apoA-I was incubated in McIlvaine buffer at neutral pH, the 
protein was stable and avoided aggregation. However, at acidic conditions, in 
particular pH 4, the protein readily aggregated into insoluble material (Ramella 
et al., 2011). Throughout this thesis, apoA-I was routinely assayed at 36 μM, 
equivalent to 1.0 mg/ml, whenever possible. Lower concentrations of apoA-I 
were used in some of the ThT experiments, in order to reduce the quantity of 
protein required. 
 
4.2.1. Quantification of protein solubility  
ApoA-I at 1 mg/ml (36 μM) was incubated in the absence and presence of a 2-
fold molar excess (72 μM) of heparin (14-15 kDa, Iduron), over a range of pH 4 to 
pH 8, at 37 °C for 3 days. Samples were then centrifuged at 13,400 rpm in a bench 
top centrifuge and the supernatant removed. The soluble protein concentration 
of the supernatant was measured in triplicate on a Thermo Scientific Nanodrop 
2000, which takes absorbance measurements at 260 nm (RNA contribution) and 
280 nm (protein contribution). These measurements were then used to calculate 
the percentage of starting material that had converted to insoluble aggregates 
and been removed by sedimentation.   
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4.2.2. Thioflavin T fluorescence 
For all assays, the fluorescence of ThT (Sigma-Aldrich) was measured using a 
Flexstation 3 Microplate Reader (Molecular Devices Ltd.) in a 96-well clear-
bottomed, black-walled microplate (Nunc), with the fluorescence read from 
below the plate, taking an average of 6 reads. ThT was excited at 450 nm and the 
emission signal recorded at 482 nm (Wolfe et al., 2010). The assay was 
conducted at 37 °C with agitation of the sample, regardless of whether it was a 
continual read or end-point measurement (see below).  
Continual read experiments were carried out on apoA-I, in the presence of 
ThT at all times. Fluorescence measurements were taken from triplicate samples 
of 20 μM ThT incubated with apoA-I at 7.2 μM every 30 s for 10 minutes prior to 
a change of conditions (see results section for specific details on each 
experiment). Measurements were then taken every 30 seconds for 10 hours, or 
until evaporation occurred. All experiments were carried out at 37 °C, with 
agitation of the plate for the duration of the experiment.  
In end-point experiments, 1 mL of apoA-I (36 μM) was incubated in sealed 
eppendorf tubes at 37 °C with agitation for 3 days, in the absence of ThT. After 
this time, 196 μL of the sample was removed and added to 4 μL of ThT (1 mM 
stock in McIlvaine buffer), to give a final ThT concentration of 20 μM, and total 
fluorescence was measured from triplicate samples and recorded as the total 
fluorescence (FT). The remaining ThT-free sample was centrifuged and the 
supernatant removed. Protein concentration of the supernatant was measured, 
according to Section 4.2.1, and 196 μL was added to 4 μL (20 μM final 
concentration) ThT. Fluorescence measurements were taken in triplicate and 
recorded as the supernatant fluorescence (FS).  
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The above procedure was adapted to examine apoA-I under various conditions. 
These included determining the effects of pH over a range of pH 4 – 8, 
determining the effects of apoA-I concentration, the role of heparin, oxidation of 
apoA-I methionine residues, and mutations in the apoA-I sequence. The protein 
concentration used, the measurement type (continual or end point), and the 
change of conditions administered during the continual read experiments will be 
described in the results section.  
 
4.2.3. ApoA-I methionine oxidation 
Approximately 25 % of circulating apoA-I contains at least one of its three native 
methionine residues oxidised, as a result of myeloperoxidase induced oxidation, 
or interacting with oxidised lipids (Wong et al., 2010). Oxidative modifications to 
apoA-I have been shown to induce amyloid formation. ApoA-I was dialysed into 
10 mM NaH2PO4 pH 7.5 overnight, before incubation with H2O2 (1000 fold molar 
excess), overnight, at 37 °C. The sample was then dialysed back into 10 mM 
NaH2PO4 at pH 7.5 twice, in order to remove any excess hydrogen peroxide.  
 
4.2.4. Congo red  
ApoA-I at 18 μM was incubated at pH 4 and pH 7 alone and in the presence of 36 
μM heparin (14-15 kDa, Iduron), for 3 days with agitation at 37 °C. Samples were 
mixed with 90 μM Congo red dye and left for 24 hours at room temperature. 
Single drops were placed onto glass slides and allowed to dry at room 
temperature, before viewing with a Zeiss axioscope A1 microscope in 
transmission mode, with 10x objective lens and polarised lenses at 0 ° for the 
uncrossed measurements, and 90 ° for the crossed measurements.  
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4.2.5. Intrinsic fluorescence of tryptophan residues 
Wild type apoA-I contains 4 tryptophan residues at positions 8, 50, 72 and 108. 
ApoA-I (18 μM) at pH 4 and pH 7, in the absence and presence of heparin (36 
μM), and oxidised apoA-I (18 μM) at pH 7.5 and pH 6 (10mM Na2HP04), were 
incubated at 37 °C, with agitation. Fluorescence spectra from 300 to 400 nm 
were collected on a Cary Eclipse spectrometer, with excitation at 279 nm and a 
band pass of 1 nm, immediately and 1 hour after preparation of the samples.  
 
4.2.6. Transmission electron microscopy 
ApoA-I (36 μM) at pH 4 and pH 5, in the absence and presence of heparin (72 
μM); oxidised apoA-I (36 μM) at pH 6, and apoA-I (46-59) at pH 4, were 
incubated at 37 °C, with agitation for 3 days. Samples were centrifuged and the 
pellets washed several times with distilled water to remove buffer salts. Pellets 
were then diluted to 18 μM, before 10 μL was loaded onto carbon-coated copper 
grids and left for 2 minutes. Excess sample was removed by blotting. The grid 
was then stained by inverting it onto a droplet of 0.2 % uranyl acetate. After 30 
seconds of staining, the grids were blotted and left to dry for 1 hour. The sample 
was then visualised on a Tecnai 10 electron microscope at 100 kV.  
 
4.2.7. Atomic force microscopy  
ApoA-I (36 μM) at pH 4, in the absence and presence of heparin (72 μM), was 
incubated at 37 °C, with agitation for 3 days. Samples were diluted to 18 μM and 
loaded onto freshly cleaved mica, prepared through the removal of a single layer 
of tape from the mica surface. The sample was left to adhere to the membrane 
overnight, followed by washing with distilled water to remove any buffer salts. 
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AFM was performed with a Keysight Technologies (Santa Rosa, Ca, USA) 5500 
series instrument fitted with a 90x90 μm scanner. All images were acquired in 
acoustic alternating contact (AAC or “tapping”) mode, using etched silicon probes 
(PPP-NCL, Keysight), with nominal fundamental resonance frequencies of 190 
kHz.  These 225 μm long cantilevers have a nominal force constant (k) of 48 N/m, 
a top height of 10-15 nm, and a tip radius of <10 nm. PicoView (V1.2, Keysight) 
was used to control the AFM and capture the images. Height (topographic), 
amplitude, and phase shift images were recorded simultaneously over an area of 
0.5 x 0.5 μm, at a frequency of 160 kHz, a scan rate of 0.5 lines/sec, and a setpoint 
(Asp) of 2.2 V. Analysis of images was performed using Gwyddian V2.44. 
 
4.2.8. X-ray diffraction  
ApoA-I (36 μM) at pH 4, both in the presence and absence of heparin (72 μM), 
was incubated at 37 °C, with agitation for several days. The fibrils were pelleted 
through centrifugation at 5,000 rpm into a glass capillary using a bench top 
centrifuge. The sample was irradiated, using a Cu-Kα radiation (1.54 Å 
wavelength), and images were collected using a charged coupled device (CCD) 
detector (Atlas-S2). Using CrysAlis software, plots of intensity against 2θ were 
taken from the image and d spacings were calculated using Bragg’s law 
(Equation 4.1). The order (n) is set to 1, and wavelength (λ) set to 1.54 Å for this 
experiment.  
 
𝒏𝝀 = 𝟐𝒅𝒔𝒊𝒏𝜽    [4.1]  
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4.3. Results 
As highlighted previously, the main aim of this chapter was to determine suitable 
conditions, in the context of the pro-inflammatory environment of 
atherosclerosis, for promoting the aggregation of apoA-I into amyloid, allowing 
structural studies. The effects of each factor are described below. 
 
4.3.1. Effect of pH on apoA-I aggregation  
ApoA-I at 36 μM was incubated for 3 days, over a range of pH conditions. During 
this time, a white precipitate formed in the acidic samples, which was removed 
through centrifugation. The concentration of the remaining soluble protein was 
then measured, in order to quantify the amount of protein that had converted 
into insoluble material. Previous studies reported that acidic environments 
promote the aggregation of soluble apoA-I into insoluble material (Ramella et al., 
2012). Here, at neutral and mildly basic pH conditions (pH 8) the percentage of 
protein that had converted to insoluble material remained negligible. This 
percentage increased to roughly 35 % at pH 6, and was considerably higher in 
the extreme acidic conditions, with 80 and 95 % of material converting into 
insoluble material at pH 5 and pH 4, respectively (Figure 4.4A).   
It was next investigated whether the insoluble aggregates produced at 
acidic pH were typical of amyloid species. This was initially done using the 
amyloid specific binding characteristics of the ThT dye. At neutral and mildly 
basic pH conditions, the total fluorescence of the ThT (FT in Figure 4.4B), after 3 
days incubation, was consistent with ThT and buffer control samples, and 
showed no significant increase in fluorescence intensity. This indicates that no 
amyloid-like material is formed at neutral and basic pH.  
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Experiments also determined that incubation of ThT across the entire pH 
range 4-8 did not induce a change in the control ThT fluorescence (FC). This 
confirms that any difference in the ThT fluorescence intensity is caused by 
aggregation of the protein, not protonation of the ThT compound. Previous work 
by Hackl et al., (2015) and Sabatè et al., (2008) identified a decrease in 
fluorescence intensity when ThT was incubated below pH 3 and above pH 8.  In 
the pH range studied here (pH 4-8) the molecule is predicted to be in its mono-
ionised form, allowing comparative study (Sabaté et al., 2008). 
However, when incubated in acidic conditions, the total fluorescence (FT) 
increased for all 3 pH conditions, with enhanced intensity at pH 4 and pH 5, 
compared to pH 6.  
After centrifugation and removal of any insoluble material, the ThT 
fluorescence of the supernatant (FS) at all 5 pH conditions are equal, and have 
similar intensities to the control samples. This suggests the absence of any 
amyloid-like material remaining in the supernatant.  
This implies that the insoluble material that is formed at low pH, which is 
removed through centrifugation, gives rise to the ThT response observed during 
incubation at acidic pH.  This is characteristic of amyloid, and infers that the 
majority of the amyloid-like species, which bind to the ThT, are confined within 








Figure 4.4 (A) Percentage of apoA-I that is converted into insoluble material 
across a range of pH conditions. (B) ThT fluorescence of apoA-I (36 μM) after 3 
days’ incubation at a range of pH conditions, showing the ThT controls at each pH 
condition (FC) total increase (FT) and remaining fluorescence after centrifugation 
(FS). Data shown is the mean of 3 samples with ± standard error.  
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4.3.2. Measuring the time course of aggregation  
ThT fluorescence was used to monitor the kinetics of apoA-I aggregation in real 
time. ApoA-I at 36 μM (1 mg/ml) was incubated at neutral pH for 10 minutes, 
prior to the addition of a sufficient volume of concentrated HCl to acidify the 
samples to pH 4. This was confirmed using a narrow Mettler Toledo pH probe. 
Previous work suggests that heparin enhances the propensity for apoA-I 
to aggregate at acidic conditions (Ramella et al., 2011). Figure 4.5 shows the ThT 
fluorescence of apoA-I, in the absence and presence of 2-fold molar excess of 
heparin, following the addition of HCl. Fluorescence at pH 7, before acidification, 
remained at the baseline level, consistent with the absence of amyloid-like 
species. This remained the case for the pH 7 sample throughout the experiment.  
However, following acidification to pH 4, an instantaneous increase in ThT 
fluorescence intensity is observed, both in the absence and presence of heparin. 
This initial ThT intensity will be referred to as FI. The rapid increase in ThT 
fluorescence at pH 4 was observed within the time taken to add the HCl to the 
sample, mix it thoroughly, return the plate to the plate reader, and take the next 
measurement. The ThT fluorescence continues to increase after this initial jump 
in fluorescence until it reaches a plateau, referred to here as the total 
fluorescence intensity (FT). 
Due to the rapid increase in ThT fluorescence upon acidification of apoA-I, 
parameters that are commonly used to compare aggregation kinetics, such as 
rate and lag time, were unable to be calculated. As such, the total ThT 
fluorescence after the intensity leveled off (FT) and the initial ThT fluorescence 
(FI), were the two main parameters used to compare ThT fluorescence in the 
continual read experiments.  
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ApoA-I at pH 7 has an FI intensity consistent with the buffer and ThT 
controls, and a similarly low FT value, consistent with the absence of any 
amyloid-like species. However, acidification of apoA-I to pH 4 causes an increase 
in both FI and FT fluorescence, the intensity of which is dramatically enhanced in 
the presence of heparin. The effects of heparin will be studied in more detail later 
in this chapter. Controls of ThT and heparin alone did not show any increase in 
fluorescence upon acidification (Figure 4.5B).  
Previous studies of amyloid have shown that agitation of the peptide 
during fibril formation can significantly increase the rate of fibril formation, by 
reducing the lag time (Nielsen et al., 2001). This occurs because mechanical 
agitation promotes the fragmentation of the peptide, leading to an increased 
number of fibril-free ends, each of which can promote fibril extension, via a 
secondary nucleation mechanism (Xue et al., 2008). Here, apoA-I was agitated 
throughout the incubation period for all experimental procedures. It was not 
possible to thoroughly mix the samples with the concentrated HCl, without 
agitating the peptide. Since the aggregation of apoA-I was so rapid, by the time 
the mixing of HCl into the solution had ceased, insoluble material had already 
begun to appear in the sample. Therefore, it was decided agitation was to 
continue, in order to produce homogenous aggregates. With the high levels of 
precipitate formed during the incubation (>90 %), agitation also facilitated 
mixing of the sample during incubation, rather than letting the insoluble material 
sediment out of solution. This could have inhibited the interaction of the 




Figure 4.5 (A) ThT fluorescence of apoA-I (36 μM) in the absence and presence 
of heparin at pH 7, and at acidic pH following the addition of concentrated HCl 
(arrow points to the time point when HCl was added) (B) FI and FT values for 
apoA-I at pH 7 and 4, in the absence and presence of heparin. Data shown is the 
mean of 3 samples, with ± standard error bars shown in Figure B. 
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4.3.3. Effects of heparin on apoA-I aggregation 
As described in section 1.1.5.1, GAGs, in particular heparin, have been shown to 
influence the aggregation and deposition of amyloidogenic proteins in vitro, and 
are commonly found co-localised with amyloid deposits (Cohlberg et al., 2002). 
GAGs have been shown to enhance the rate of amyloid formation in amyloid-
associated proteins, as well as induce the formation of amyloid in proteins with 
no natural propensity to aggregate (Madine et al., 2013). The percentage 
sedimentation and end-point ThT experiments, described in Figure 4.4, were 
repeated with the inclusion of 15 kDa heparin at a 2-fold molar excess to the 
apoA-I (36 μM).  
The presence of heparin has no significant effect on the amount of 
insoluble material produced after 3 days, over the entire pH range of 4 to 8, 
compared to the protein alone (Figure 4.6A). At neutral and basic pH, the 
percentage of insoluble material formed remains negligible, as was the case for 
apoA-I incubated alone. At pH 6, approximately 35 % of protein is converted to 
insoluble material, whilst at more acidic conditions this percentage increases to 
roughly 80 and 95 % for pH 5 and pH 4, respectively. These percentages are 
similar to those in Figure 4.4, when apoA-I was incubated alone. 
Conversely, ThT fluorescence was dramatically enhanced at acidic pH in 
the presence of heparin, compared to the protein alone (Figure 4.6B). At neutral 
and basic pH, the ThT fluorescence produced after 3 days’ incubation was 
consistent with control samples, showing no increase in ThT fluorescence 
intensity (FT) and suggesting that no amyloid-like material was formed. This is 
the same as when apoA-I was incubated in the absence of heparin under the 
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same conditions. Upon centrifugation, no change in fluorescence intensity was 
observed (FS). 
However, after incubation for 3 days in acidic conditions, the 3 acidic 
samples, pH 6, pH 5 and pH 4, all showed an increase in ThT fluorescence. 
Furthermore, this increase in intensity was greatly enhanced by the presence of 
heparin, as shown by comparing the FT values in Figures 4.6B. Similar to the 
samples of apoA-I without heparin, pH 4 and pH 5 produced a much higher FT 
intensity than the pH 6 sample. Upon centrifugation and removal of the insoluble 
material, the FS values at acidic conditions were reduced to the level associated 
with no amyloid formation.  
This confirms, as with the un-heparinated samples, that the insoluble 
material that is formed from the incubation of apoA-I in the presence of heparin 
at acidic conditions is the source of the ThT fluorescence. Therefore, this also 
confirms that the majority of the amyloid-like species are confined to the 






























Figure 4.6 (A) Percentage of apoA-I that is converted into insoluble material 
across a range of pH conditions, in the absence and presence of 2-fold molar 
excess of heparin. (B) ThT fluorescence of apoA-I (36 μM) after 3 days incubation 
in the absence and presence of heparin (72 μM), at a range of pH conditions, 
showing the total (FT) and remaining fluorescence after centrifugation (FS). Data 
shown is the mean of 3 samples with ± standard error bars. 
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In order to quantify the effect heparin has on the ability for apoA-I to form 
amyloid-like insoluble material, apoA-I at 7.2 μM (0.2 mg/ml) was incubated 
with increasing concentrations of heparin, in molar ratios of apoA-I to heparin of 
1:0.25, 1:0.5, 1:1, 1:2 and 1:5. After incubation at pH 7 for 10 minutes, 
concentrated HCl was added to reduce the sample to pH 4.  
Upon addition of HCl, an instantaneous increase in ThT fluorescence was 
observed for all heparin concentrations (Figure 4.7A). The intensity of this 
initial jump in ThT fluorescence (FI) was dependent on the concentration of 
heparin, with higher concentrations resulting in a larger FI values (Figure 4.7B). 
Following the initial increase, the ThT fluorescence intensity continued to rise at 
a roughly equal rate, regardless of heparin concentration (Figure 4.7C), resulting 
in a final FT value that appeared dependent on the FI intensity, and thus, the 
heparin concentration. The ThT response of the control sample of apoA-I alone at 
pH 4 is negligible, due to the low protein concentration used in the experiment.  
In Tris buffer, apoA-I remained soluble at pH 4 and aggregation into 
insoluble material only occurred in the presence of heparin. Figure 4.8A shows 
the ThT response of apoA-I incubated in Tris buffer at pH 4, in the absence of 
heparin for 10 minutes, and then upon addition of increasing concentrations of 
heparin. In the absence of heparin there was no increase in ThT fluorescence 
over the course of the incubation. However, upon addition of heparin, an instant 
increase in ThT was observed for all heparin concentrations. The FI intensity was 
dependent on the concentration of heparin, as observed previously in Figure 
4.7B. Again, following the initial increase the ThT intensity continued to increase 
at a similar rate (Figure 4.8C), independent of heparin concentration, until the 























Figure 4.7 (A) ThT fluorescence of apoA-I (7.2 μM) in McIlvaine buffer at pH 4 
with increasing concentrations of heparin, following acidification. (B) FI and FT 
parameters taken from the continual ThT data in A. (C) Rate of increase between 























Figure 4.8 (A) ThT fluorescence of apoA-I (7.2 μM) in Tris buffer at pH 4 
following the addition of increasing concentrations of heparin. (B) FI and FT 
parameters taken from the continual ThT data in A. (C) Rate of increase between 
FI and FT. Data shown is the mean of 3 samples with ± standard error bars. 
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The rate of aggregation was determined by fitting the fluorescence intensity 
between the FI and FT points with the exponential equation 4.2, where k is the 
rate constant, y is the fluorescence intensity, a is the intercept and x is the time in 
minutes. The fittings are shown in Appendix 4.  
 
𝒀 = 𝒂 + 𝒃 ∗ 𝒆𝒙𝒑(−𝒌𝒙)   [4.2] 
Heparin is thought to act as a scaffold for stabilising proteins in a conformation 
that promotes the formation of β-sheet structures (Madine et al., 2013; Iannuzzi 
et al., 2015). In order for this to occur, apoA-I has to bind to heparin. Heparin, the 
structure of which is shown in Figure 1.3, carries a highly negative charge. It is 
assumed that heparin binds ionically to apoA-I, carrying a positive charge on its 
basic residues, when incubated at a pH lower than the PI value of 5.6 for apoA-I, 
hence the increased ThT response only at acidic pH (Figure 4.6).  
The FI enhancement observed in Figures 4.7B and 4.8B following the addition of 
HCl and heparin, respectively, could be modelled using the Hill equation 
(Equation 4.3) and Origin Pro software. Where the fluorescence (V) is 
dependent on the maximum fluorescence (VMax), the concentration of heparin (S), 
the Hill co-efficient (n) and the dissociation constant (KD).  
 
V = VMax [S]n / KD+[S]n [4.3] 
This produced apparent dissociation constants for heparin of 2.6 (±1.1) 
μM and 5.1 (±1.5) μM at pH 4 (Figure 4.9), with a free enthalpy change of -31.8  
kJ/mol and 30.2 kJ/mol, based on the addition of HCl and heparin, respectively. 
This value is the mean of 3 samples. These 2 dissociation constants are similar, 
and suggest a strong affinity of apoA-I for heparin.  
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Figure 4.9 Heparin concentration dependence of apoA-I aggregation, measured 
by ThT fluorescence (FI) and modelled by the Hill equation. FI values were used 
following acidification of apoA-I incubated in the presence of heparin (A) and 
addition of heparin to apoA-I, already incubated at pH 4 (B).  
 134 
ApoA-I was incubated at pH 4 in Tris buffer, with increasing concentrations of 
NaCl salt, prior to the addition of a 2-fold molar excess of heparin. This was in 
order to determine whether NaCl was able to interfere with the ionic interaction 
between heparin and apoA-I.  
A control for apoA-I incubated in the presence of heparin but no NaCl is 
the baseline for this experiment, and any ThT intensity decrease in comparison, 
is suggestive of inhibition of the heparin-mediated aggregation. No decrease in 
fluorescence intensity was observed as a result of increasing the concentration of 
NaCl when added to apoA-I alone, (data not shown) confirming that the presence 
of NaCl does not affect the natural propensity of apoA-I to aggregate.  
However, when apoA-I is incubated with a 2-fold molar excess of heparin, 
a decrease in ThT fluorescence intensity in the presence of NaCl is observed. 
Increasing the concentration of NaCl leads to a further decrease in both the FI 
and FT fluorescence measurements (Figure 4.10). This suggests that NaCl can 
inhibit the pro-amyloidogenic properties heparin exhibits on apoA-I aggregation 
into amyloid-like material. Thus confirming an ionic interaction between heparin 





























Figure 4.10 Effects of salt on heparin induced apoA-I aggregation. (A) ThT 
response of apoA-I (7.2 μM) incubated at pH 4 with increasing concentrations of 
NaCl, following the addition of heparin (14.4 μM). (B) Initial increase in ThT 
upon addition of heparin (FI), and the total increase in ThT fluorescence (FT).  
Data shown is the mean of 3 samples with ± standard error bars.  
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4.3.4. Effects of concentration of apoA-I aggregation 
ApoA-I was incubated at pH 4 at increasing concentrations (7.2, 18 and 36 μM), 
alone and in the presence of a two-fold molar excess of heparin for 3 days. After 
this time, end point ThT measurements were taken. All three concentrations gave 
rise to an increase in ThT fluorescence (Figure 4.11), with higher concentrations 
of protein leading to higher fluorescence intensity, with an enhancement of 
fluorescence in the presence of heparin at each of the three concentrations. This 
shows that the formation of ThT reactive material increased with protein 
concentration. Following removal of the insoluble material by centrifugation, the 
FS value of all 3 concentrations decreased to levels associated with no amyloid-
like material. This shows that the soluble ThT reactive element remains small 









Figure 4.11 ThT fluorescence of apoA-I at 0.2, 0.5 and 1 mg/ml (7.2, 18 and 36 
μM) in the absence and presence heparin, following acidification to pH 4. Data 
shown is the mean of 3 samples with ± standard error bars. 
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4.3.5. Ability of apoA-I mutants to aggregate 
ApoA-I has many naturally occurring mutants, as outlined in section 2.4.9 of this 
thesis. Mutants corresponding with single amino acid changes were produced, as 
described in section 3.3.2.2, for two reasons: i) in order to compare the 
differences in aggregation propensity between wild type apoA-I and the mutant 
apoA-I G26R species, and ii) to incorporate a unique cysteine residue into the 
apoA-I sequence, in order to attach a fluorescent tag for cellular imaging 
purposes (K96C and R173C). All mutants were subject to end-point ThT analysis 
to determine their propensity to aggregate, compared to the wild type apoA-I. 
 
4.3.5.1. ThT responsiveness of apoA-I G26R 
The naturally occurring G26R Iowa mutant of full-length apoA-I has been found 
deposited as amyloid-like aggregates within arterial plaques. This mutation also 
induces aggregation of the apoA-I (1-83) peptide, the mechanism of which is 
thought to be linked to the destabilisation of the N-terminus of apoA-I (Adachi et 
al., 2012; Adachi et al., 2014).  However, the mutation has been shown to have no 
effect on the ability of full-length apoA-I to form amyloid-like aggregates 
(Raimondi et al., 2011). 
Here, putative apoA-I G26R produces a similar ThT response to the wild 
type protein after 3 days of incubation at pH 4. However, unlike the wild type, the 
G26R mutant gives rise to an enhanced FT value at neutral pH (Figure 4.12 A and 
B). The ThT response of the protein remaining in solution (FS) was minimal, 
following centrifugation. This is consistent with no amyloid formation. This 
confirms that the ThT responsive material is confined to the insoluble material, 
formed at both pH 4 and pH 7.  
 138 
4.3.5.2. ThT responsiveness of apoA-I K96C and R173C 
The putative apoA-I K96C and R173C peptides were produced, in order to allow 
tagging of the novel cysteine residue for cell imaging purposes. Therefore, it was 
preferable that both mutants had similar amyloidogenic properties to the wild 
type apoA-I peptide, allowing direct comparison of their cellular uptake and 
distribution.  
Figures 4.12 C and D show that at pH 7 neither mutant produced a 
significant increase in the FT, consistent with control samples and the absence of 
amyloid-like material.  
At acidic pH, wild type apoA-I is shown to produce an increase in the FT 
value, which is greatly enhanced in the presence of heparin. However, the K96C 
and R173C mutants produce an increase in FT, only in the presence of heparin at 
pH 4. This fluorescence increase is shown to be caused by the insoluble material 
produced during incubation at pH 4 in the presence of heparin, since the FS value 
returns to the baseline level, following its sedimentation.   
 
4.3.5.3. Quantification of apoA-I mutant solubility  
Quantification of the conversion from soluble apoA-I to insoluble material for the 
wild type protein is discussed in section 4.2.1 and 4.3.1. At neutral and basic pH, 
less than 10 % of apoA-I becomes incorporated into insoluble material and 
removed through centrifugation. This percentage increases dramatically at acidic 
pH, with almost 95 % of the protein having been converted into insoluble 
material. This is the case for samples both in the absence and presence of 
heparin.  
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The G26R mutant produces a similar percentage conversion into insoluble 
material at acidic pH to the wild type apoA-I. However, at pH 7, the G26R mutant 
loses ≈ 60 % of its soluble protein, following centrifugation (Figure 4.13 red).  
ApoA-I K96C and R173C mutants produce very similar sedimentation 
data. Neither mutation leads to the conversion of insoluble material at neutral 
pH, consistent with the wild type apoA-I. At pH 4 alone, no insoluble material is 
formed, unlike the wild type apoA-I. Conversion from soluble apoA-I to insoluble 
aggregates only occurs at pH 4 in the presence of heparin (Figure 4.13 blue and 
green). This mirrors the ThT findings for the cysteine mutants, discussed in 
Section 4.3.5.2. 
 
Figure 4.12 End-point ThT fluorescence of apoA-I wild type (A), G26R (B), K96C 




Figure 4.13 Percentage of starting material converted into insoluble material for 
apoA-I wild type (black) G26R (red), K96C (blue) and R173C (green).  
 
4.3.6. Ability of oxidised apoA-I to aggregate  
4.3.6.1. Characterisation of oxidised apoA-I 
ApoA-I was oxidised, following procedures outlined by Chan (2015). After 
incubation with H2O2 and dialysis back into 10 mM phosphate at pH 6, oxidised 
apoA-I produced a white precipitate. As such, dialysis into phosphate buffer at 
pH 7.5 was attempted instead, resulting in a clear protein sample. The oxidised 
product was shown to be slightly heavier than the wild type apoA-I when run on 
an SDS gel (Figure 4.14), consistent with oxidation of at least one of the three 












Figure 4.14 15 % SDS PAGE gel of chemically oxidised apoA-I and untreated, 
wild type apoA-I. 
 
In order to determine the extent at which incubation in hydrogen peroxide 
oxidised the methionine residues of apoA-I, oxidised apoA-I underwent mass 
spectrometry analysis. Oxidation of apoA-I at all three methionine residues 
results in a predicted mass of 27882 Da, compared to the predicted mass of 
27834 Da for the un-oxidised apoA-I. Figure 3.16 indicates a mass for the intact 
un-oxidised apoA-I of 27837 Da, whilst Figure 4.15 shows that oxidised apoA-I 
has an intact mass of 27891 Da, 54 Daltons higher than the un-oxidised apoA-I. 
Oxidation of three methionine residues would result in a mass increase of 48 
Daltons but, given the variance between the detected mass and the predicted 
mass for the un-oxidised apoA-I, the difference of 4 Daltons is deemed negligible. 
As such, the putative oxidised apoA-I is considered oxidised at all three 
methionine residues, as expected following the methods outlined by Chan et al. 
(2015). 
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4.3.6.2 Oxidised apoA-I aggregation 
Oxidation of 3 methionine residues (86, 112, 148) in apoA-I has been shown to 
induce aggregation of apoA-I into amyloid species at pH 6 (Wong et al., 2010; 
Chan et al., 2015). Here, the effect of chemical oxidation of apoA-I on the ability to 
form amyloid-like aggregates will be determined across a more physiologically 
relevant pH range (pH 6–7.5), and used to produce aggregates for structural 
analysis by solid-state NMR.  
Here, Figure 4.16A indicates that at neutral pH, a negligible amount (<10 
%) of oxidised apoA-I becomes converted into insoluble material, consistent with 
the percentage conversion of wild type apoA-I at pH 7. The ThT fluorescence (FT) 
of the oxidised apoA-I at neutral pH also remains negligible and is consistent 
with control samples, suggesting that oxidised apoA-I does not form amyloid-like 
material under these conditions.  
At pH 6, the percentage of apoA-I converted to insoluble material 
increases to roughly 40 %, similar to the wild type protein at this pH. This is 
despite the formation of a large white precipitate upon acidification of oxidised 
apoA-I to pH 6. The formation of a visible precipitate was only seen for the wild 
type protein at pH 4 and 5, where upwards of 90 % of the protein was converted 
into insoluble material.  
Oxidised apoA-I produced a significant increase in ThT fluorescence (FT) 
at pH 6, which was reduced upon centrifugation and removal of the insoluble 
material to FS, consistent with no amyloid-like material. This suggests that the 
amyloid-like material was confined solely to the insoluble material and not the 
remaining soluble oxidised apoA-I.  
 143 
These results suggest that oxidised apoA-I has an increased propensity 





Figure 4.16 Percentage insolubility (A) and ThT fluorescence (B) of oxidised 
apoA-I at pH 7.5 and pH 6. Data shown is the mean of 3 samples with ± standard 
error bars. 
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4.3.7. Ability of apoA-I (46-59) to aggregate  
As mentioned earlier, several groups have reported the amyloidogenic 
properties of peptides comprising the first 90/100 residues from the N-terminus 
of apoA-I (Rosú et al., 2015; Sipe et al., 2012; Mucchiano, Häggqvist, et al., 2001; 
Adachi et al., 2012). In particular, the peptide comprising of residues 46-59 has 
been shown to bind ThT, form fibrils with a typical amyloid morphology, and 
produce an XRD reflection pattern, consistent with the formation of amyloid at 
neutral pH (Wong et al., 2012). Here, the ability of apoA-I (46-59) to seed, and be 
seeded, by full-length apoA-I into amyloid-like aggregates was studied, as well as 
the effect heparin has on apoA-I (46-59) aggregation.  
ThT fluorescence data shown in Figure 4.17, suggests that apoA-I (46-59) 
does not form amyloid-like material at neutral pH, neither in the absence nor the 
presence of heparin. However, at acidic pH, apoA-I (46-59) produces a large 
increase in ThT fluorescence, both in the absence and presence of heparin, but 
not in a similar manner to the full-length apoA-I. Full-length apoA-I undergoes a 
dramatic increase in ThT fluorescence, following acidification, measured as the 
ΔFI parameter. However, apoA-I (46-59) has a much slower increase in ThT 
fluorescence following acidification, which is more common of amyloid-like 
aggregates (Wong et al., 2012).  Wild type apoA-I showed a dramatic 
enhancement in the presence of heparin, whereas no significant difference is 
observed when heparin is incubated with the apoA-I (46-59) peptide. This 













Figure 4.17 ThT fluorescence of apoA-I (46-59) at pH 4 and pH 7 alone, and in 
the presence of heparin, following acidification by addition of concentrated HCl. 
Data shown is the mean of 3 samples. 
 
4.3.7.1. Ability of full-length apoA-I to seed apoA-I (46-59) 
The ability of amyloid aggregates formed by full-length, wild type apoA-I in the 
presence of 2-fold molar excess of heparin, to seed apoA-I (46-59) aggregation 
was studied. At pH 4, apoA-I (46-59) was shown to aggregate spontaneously 
(Figure 4.17), with a less dramatic FI increase compared to full-length apoA-I.  
The incubation of full-length seeds with apoA-I (46-59), prior to 
acidification, results in a similar FI increase upon addition of HCl. However, the 
presence of seeds results in a lower FT intensity (Figure 4.18). This is more 
consistent with the ThT response of full-length apoA-I at pH 4 (Figure 4.5), 
rather than the ThT response of apoA-I (46-59) alone.  
At pH 7, apoA-I (46-59) shows no ThT response when incubated alone, 
but an FI increase following addition of full-length apoA-I seeds. However, this 
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increase in ThT intensity is similar to the ThT response of the full-length apoA-I 
seeds controls (Figure 4.18B). This suggests that full-length seeds cannot 
promote the aggregation of apoA-I (46-59) at neutral pH. However, at acidic pH, 
the seeds affect the ThT response of the aggregates formed. The reduction in ThT 
fluorescence, following the initial increase in Figure 4.18B, could be caused by 













Figure 4.18 ThT fluorescence of apoA-I at pH 4 and 7 in the absence and 
presence of seeds formed from full-length aggregates.  
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4.3.8. Congo red binding ability of apoA-I 
Congo red is an amyloid specific dye that binds selectively to β-sheet structures 
of amyloid, staining the deposited, insoluble material red. Upon visualisation 
under polarised light, a green birefringence is observed, indicating a positive 
result for amyloid (Puchtler et al., 1962; Klunk et al., 1999a; Li et al., 2009).  
ApoA-I, both in the absence and presence of heparin, does not produce 
any aggregated material at pH 7, thus there is no insoluble material to which the 
Congo red dye can bind. This is shown in the images taken with uncrossed 
polarising lenses, where no red material is visible (Figure 4.19). When the 
polarising lens is rotated 90 degrees, a lack of green birefringence confirms 
amyloid is not formed under these conditions.  
Upon acidification of apoA-I to pH 4, both in the absence and presence of 
heparin, apoA-I forms insoluble material (as defined above in section 4.3.1 and 
4.3.3) that binds to the Congo red dye and is visualised as a red deposit with 
uncrossed lenses. Upon cross polarisation of the lenses, the dye produces a 
yellow-green birefringence, confirming the insoluble material is characteristic of 
amyloid.  
This data suggests that, despite a large difference in the ThT response 
produced by aggregates formed in the absence and presence of heparin at pH 4, 






























Figure 4.19 Congo red-stained apoA-I samples at pH 7 and pH 4 in the absence 
and presence of heparin, following incubation for 3 days. Lenses were at 0 and 
90° for the uncrossed and crossed images, respectively.  
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4.3.9. Intrinsic fluorescence of tryptophan residues 
Intrinsic fluorescence studies of apoA-I were carried out to determine whether 
any significant change in the environment surrounding the aromatic residues, in 
particular tryptophan (8, 50, 72 and 108) occurred. A change of environment 
could give insights into a structural rearrangement occurring during the 
aggregation of apoA-I. Solvent-exposed tryptophan residues have a peak 
emission at roughly 355 nm, with slight variance for the specific environment, 
upon excitation at 279 nm. However, tryptophan residues in hydrophobic 
environments, such as those experienced when the residues are buried within 
secondary structural elements, undergo a blue shift in the spectrum and have 
their peak emission centred around 335 nm (Touchette et al., 2010). ApoA-I 
consists of a majority α-helical content in the native structure, and all four of the 
tryptophan residues are located within helical structures, as shown in Figure 











Figure 4.20 (A) Structure of monomeric apoA-I (Δ185-243), highlighting the 
tryptophan residues in the native sequence. Tryptophan fluorescence emission 
spectra for apoA-I samples at pH 7 (B/C) and pH 4 (D/E), after excitation of 
tryptophan residues at 279 nm.  Peak emission wavelengths are highlighted for 
each spectrum. 
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At pH 7, the emission maximum occurs at 337 nm in both the absence and 
presence of heparin (Figure 4.20 B and C), which remains unchanged after 2 
hours incubation, despite a small decrease in intensity. These emission maximum 
are consistent with hydrophobic environments (Touchette et al., 2010). This was 
expected, given that many of the tryptophan residues are located at the 
hydrophobic interface of monomeric apoA-I. 
Incubation of apoA-I at pH 4 in the absence of heparin produces a similar 
spectrum to the pH 7 sample, with a maximum fluorescence of 337, although the 
decrease in fluorescence intensity is considerably higher, consistent with 
increased protein precipitation at acidic pH (Figure 4.20 D). In the presence of 
heparin at pH 4, the fluorescence intensity is reduced considerably compared to 
the other 3 samples, suggesting a faster aggregation and precipitation. A blue 
shift in the spectrum also occurs, resulting in a maximum fluorescence peak of 
334 nm for the fresh solution (Figure 4.20 E). This shift suggests that heparin 
causes a change in the environment surrounding one or more of the tryptophan 
residues, and a blue shift in particular is consistent with movement to a less polar 
environment.   
In summary, heparin appears to induce a different aggregation pathway. 
Oxidation of methionine residues within apoA-I causes a red shift in the peak 
emission wavelength, compared to the native apoA-I at pH 7.4, towards 345 nm 
(Figure 4.21). This red shift suggests that apoA-I undergoes unfolding, following 
oxidation of the three methionine residues, consistent with previous studies that 
oxidation leads to the destabilisation of the native apoA-I structure (Wong et al., 
2010). Upon incubation for 1 hour at pH 6, a slight decrease in signal intensity is 
observed, due to the formation of insoluble material. A blue shift in the 
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spectrum’s peak emission, from 345 nm at pH 7.4 to 340 nm at pH 6, also occurs, 
suggesting that the tryptophan residues become incorporated into more 



























Figure 4.21 Tryptophan fluorescence emission spectra for oxidised apoA-I at pH 
7.4 (A) and pH 6 (B). Peak emission wavelengths are highlighted. 
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4.3.10. Morphology of apoA-I aggregates 
4.3.10.1. Transmission electron microscopy 
Insoluble aggregates produced during incubation of apoA-I at acidic pH were 
visualised via TEM. Figure 4.22 shows negatively-stained apoA-I aggregates 
formed at pH 4 and pH 5, in both the absence and presence of heparin; oxidised 
apoA-I at pH 6 and apoA-I (46-59) at pH 4.  
In the absence of heparin, large quantities of amorphous aggregates are 
deposited at pH 4 and pH 5, which do not resemble amyloid species (Figure 4.22 
A and C). However, in the presence of heparin, apoA-I forms dense networks of 
long, un-branched fibrils that are more characteristic of amyloid, at both pH 4 
and pH 5 (Figure 4.22 B and D).  
Oxidised apoA-I at pH 6 produced long, thin fibrils (Figure 4.22E), 
characteristic of amyloid and consistent with previous TEM images, observed 
under the same conditions (Wong et al., 2010). Large quantities of smaller 
spherical structures also appeared, which could potentially be oligomeric 
species.  
Finally, apoA-I (46-59) incubated at pH 4 also produced fibrils 
characteristic of amyloid species (Figure 4.22 F). 
In summary, aggregates with a highly conserved amyloid morphology are 
only observed following the aggregation of oxidised apoA-I or apoA-I (46-59). 
Although the aggregates formed at pH 4 and pH 5 do not resemble true amyloid 




Figure 4.22 TEM images of apoA-I (36 μM) after 3 days’ incubation at pH 4 
(A/B) and pH 5 (C/D) in the absence (A/C) and presence (B/D) of heparin, 
oxidised apoA-I at pH 6 (E) and apoA-I (46-59) at pH 4 (F).  
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4.3.10.2. Atomic force microscopy  
ApoA-I aggregates formed at pH 4 in the presence of heparin for 3 days were 
loaded onto mica sheets and visualised using AFM. Figure 4.23 shows networks 
of thin, un-branched fibrils are formed, similar to the TEM results. Furthermore, 
AFM allows a height calculation of approximately 5 nm, which is an additional 
characteristic of amyloid fibrils (Serpell et al., 1997). This technique was also 
attempted for apoA-I aggregates formed in the absence of heparin, however, no 
















Figure 4.23 AFM phase (A) and topography (B) images of apoA-I (36 μM) after 
several days’ incubation at pH 4 in the presence of heparin (72 μM). 
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4.3.11 X-ray diffraction 
Samples of insoluble material formed following incubation of apoA-I at pH 4, in 
the absence and presence of heparin, were analysed by X-ray diffraction, in order 
to determine if any reflections consistent with β-sheet spacings were detectable. 
In the absence of heparin, the diffraction pattern of apoA-I suggests that the 
aggregates are amorphous, with no deducible secondary structural content. A 
large reflection at 3.27 Å, does not coincide with β-sheet spacing. Thus, it does 
not suggest that the formation of amyloid occurs under these conditions (Figure 
4.24A and B).  
However, in the presence of heparin, 2 distinct reflections are detected 
with d-spacings of 4.47 Å and 9.7 Å (Figure 4.24C and D). These both coincide 
with the predicted spacings for β-sheet structures, approximately 4.7 Å and 10 Å 
for equatorial and meridional reflections, respectively (Li et al., 2009). These 
reflections coincide with the spacings between the individual β-strands, running 
perpendicular to the fibril axis; and the distance between the multiple β-sheet 
layers, as described in Figure 1.10. Separation of the equatorial and meridional 
reflections was not possible, due to the inability to align the fibrils in the capillary 
tube.  
In summary, despite both the aggregates formed alone and in presence of 
heparin exhibiting a ThT response and binding to Congo red, only the aggregates 
formed in the presence of heparin produce X-ray diffraction reflections, 






Figure 4.24. X-ray diffraction pattern of apoA-I (36 μM), after incubation at pH 4 
in the absence (A and B) and presence (C and D) of heparin for several days. 




4.4. Discussion  
Much of the current literature on apoA-I aggregation in vitro focuses on the first 
90-100 residues of the N-terminus, which become cleaved from the full peptide 
and deposited as amyloid, leading to familial apoA-I amyloidosis (Raimondi et al., 
2011; Girych et al., 2014; Das et al., 2016; Monti et al., 2011; Sipe et al., 2014). 
Studies into the aggregation of full-length apoA-I have determined that 
acidification or oxidation of the protein can induce misfolding, which leads to a 
structural rearrangement, resulting in the formation of insoluble material, with 
many amyloid characteristics (Ramella et al., 2011; Chan et al., 2015; Mucchiano, 
Jonasson, et al., 2001).  
The aim of this chapter of research is to provide a more detailed 
description of the factors that influence apoA-I aggregation, and to identify 
physiologically suitable conditions for promoting the aggregation of full-length 
apoA-I into amyloid species. These conditions will then be used to produce large 
quantities of apoA-I derived amyloid, allowing structural analysis of the insoluble 
material.  
 
4.4.1. Acidic pH induces apoA-I aggregation 
Initial experiments repeated the work by Ramella (2011) and looked at the effect 
of pH on apoA-I aggregation. By incubating apoA-I over a pH range of 4-8 for 3 
days, it was shown that apoA-I readily forms insoluble aggregates at acidic pH, in 
particular, pH 4 and pH 5. This experiment also confirmed that apoA-I was not 
converted into insoluble material at neutral and basic pH, suggesting the protein 
is stable in these conditions.  
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The insoluble material at acidic pH also produced an increase in ThT 
fluorescence at 482 nm. Upon sedimentation of the insoluble protein through 
centrifugation, a large decrease in ThT fluorescence in the supernatant was 
observed. This confirms that the insoluble aggregates were the source of the ThT 
response, and that the majority of the ThT responsive material is retained in the 
insoluble material. At neutral and basic pH, no increase in ThT fluorescence was 
observed, confirming the stability of apoA-I under these conditions. ThT 
fluorescence response was shown to be dependent on protein concentration, 
suggesting a nucleation-based growth mechanism of apoA-I in the absence of 
heparin. The amount of amyloid formed, and thus the ThT response, is a linear 
function of the free monomeric protein available (Cabriolu et al., 2010).  
ApoA-I aggregates formed at pH 4 in the absence of heparin were able to 
bind to Congo red and exhibited a green birefringence upon cross-polarisation, 
suggesting the aggregates are amyloid-like. However, when visualised by TEM, 
large amorphous aggregates became deposited as clumps of non-fibrillar 
material. These aggregates did not produce X-ray diffraction patterns consistent 
with β-sheet structures, although a broad reflection at 3.3 Å may mask any β-
sheet contributions. 
Maximum fluorescence emission of the 4-tryptophan residues in apoA-I at 
337 nm suggests they are located within hydrophobic regions, which is 
consistent with natively folded apoA-I at neutral pH. The reduction in intensity 
results from the high percentage of material that becomes converted into 
insoluble aggregates at pH 4, but the emission peak remains mostly unchanged.    
These findings are physiologically relevant. In normal circulation, where 
the pH of serum is roughly neutral, lipid-free apoA-I avoids aggregation, in order 
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to carry out its role in cholesterol clearance. However, at acidic pH, such as those 
experienced at sites of inflammation or atherosclerotic plaques (Ross, 1999a; 
Thijssen and Mensink, 2005), the protein readily undergoes aggregation into 
insoluble material. This is significant, since it is at atherosclerotic sites where 
full-length apoA-I has been found deposited as amyloid. This material gives rise 
to a ThT response and a green birefringence when stained with Congo red, both 
of which are suggestive of amyloid. However, these aggregates lack many of the 
amyloid hallmarks, including their morphology, XRD patterns and the 
fluorescence of tryptophan residues suggesting the environments remain similar 
to the natively folded apoA-I.  
 
4.4.2. Heparin induced apoA-I aggregation 
Glycosaminoglycans, as described in section 1.1.5, have been shown to associate 
with amyloid deposits (Cohlberg et al., 2002; Iannuzzi et al., 2015), and are 
involved in promoting amyloidosis in protein species with no natural propensity 
to form amyloid (Madine et al., 2013). Sedimentation experiments deduced that 
the percentage of starting material that was converted into insoluble material 
remained the same in both the absence and presence of heparin, across the 
entire pH range studied.  
However, the insoluble material formed at acidic pH in the presence of 
heparin showed enhanced ThT fluorescence, compared to the material formed in 
its absence. The enhanced ThT response in the presence of heparin is not 
observed at neutral and basic pH, suggesting that the binding of heparin to apoA-
I is dependent on ionic interactions (Stewart et al., 2016). Heparin only induces 
an aggregation response in apoA-I when incubated at acidic pH, with a dramatic 
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enhancement in ThT fluorescence at pH 4 and pH 5. These two pH conditions are 
both below the isoelectric point of apoA-I, which was predicted by the online 
Expasy server to be 5.4 (Gasteiger et al., 2003). At pH 4 and 5, apoA-I carries net 
positive charges, which can bind ionically to the heparin molecule. The addition 
of sodium chloride systematically reduces the ThT enhancement caused by the 
introduction of heparin, further confirming the interaction between apoA-I and 
heparin is electrostatic.  
ApoA-I was shown to bind heparin with micromolar affinity, and induce 
aggregation in a concentration-dependent manner. The addition of increasing 
concentrations of heparin led to a rapid increase in ThT fluorescence, which was 
dependent on the heparin concentration and not consistent with a nucleation-
dependent mechanism. This initial increase was followed by a slower increase in 
ThT fluorescence, the rate of which was independent of heparin concentration, 
consistent with a secondary nucleation event. 
ApoA-I aggregates formed in the presence of heparin bind to Congo red, 
and exhibit a green birefringence upon cross-polarisation. Unlike the insoluble 
aggregates formed from apoA-I alone, apoA-I aggregates formed in the presence 
of heparin also have a morphology more consistent with amyloid-like fibrils, and 
produce XRD patterns that suggest the presence of β-sheet structures.  Intrinsic 
fluorescence spectra suggest that aggregation of apoA-I in the presence of 
heparin results in a less polar environment surrounding the tryptophan residues, 
consistent with amyloid formation.  
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4.4.3. Oxidation induced apoA-I aggregation 
Oxidation of methionine residues in apoA-I has been shown to promote 
aggregation of the apoA-I at pH 6 (Wong et al., 2010). Here, upon acidification to 
pH 6, the oxidised apoA-I produced large quantities of white precipitate. This 
insoluble material gave rise to a ThT response, a morphology consistent with 
both amyloid fibrils and oligomeric species, and a blue shift in the fluorescence 
maximum of tryptophan residues. This blue shift suggests the conversion to a 
less polar structure, consistent with amyloid formation. This data suggests that 
oxidised apoA-I is more susceptible to amyloidosis than un-oxidised apoA-I.  
 
4.4.4. Aggregation of apoA-I mutants 
ThT fluorescence and the percentage insolubility of mutant apoA-I species were 
used to determine the aggregation propensity of apoA-I mutants, compared to 
wild type apoA-I. The G26R mutant was shown to have similar propensity to 
aggregate as the wild type at acidic pH but unlike the wild type, G26R had an 
increased ThT fluorescence and percentage insolubility at neutral pH. Both of the 
cysteine mutants, the K96C and R173C, showed no increased propensity to 
aggregate when compared to the wild type apoA-I. This makes them both 
suitable candidates for fluorescent tagging, in order to study cellular 
internalisation and distribution of apoA-I models. The apoA-I (46-59) peptide 
was monitored, via ThT and sedimentation experiments, in order to determine 
suitable conditions to allow structural comparisons to the wild type, full-length 
apoA-I. ApoA-I (46-59) at pH 4 in the absence of heparin produced a ThT 
response and morphology consisting of amyloid fibrils. However, the addition of 
heparin showed no increase in ThT fluorescence, unlike the full-length peptide.  
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4.4.5. Conclusion  
In conclusion, the data presented here confirm that the acidification of apoA-I 
induces at least a partial conversion from the native structure of apoA-I into 
insoluble aggregates that, despite giving rise to a ThT response and Congo red 
birefringence, lack many of the hallmarks of amyloid.  
However, upon inclusion of heparin, more ordered aggregates are formed 
with an enhanced ThT response. These aggregates produce a birefringence when 
stained with Congo red, have a more fibrillar morphology, and produce an X-ray 
diffraction pattern, suggestive of β-sheet structures. Intrinsic fluorescence 
suggests a difference in the aggregation mechanism of apoA-I in the presence of 
heparin, resulting in a more amyloid-like structure.  
Oxidation of apoA-I gives rise to insoluble aggregates that match all of the 
amyloid characteristics of the apoA-I aggregates formed at pH 4 in the presence 
of heparin, but produce fibrils with a typical amyloid morphology, including 
potential oligomeric species.  
Work in Chapter 5 will look into whether the inclusion of heparin or 
oxidiation of apoA-I results in a structural difference between the insoluble 
aggregates, compared to apoA-I alone. The conditions determined here that will 
be taken forward for the structural analysis of apoA-I include: a concentration of 
36 μM wherever possible, an apoA-I: heparin molar ratio of 1:2 and incubation at 
pH 4 with agitation for 3 days.   
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5. Structural analysis of apoA-I aggregates 
5.1. Introduction 
Characterising the structure of apoA-I derived amyloid is essential for 
understanding the mechanism of apoA-I aggregation. With this knowledge, 
advancing the design of apoA-I amyloid inhibitors is possible, as is determining 
whether any intermediate aggregates are formed during the aggregation 
mechanism that could be cytotoxic (Amijee et al., 2012; Walsh et al., 2002; 
Uversky, 2010). Given the insolubility of amyloid, and the rate at which apoA-I 
readily aggregates into insoluble material upon acidification, the aggregates 
prove difficult to study using standard structural techniques. X-ray 
crystallographic analysis of amyloid fibrils has proved difficult, due to the large 
and heterogeneous nature of the aggregates (Toyama and Weissman, 2011).  
Eisenberg’s group were able to produce micro-crystals, 6-7 residues in length, for 
the yeast Sup35 amyloidogenic protein, and acquire adequate diffraction data 
(Nelson et al., 2005).  However, the limitations on the size of these amyloid 
fragments, and the inability of all peptides to form micro-crystals still restrict the 
use of X-ray crystallography (Toyama and Weissman, 2011). Studying amyloid is 
also not amenable to solution NMR and therefore, solid-state NMR is required.  
Currently, there are no structural models for apoA-I derived amyloid 
deposited within the protein databank. In fact, there are only full-length models 
for the most studied amyloidogenic proteins, in particular: Aβ (Tycko, 2011; 
Madine et al., 2012; Paravastu et al., 2009; Paravastu et al., 2008; Serpell, Blake, 
et al., 2000), α–synuclein (Tuttle et al., 2016), IAPP (Soriaga et al., 2015) and AL 
amyloidosis (Brumshtein et al., 2015; Brumshtein et al., 2014).   
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Many studies get around the challenges in studying the structure of amyloid by 
utilising model systems consisting of peptide regions from within the full-length 
amyloid-associated protein (Nelson et al., 2005; Petrlova et al., 2014; Serpell, 
Blake, et al., 2000; Gursky et al., 2012; Borhani et al., 1997). However, the 
structure of the aggregated material is very sensitive to the protein sequence, 
thus, truncation or mutation of amino acid residues can dramatically change the 
overall structure of the amyloid deposited, compared to the parent protein. For 
example, full-length Aβ (1-40), forms parallel β-sheets (Petkova et al., 2002), 
whilst fragments of the peptide, including the 16-22 and 11-25 residues, form 
anti-parallel β-sheets (Petkova et al., 2004).   
 
5.1.1. Structure of natively folded apoA-I 
As described in section 2.4.3, and shown in Figure 2.4 of this thesis, only 4 
structural models for soluble, native apoA-I exist in the protein databank, all of 
which are derived from soluble apoA-I. The 3 models corresponding to the most 
complete protein are of (i) lipid-free apoA-I (Δ185-234) at 2.2 Å resolution, 
deduced by X-ray crystallography (Mei and Atkinson, 2011); (ii) the full-length, 
lipid-bound apoA-I at a much lower resolution, using small angle neutron 
scattering (Wu et al., 2009); and (iii) lipid-bound apoA-I (44-243) at a resolution 
of 4 Å, using X-ray crystallography (Borhani et al., 1997). Crucially, there are no 
structural details for the insoluble apoA-I aggregates. Here, structural analysis 
via circular dichroism and nuclear magnetic resonance will be acquired for the 
lipid-free apoA-I aggregated material. As such, all future comparisons to the 
native apoA-I will refer to the PDB 3R2P (Mei and Atkinson, 2011) lipid-free 
structure.     
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5.1.2. Secondary structural content 
The structure of apoA-I (Δ185-243), described in section 2.4.4.1, contains 
approximately 60-80 % α-helical content (Mei and Atkinson, 2011), and is in 
good agreement with other studies of the full-length apoA-I (Chetty et al., 2009). 
The remaining peptide, such as the region corresponding to residues 44-55, 
consists of predominantly β-sheet structures (Mei and Atkinson, 2011; Gursky et 
al., 2012). The C-terminus of apoA-I is involved in lipid binding and, as such, it 
possesses a large degree of flexibility. In the absence of lipids, this region is 
disordered. However, upon interaction with lipids or other apoA-I molecules, it 
reforms into an amphipathic helix, as shown in Figure 5.1 (Chetty et al., 2009). 
This structural change was determined by site-directed, spin-label electron 











Figure 5.1 Structural conversion of the apoA-I C-terminus (residues 163-243), 
from a lipid-free conformation (green), to the extended helices, observed in the 
presence of lipids (yellow). Image taken from Oda et al. (Oda et al., 2003) 
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5.1.3. Techniques used to study the structure of apoA-I 
Here, circular dichroism and, for the first time, SSNMR were used to determine 
the structural changes underlying apoA-I aggregation. Circular dichroism 
techniques can be used for solution and solid-states (thin film CD), with solution 
CD having been used to study many amyloidogenic proteins (Bieschke et al., 
2010; Huang et al., 2000; Raimondi et al., 2011; McLaurin et al., 1998; Srinivasan 
et al., 2003; Jiménez et al., 2002; Chiti and Dobson, 2006).  
 
5.1.3.1. Circular Dichroism 
Circular dichroism (CD) is a powerful spectroscopic technique that can be used to 
rapidly determine the local secondary structure of proteins. Circular dichroism 
measures the difference in absorption of left and right handed circularly 
polarised light by molecules with chiral centres, as a function of wavelength (Li et 
al., 2009; Fasman, 1996). A beam of light contains electric and magnetic fields, 
and upon polarisation, the electric field (E) will oscillate in a single plane. This 
wave can be visualised as the combination of two vectors of equal length, but 90 ° 
out of phase (Figure 5.2A). These vectors trace out circles, one of which that 
rotates clockwise (ER) and the other counter-clockwise (EL), oscillating about the 
direction of propagation (Z). The X and Y components of right-handed circular 
polarised light are shown in Figure 5.2B, and the vector sums in Figure 5.2C. 







Figure 5.2 Description of right hand circularly polarised light. (A) The electric 
vectors, 90 ° out of phase, along the direction of light propagation (z), (B) the X 
and Y components of the electric vectors, (C) resulting sum of the vectors, 
highlighting a circular motion when viewed along the Z axis, and (D) right-
handed circularly polarised light oscillating along the Z axis. Figure taken from 
Fasman (1996). 
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When asymmetric molecules with chiral centres interact with light, the 
chromophores in the molecule will absorb the left and right-handed circularly 
polarised light to different extents. In proteins, the CD active chromophores 
include the amide group in the peptide backbone, and the phenyl, phenolic and 
indole groups of the Phe, Tyr and Trp aromatic amino acid side chains, 
respectively (Fasman, 1996). The UV-CD spectra of proteins are dominated by 
contributions from the π to π* and n to π* electron transitions of the amide group 
in the peptide backbone (Figure 5.3). These transitions, and thus the spectra, are 
influenced by the geometry of the protein backbone, in particular the ϕ and ψ 
angles, which is highly sensitive to secondary structure (Whitmore and Wallace, 
2008). Due to the well-defined ϕ32 and ψ angles in α-helical conformations, 
compared to the variability in β-sheet structures, structural analysis by circular 
dichroic is much more accurate at determining helical contributions (Whitmore 
and Wallace, 2008).  However, CD spectra reflect the overall secondary structure 









Figure 5.3 Structure of the peptide bonds with the orientation of the transition 
dipoles π to π* and n to π*.  
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For example, α-helical proteins produce a spectrum with negative bands at 222 
nm, from the nπ transition; 206 nm, from the parallel ππ* transition; and a 
positive band at 190 nm from the perpendicular excitation ππ* transition, as 
shown in Figure 5.4 (Holzwarth and Doty, 1965). β-sheet structures produce 
negative bands at 218 nm and positive bands at 195 nm (Greenfield, 2007). CD 
values can be de-convoluted and fitted using algorithms based on libraries of 
proteins with known secondary structure to deduce the protein’s secondary 
structural content (Whitmore and Wallace, 2008). However, the disadvantages to 
this technique include its inability to distinguish between a solution of 
homogenous proteins containing multiple secondary structure elements, and a 
heterogeneous sample consisting of some proteins containing just one secondary 












Figure 5.4 Far UV circular dichroism spectra of the main protein secondary 
structural elements. 
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5.1.4. Nuclear magnetic resonance 
NMR is a powerful technique that can be utilised to study the structure and 
dynamics of proteins and has been since the late 1950’s (Wuthrich, 2001; Kay, 
2005), following its discovery in 1946 (Mlynarik, 2016). To date, 11,732 protein 
structures have been deposited in the Protein Data Bank determined by NMR, 
whilst only 99 have been produced through solid-state NMR techniques, with 
over 10 % of these structures based on the Aβ peptide (Berman et al., 2000). 
 
5.1.4.1 Nuclear magnetic resonance theory 
Nuclear magnetic resonance is a phenomenon in which the nuclei of atoms that 
contain a non-zero spin and a magnetic moment (μ0), for example 1H, 13C and 15N, 
interact with a static magnetic field (Bo). In the absence of a magnetic field, the 
nuclei’s magnetic moments are randomly orientated, with equal energies and no 
net magnetisation. Upon its application, the B0 magnetic field orientates the 
nuclear spins, which acts as a magnetic dipole moment, into either a low or high-
energy state, with respect to the direction of B0. This process is called the Zeeman 
effect (Mlynarik, 2016; Luca et al., 2003; Veeman, 1997; Hore, 1995).   
For this introduction, the high-energy, antiparallel state will be referred to as β 
and the low-energy, parallel state as α. The difference between these 2 energy 
states (ΔE) is dependent on the strength of B0 (as described in Figure 5.5), the 
gyromagnetic value of the nucleus of interest (γ) and Planck’s constant (h/2π), 
which is outlined in Equation 5.1 (Hore, 1995). At equilibrium, more nuclei align 
with B0 in the low-energy state, than oppose B0 in the high-energy state.  
 
𝜟𝑬 =  𝒉𝜸𝑩𝟎           [5.1] 
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Figure 5.5 Schematic detailing the orientations of a nuclei’s magnetic moment 
upon interaction with a magnetic field (B0), in either the high (β) or low (α) 
energy state, giving rise to an energy difference (ΔE).   
 
The population of nuclei in the high and low energy states is temperature-
dependent, and thus, can be calculated by the Boltzmann distribution in 
Equation 5.2. In this equation, Nα and Nβ refer to the population of nuclei in the 
low and high-energy states, respectively; kB is Boltzmann constant (1.3805 x10-23 











The net magnetisation difference observed between the high and low energy 
states is negligible, compared to the perpendicular B0 strength, thus it cannot 
accurately be measured. Therefore, the orientation of the net magnetisation is 
transferred to a transverse plane by addition of a second, pulsed magnetic field 
B1 at radiofrequency and perpendicular to the B0 field, at 90 °. This results in the 
net magnetisation shifting away from the B0 direction towards the B1 (Figure 
5.6), allowing detection (Mlynarik, 2016).  
If the B1 magnetic field is at a frequency that matches the ΔE of the target 
nuclei, referred to as the Larmor frequency, the nucleus absorbs the energy. This 
energy causes a perturbation in the orientation of the nuclear spin, causing re-
alignment, with respect to the direction of B0 (Rabi et al., 1938; Becker, 1993; 
Cavanagh et al., 1995; Becker, 1999; Bothwell and Griffin, 2011; Veeman, 1997).  
 
Figure 5.6 Net magnetisation of the nuclei’s magnetic moments in (A) the B0 
magnetic field, along the Z axis, and (B) the B0 and B1 magnetic fields 
perpendicular to each other, resulting in a transfer of the net magnetisation away 
from the Z axis.   
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5.1.4.2 Relaxation times 
The relaxation time of atoms in NMR experiments is described by two factors. 
The longitudinal relaxation (T1), is the time required for the populations of the 
two nuclei spins to return to equilibrium, and has the rate constant R1=(1/T1). 
The transverse relaxation (T2), refers to the loss of phase coherence from the 
nuclei, and is the time taken for the net magnetisation to restore back to the 
original orientation, parallel to B0, following the pulsed B1. T2 and has the rate 
constant R2=(1/T2). T2 is usually smaller than T1 (Mlynarik, 2016). The rate at 
which repeated NMR scans can be obtained is dependent on the T1 time (Wink, 
1989; Cavanagh et al., 1995).    
 
5.1.4.3 Chemical shift 
The location of a nucleus with a molecule alters the magnetic field strength 
observed (B0), and therefore, the size of the ΔE and Larmor frequency. These 
changes are referred to as the chemical shift (σ), a standardised unit described in 
parts per million (ppm), and calculated using Equation 5.3. This equation is 
based on the Larmor frequency of the nucleus of interest (ϖ) and the Larmor 
frequency of a standard nucleus (ϖref), both measured in Hz. For 1H NMR this 
standard is a proton in tetramethylsilane (TMS), which is given a chemical shift 





) ×106  [5.3] 
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5.1.4.4 Chemical shielding  
The biggest contributor to changes in chemical shift come from electron 
shielding. The observed nuclei are surrounded by electrons, each of which 
possesses their own small magnetic moment. These magnetic moments align in 
an orientation against the external magnetic field (B0) direction. This leads to a 
net loss in magnetisation observed at the nucleus, resulting in a smaller Larmor 
frequency. Equation 5.4 shows how BLocal (the effect of electron shielding) 
decreases the B0, resulting in Bob, the observed magnetic field.  
 
𝑩𝑶𝒃𝒔𝒆𝒓𝒗𝒆𝒅 = 𝑩𝑨𝒑𝒑𝒍𝒊𝒆𝒅 − 𝑩𝑳𝒐𝒄𝒂𝒍   [5.4] 
 
The electron shielding of nuclei varies dramatically (Hz scale), depending on the 
specific environment of the nucleus (Cavanagh et al., 1995; Mlynarik, 2016). This 
is why TMS is used as the standard for both 1H and 13C NMR spectroscopy 
(Figure 5.7), the highly electron-donating silicon means that both the 1H and 13C 
nuclei are fully shielded (Hoffman, 2006; Mlynarik, 2016). Any reduction in 
electron shielding caused by the attachment of target nuclei to electron 
withdrawing groups results in a downfield shift of the chemical shift, to higher 





Figure 5.7 Chemical structure of TMS, highlighting the electron donating silicon 
that ensures full electron shielding of the adjoining carbon atoms.  
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5.1.4.5 Spin-spin (J) coupling 
Nuclei of the same atom experiencing the same environment are referred to as 
equivalent, and will have the same chemical shift. Non-equivalent nuclei can 
interfere with the chemical shift of other nuclei by exerting an influence, both 
positive and negative, on the strength of the magnetic field observed (Bob) by the 
nuclei of interest (Fukui, 1999; Becker, 1999; Bothwell and Griffin, 2011). This is 
called J coupling and effects nuclei within 3 bond lengths. J coupling leads to 
“splitting” of the NMR peaks by the n+1 rule, where n is the number of 
neighbouring nuclei (Cavanagh et al., 1995; Foster et al., 2007; Mlynarik, 2016), 
as demonstrated by the schematic in Figure 5.8. This coupling is independent of 
the orientation of the nucleus (Veeman, 1997). Splitting by spin-spin coupling 
can be used to assign NMR signals of similar nuclei, such as multiple CH3 groups. 
 
 
Figure 5.8 (A) Structure of propan-2-ol, highlighting the CH3 protons of interest 
(blue) and (B) the energy states possible from splitting of the CH3 environment 
by the hydrogen on the adjacent carbon. (C) The doublet peak in the CH3 region 





5.1.4.6 Dipolar coupling  
J coupling requires the two interacting nuclei to be connected via chemical 
bonds. However, dipole-dipole interactions occur through space, and their 
strength is related to the distance (r) between 2 nuclei (I and S) cubed, and the 
angle of interaction (θ), as shown in Figure 5.9. The limit of dipole interactions is 
approximately 10 Å. The relationship between the strength of the dipole 
coupling, the distance and the angle are given in Equation 5.5. Here, μ0 is the 





















Figure 5.9 Dipolar coupling between two nuclei, I and S each with their own 
gyromagnetic value (γ) and a distance (r) of up to 10 Å.   
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Therefore, these couplings can be influenced by the tertiary or quaternary 
structure of a protein. Dipole-dipole interactions are caused by the magnetic 
effect of one nucleus influencing the observed magnetic field on a neighbouring 
nucleus; this can be the same nucleus (homonuclear) or a different nucleus 
(heteronuclear). These interactions are averaged out in solution-state NMR via 
Brownian tumbling. However, in solid-state NMR, these anisotropic dipolar 
interactions cause increased breath of peaks and lead to lower resolution spectra 
(Foster et al., 2007; Becker, 1999; Veeman, 1997).  
 
5.1.4.7 Solution and solid-state NMR 
In solution-state NMR, the natural Brownian tumbling of molecules within the 
solution averages out the anisotropy of dipole and chemical shielding 
interactions, leading to a well resolved spectrum with narrow peaks. In SSNMR, 
the fixed orientations of each molecule leads to orientationally distributed 
chemical structures, which produce broad peaks on the spectrum (Foster et al., 
2007; Pines et al., 1973; Veeman, 1997), as shown in Figure 5.10. By utilising a 
combination of ultrahigh magnetic fields, magic angle spinning, proton 
decoupling and cross-polarisation techniques, high resolution solid-state spectra 
can be achieved that allow assignment of individual residues and determination 
of protein structure (Luca et al., 2003). The effect of each of these techniques will 







Figure 5.10 (A) Solution 31P NMR and (B) solid-state 31P CP MAS SSNMR spectra 
of DPPBA-truncated gold nanoparticles. Image taken from Marbella et al. (2016). 
 
5.1.4.8 Magic angle spinning 
Increased line width is a result of the inability of solid samples to tumble freely, 
leading to anisotropic dipole-dipole interactions and chemical shifts. Only the 
spin-spin interactions (J couplings) are consistent between solution and solid-
state NMR, since these are not dependent on the nuclei’s orientation. Equation 
5.5 indicates the angular dependence on the Hamiltonian equation, with the 
dipole-dipole interaction proportional to (3cos2θ-1). In solid-state experiments, 
the orientation of the nuclei, and thus the angle between two interacting dipoles 
(θ), is not consistent. However, when the sample is spun at an angle of 54.7 °, the 
angular term is removed (Bothwell and Griffin, 2011; Tycko, 2006). 
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Under these conditions, removal of the anisotropic chemical shifts and dipole-
dipole interactions leads to a narrow spectrum, as shown in Figure 5.11 















Figure 5.11 13C SSNMR spectrum of L-valine powder with increasing frequencies 
of MAS spinning. Image taken from Tycko (2006).  
 
5.1.4.9 Cross-polarisation  
Cross-polarisation (CP) involves transferring polarisation from nuclei with a high 
gyromagnetic ratio, such as hydrogen, to nuclei with a low ratio, such as 13C and 
15N. This technique is often used to increase the relatively low sensitivity of 13C 
and 15N signals in proteins (Levitt et al., 1986; Kolodziejski and Klinowski, 2002; 
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Morris, 1980).  In order for this to occur, the system has to adhere to the 
Hartmann-Hahn principle, outlined in Equation 5.6, where γ and B1 are the 
gyromagnetic ratio and magnetic field strength of the abundant I nucleus, usually 
1H and the less sensitive S nucleus, such as 13C, respectively.  
 
  𝛾𝐼𝐵1𝐼 = 𝛾𝑆𝐵1𝑆         [5.6] 
The 1H magnetisation is orientated by an electromagnetic field at its Larmor 
frequency. The 13C or 15N resonance is obtained at the same time with a second 
electromagnetic field. As long as the 2 separate nuclei have the same Larmor 
frequency, a cross-relaxation and transfer of magnetisation will occur, from 1H to 
13C or 15N (Hartmann and Hahn, 1962). In the case of 13C, the signal is enhanced 
up to 4 fold, as shown in Figure 5.12. The magnetisation grows, based on the CP 
rate (THC), which is dependent on the number of protons (Kolodziejski and 
Klinowski, 2002) and the distance between two nuclei. After reaching a 
maximum, the magnetisation decays, based on the I spin T1 relaxation time (Fyfe 
et al., 2005). This allows increased acquisition of the spectra, since the T1 
relaxation time is dependent on the pulsed excitation of the proton, rather than 
the carbon nucleus. The pulse sequence for a basic Hartmann-Hahn cross-
polarisation experiment is shown in Figure 5.13. The net magnetisation of the 
proton nucleus is shifted from the Z plane into the XY transverse plane by 
addition of a pulse at 90 °. Simultaneous spin locking pulses (B1I and B1S) are 
applied at, or close to, the resonance frequency of both the I and S nuclei, 
satisfying the Hartmann-Hahn condition. During this period (the contact time) 
the polarisation transfers from the I to the S nucleus. The B1S field is switched off, 
allowing its free induction decay (Kolodziejski and Klinowski, 2002).  
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Figure 5.12 Magnetisation on the 13C grows, based on the CP rate (THC), to a 
maximum contact time, before decaying, which is dependent on TI1, not the TS1. 
 
 
Figure 5.13 Cross-polarisation pulse sequence. The net magnetisation of the 
abundant nuclei (I) is shifted into the transverse plane by an initial magnetic field 
at 90 °. B1I and B1S, which satisfy the Hardmann-Hahn principle, are applied 
simultaneously, producing a contact time (t) where polarisation can cross from 
the I nucleus to the more sensitive S nucleus. (Kolodziejski and Klinowski, 2002). 
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5.1.4.10 INEPT polarisation transfer 
Cross-polarisation, as mentioned above, is utilised in the majority of protein solid 
state MAS NMR experiments, in order to increase the signal detectable from the 
13C and 15N nuclei. However, this technique requires heteronuclear dipolar 
couplings in order to transfer the cross-polarisation.  These dipole interactions 
are averaged out by Brownian tumbling in soluble or dynamic protein regions, 
rendering this technique useful only in static systems (Zhang et al., 2016).  
Insensitive nuclei enhanced by polarisation transfer (INEPT) uses a different 
pulse sequence in order to transfer the magnetisation through J couplings, rather 
than dipole interactions, thus allowing analysis of dynamic systems (Zhang et al., 
2016; Nowacka et al., 2013). The J couplings rely on bound 1H and 13C nuclei, 
meaning only signals from protonated carbons are detected.  
 
5.1.4.11 Combined CP and INEPT NMR analysis 
Depending on the type of SSNMR experiment that is conducted, information can 
be gathered on the dynamics of a protein. Direct polarisation experiments allow 
observation of signals, regardless of whether the molecule is in a solid or mobile 
phase. Cross-polarisation is reliant on 1H-X dipole interactions that become 
averaged out in a protein’s dynamic regions (Zhang et al., 2016). As such, the CP 
spectra only gives rise to chemical shift intensities from regions of the protein 
that remain in a static state. Conversely, INEPT spectra record chemical shifts of 
nuclei from only mobile regions (Zhang et al., 2016; Sackewitz et al., 2008; Heise 
et al., 2005). By comparing all three of these spectra, the DP, CP and INEPT, it is 
possible to determine global changes in the secondary structure of proteins, and 
establish whether these structural changes cause a change in dynamics. 
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The combined use of CP and INEPT NMR spectra to establish amyloid mobility 
was utilised by Debelouchina et al. (2011) on the study of β2-microglobulin. 
Comparison of amyloidogenic aggregates formed at two pH conditions 
determined different morphologies, not only in the β-sheet content but also in 
the aggregate’s structural mobility. INEPT NMR experiments of β2-microglobulin 
have also been utilised in the analysis of the SUP35 amyloid aggregates.  INEPT 
spectra identified a rigid, amyloid core, referred to as the M domain, formed by 2 
β-strands in the sequence. These regions were detected and assignable on the 
INEPT spectra, whereas the remaining regions of the protein did not, suggesting 
that these regions show increased mobility (Luckgei et al., 2014).  
 
5.1.4.12 Multi-dimensional NMR 
For small molecules, the chemical shift and splitting patterns of peaks should be 
sufficient to identify the chemical group to which they belong. However, due to 
overlapping signals and small differences in chemical shift values, identification 
of individual peaks is often difficult for larger systems, such as proteins. Instead, 
multi-dimensional NMR can be used to detect the nuclei from more than one 
element in an experiment. This allows deduction, for example, of 1H nuclei 
connected to 13C nuclei, via heteronuclear pulsed experiments. These 
experiments are essential for the structural analysis of proteins, where large 
number of resonances, all in close proximity, cause extensive overlap. Protein 
backbones contain amide bonds, meaning that a combination of carbon, nitrogen 
and hydrogen nuclei can all be probed, including simultaneously in 3D NMR 
experiments (Bothwell and Griffin, 2011; Wuthrick, 1990). 
Mixing techniques such as dipole assisted rotational resonance (DARR) 
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allows the recoupling of long-range dipolar interactions. Magnetisation is 
transferred from the 1H (I) to the 13C (S1) nuclei. This 13C (S1) can then transfer 
the magnetisation to other 13C nuclei (S2), which are close in space and have 
overlapping spinning sidebands (Takegoshi et al., 2001). This mechanism of 
transfer requires S1 and S2 to be dipolar coupled.  
 
5.1.5. Aims 
This chapter describes the structural analysis of native-lyophilised, and 
aggregated apoA-I, formed under conditions determined in Chapter 4. A 
mechanism for apoA-I aggregation has already been proposed by Das et al. 
(2016), based on the crystal structure of apoA-I. However, there is currently no 
structure for apoA-I amyloid. Information on the structure of the aggregated 
material, deduced by NMR, could either confirm this theory, or suggest 
refinements. In Chapter 4 it was shown that apoA-I is stable at pH 7, and that 
acidification to pH 4, or oxidation of the three-methionine residues, leads to its 
rapid conversion into insoluble material. The presence of heparin or oxidation of 
methionine residues on apoA-I enhances the aggregation, and leads to a more 
ordered amyloid morphology. This chapter of study will utilise a combination of 
circular dichroism and, for the first time, solid-state NMR in order to determine 
whether the native apoA-I structure undergoes a conformational change upon 




5.2.1 Circular Dichroism  
5.2.1.1 Stability of apoA-I to UV radiation 
UV stability tests of apoA-I were carried out on a Chirascan plus qCD 
spectrometer (Applied Photophysics) between 200 and 250 nm with a 
bandwidth of 1 nm and a path length of 2 mm. 50 scans of apoA-I and oxidised 
apoA-I (7.2 μM) in McIlvaine buffer at pH 7 were taken. 
 
5.2.1.2 Thermal stability of apoA-I 
The thermal stability of apoA-I and oxidised apoA-I (7.2 μM) in McIlvaine buffer 
at pH 7 was determined on a Chirascan plus qCD machine with a bandwidth of 1 
nm and a 2 mm path length, between 200 and 250 nm, across a temperature 
range of 20 – 90 °C. The temperature was controlled with a Quantum Northwest 
temperature controller, with 1 °C increment. The temperature was maintained 
during the scan acquisition. The thermal denaturation data was analysed using 
the Global 3 Thermal Analysis Software.  
 
5.2.1.3. ApoA-I secondary structure analysis    
Secondary structure of apoA-I was determined by synchrotron radiation circular 
dichroism (CD) using a nitrogen flushed Module X end-station spectrometer at 
B23 Synchrotron Radiation CD Beam line at the Diamond Light Source, 
Oxfordshire UK. ApoA-I (72 μM) at pH 7 and pH 4, in the absence and presence of 
heparin (144 μM), was incubated at 37 °C with agitation. The concentration was 
increased to 72 μM to allow a narrow path length. This reduced the background 
noise resulting from the citrate in the buffer, which absorbs in the far UV region 
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(Miles and Wallace, 2006). Samples were taken at 0, 1, 2 and 5 hour intervals and 
centrifuged at 13,400 rpm, in a bench top centrifuge, to pellet any insoluble 
material. The concentration of the supernatant was measured before loading into 
quartz cuvettes with a path length of 0.2 mm. Circular dichroism experiments 
were performed between 185 and 260 nm, with an increment of 1 nm. The data 
was analysed using CDApps software (Siligardi et al., 2002) and fitting was 
performed using the CONTINLL algorithm with dataset SMP56 between 190 and 
250 nm. The CONTINLL algorithm factors in the sample concentration, the 
protein molecular weight, path length and the mean mass of amino acids (113 
Da), to produce spectra with a Δε scale, the per residue molar absorption unit (M-
1cm-1). 
 
5.2.1.4. Thin film circular dichroism 
Samples of aggregated apoA-I, formed at pH 4 in the absence and presence of 
heparin, were deposited on Suprasil type quartz plates and dried under a stream 
of nitrogen at 23 °C to form a thin film. CD spectra were acquired between 180 
and 260 nm using an integration time of 1 second and a bandwidth of 1.2 nm on a 
nitrogen flushed module B end-station spectrometer at the B23 Synchrotron 
radiation CD beam line at Diamond Light Source, Oxfordshire UK.  
 
5.2.2. Preparation of samples for solid-state NMR 
Uniformly 13C and 15N isotopically labeled apoA-I was incubated at 36 μM, alone 
and in the presence of 72 μM heparin, at pH 4 for 3 days at 37 °C, with agitation. 
Fibrils were harvested through centrifugation at 12,000 g and the supernatant 
removed. Samples were flash frozen in liquid nitrogen, prior to centrifugation 
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into a zirconium 3.2 mm rotor with a Kel-F cap (Brucker, U.K).  ApoA-I at pH 7 
was 189yophilized in order to produce a solid, apoA-I product. This was then 
centrifuged into a 3.2 mm zirconium NMR rotor.  
 
5.2.2.1 One-dimensional solid-state NMR 
One-dimensional proton-decoupled 15N CP-MAS SSNMR experiments were 
carried out on a Brucker Avance 400 MHz spectrometer, operating at a magnetic 
field of 9.3 Tesla, equipped with a 3.2 mm HXY MAS probe at 25 °C. Hartmann-
Hahn cross-polarisation was achieved at a proton nutation frequency of 78 kHz, a 
2 ms contact time, 100 kHz proton decoupling with SPINAL-64 during the signal 
acquisition, and a recycle delay of 2 ms. Magic angle spinning was controlled at a 
frequency of 8 kHz ± 1 Hz. Each spectrum was the result of accumulating 20,000- 
100,000 transients.  
 
5.2.2.2 Two–dimensional solid-state NMR 
Two-dimensional 13C-13C spectra were recorded at a magnetic field of 9.3 Tesla 
with a 3.2 mm HXY probe operating in double resonance mode, with magic angle 
spinning at 14 kHz and the temperature maintained at 4 °C. Hartmann-Hahn 
cross-polarisation was achieved with a 2 ms contact time and 100 kHz proton 
decoupling with SPINAL-64 applied during signal acquisition. For broadband 
dipolar recoupling, spectra were recorded with a 10 ms mixing time, during 
which the proton nutation frequency was adjusted to the MAS frequency of 14 
kHz to meet the dipolar assisted rotational resonance (DARR) condition. The 
time domain matrix was the result of 400 T1 increments, each averaged over 
between 128 and 320 transients. Phase sensitivity was achieved using the States-
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TPPI method. For selective dipolar recoupling, the proton nutation frequency 
was set to 100 kHz during a mixture time of 1-15 ms and the spinning frequency 
was adjusted to the frequency difference of the nuclei to be coupled. 
 
5.2.2.3 Simulated spectra 
Simulated spectra of the natively folded apoA-I (Δ185-243) were produced in 
order to establish whether the SSNMR spectra acquired here, were consistent 
with the crystal structure deduced by Mei and Atkinson (2011). SHIFTX2 online 
server was used to calculate the chemical shifts from the PDB 3R2P structure. 
This program combines sequence alignment and ensemble machine learning 
methods to calculate the backbone and side chain 1H, 13C and 15N chemical shift 
from a library of 197 proteins, each with a resolution of at least 2.1 Å, deduced by 
X-ray crystallography (Han et al., 2011).  These predicted chemical shift values 
were then used to generate a simulated DARR spectrum, using a C program 
developed by Professor D. Middleton. In order to simplify the spectra, only short-





5.3.1. Circular Dichroism  
Solution circular dichroism was used to determine the secondary structural 
content of apoA-I. Scans were acquired during the early stages of aggregation, 
prior to removal of insoluble material by centrifugation. The time window 
available was dependent on the pH, heparin and oxidation state, as shown in 
Chapter 4. The insoluble material was measured separately, after being dried 
down into a thin film.  
 
5.3.1.1. Stability of native apoA-I 
ApoA-I was incubated at pH 7 and scanned 50 times with single scans of far UV 
synchrotron radiation, in order to monitor the stability of the peptide (Figure 
5.14A). The data show no sign of protein degradation after 50 scans, suggesting 
that apoA-I is stable when exposed to UV radiation, and that changes observed 
following aggregation are caused by changes in structure, not radiation damage.  
A fresh apoA-I solution at pH 7 was then monitored over 7 hours, under 
which conditions the protein was shown previously to be stable and not to 
aggregate (Figure 4.4), in order to monitor any structural changes during this 
time and to determine the secondary structural content of native apoA-I.  
Prior to each measurement over the 7 hour period, apoA-I was incubated 
at 37 °C, with agitation. Insoluble material was removed through centrifugation, 
and the concentrations were measured using a nanodrop. CD scans were then 
acquired. Figure 5.14B shows the spectra remain similar over the 7-hour period, 
apart from a small change in intensity at the 2-hour point, confirming that no 
structural change occurs during incubation at pH 7.  
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Figure 5.14. Far UV synchrotron radiation circular dichroism of apoA-I at pH 7. 
(A) 50 repeated scans of apoA-I (7.2μM) to determine the stability of the peptide 
under UV radiation. The numbers represent the number of repeated exposures to 
UV radiation. (B) ApoA-I (72 μM) monitored over 7 hours.  
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5.3.1.2 Secondary structure of native apoA-I 
The spectrum of apoA-I (72 μM) at pH 7, after 0 and 5 hours incubation, are 
shown in Figure 5.15A, and are consistent with a high degree of α-helical 
structure, shown by the characteristic minima at 208 and 222 nm. Fits calculated 
from the CONTINLL algorithm are also shown, and were used to estimate the 
percentage secondary structure of apoA-I.  
The CD spectra of proteins can be expressed as a combination of the 
individual secondary structural elements. The CONTINLL algorithm is based on 
the CONTIN method, which uses a ridge regression procedure, fitting the 
observed CD spectrum to a large database of reference proteins (Sreerama and 
Woody, 2000; Greenfield, 2007). This results in accurate estimates for proteins 
containing α-helical and β-sheet structures, which is of particular interest in 
amyloidogenic proteins, especially for those that contain a high proportion of 
native α-helices (Greenfield, 2007).  
At pH 7, apoA-I is shown to consist of a majority of α-helical elements, 
which make up 60 % of the overall secondary structure. This value is consistent 
with previous studies (Nagao et al., 2014; Saito et al., 2003; Chetty et al., 2012; 
Chetty et al., 2009; Gursky et al., 2012; Das et al., 2014), which range between 60 
and 80 % of α-helices, when measured with CD. The structure is also shown to 





Figure 5.15 (A) CD spectra of apoA-I (72 μM) at pH 7 after 0 h and 5 h 
incubation, along with fits using the CONTINLL algorithm. 
 
Table 5.1 Secondary structural content of apoA-I at pH 7 after 0, 2 and 5 hours 
incubation in the absence of heparin, calculated using CONTINLL algorithm fits, 
with the standard deviation (SD) shown.  
 
 
Percentage Secondary Structure   
Time α-helix β-sheet Turn Unordered S.D 
0 Hours 65 8 13 14 0.032 
2 Hours 62 9 24 5 0.031 




5.3.1.3. Structural rearrangement of apoA-I upon aggregation 
In order to determine whether any structural rearrangement occurs upon 
aggregation, apoA-I was incubated under the conditions determined in section 
4.3, at pH 4, in the absence and presence of heparin, at 37°C. After 2 hours 
incubation, samples of the aggregating apoA-I were removed and centrifuged to 
remove any insoluble material that could distort the CD signal, through light 
scattering and/or absorption flattening. The concentration was then re-
measured and the sample loaded into quartz cuvettes. The supernatant was 
analysed by SRCD and the molar CD (Δε) calculated based on the new 
concentration.  
The CD spectra for apoA-I alone, and in the presence of heparin at pH 4 
(Figure 5.16, A and B, respectively) are shown after 0 and 2 hours of incubation. 
Fits of these spectra using the CONTINLL method were also performed to deduce 
the percentage secondary structure, and are also shown in Figure 5.16.  
At pH 4, large quantities of apoA-I were precipitated, as described in 
Chapter 4, which after its removal, led to a reduced signal to noise ratio. In the 
absence of heparin, the remaining soluble protein retained a significant 
proportion of the native α-helical content, even after 2 hours (Figure 5.16A). 
However, in the presence of heparin, the intensities of the spectra are reduced, 
even at the initial time point, to the extent that the characteristic α-helical 
minima at 208 and 222 nm, are not distinguishable (Figure 5.16B).  
Upon fitting of the apoA-I spectra, using the CONTINLL algorithm, the data 
was able to be accurately de-convoluted. This facilitated the calculation the 
secondary structural contributions, with a standard deviation of <0.1, apart from 
apoA-I in the presence of heparin, which was too close to the baseline. The fits for 
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the heparinated sample after 0 and 2 hours had a standard deviation of 0.52 and 
0.68, respectively. This means the structural information deduced from this 
fitting must be treated with more caution. The protein concentration of the 
supernatant was so low that the data was not deemed to represent the 

















Figure 5.16. Far UV circular dichorism spectrum for apoA-I (72 μM ) at pH 4 in 
the absence (A) and presence (B) of 144 μM heparin after 0 h and 2 h incubation, 
at 37 °C with agitation. Fits derived using the CONTINLL algorithm are also 
shown for each spectrum as dotted lines.   
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De-convolution of the apoA-I CD spectrum at pH 7, revealed a predominantly α-
helical structure (65 % α-helical, 8% β-sheet, 13% turns and 14% unstructured), 
consistent with the crystal structure of C-terminally truncated apoA-I (Mei and 
Atkinson, 2011).  
At pH 4, apoA-I alone has a slightly lower α-helical content, and an 
increase in unstructured regions (Table 5.2), but is still predominantly helical. 
After incubation for 2 hours, the helical contribution remains similar to the 
native structure, but an increase in β-sheet is observed (Table 5.2).  
However, in the presence of heparin, at pH 4, a dramatic reduction in α-
helical content, and an increase in β-sheet and unstructured regions are observed 
instantaneously. After 2 hours incubation, the reduction in protein concentration 
by precipitation means that the remaining soluble material does not accurately 
represent the aggregating material, as shown by the dramatic increase in the 
standard deviation. Therefore, the insoluble material was dried into thin films 
and analysed using thin film CD (Section 5.3.1.4).  
 
Table 5.2. Secondary structural content of apoA-I at pH 7 and 4, in the absence 
and presence of heparin after 0 and 2 hours incubation, calculated using 
CONTINLL algorithm fits with standard deviation (SD) shown. 
  
Percentage secondary structure   
Condition Time (h) α-helix β-sheet Turn Unordered S.D 
pH 7 0 65 8 13 14 0.032 
 
2 62 9 24 5 0.031 
pH 7 + heparin 0 60 8 21 11 0.028 
 
2 65 9 14 12 0.033 
pH 4 0 53 5 18 24 0.057 
 
2 61 16 21 2 0.095 
pH 4 + heparin  0 4 41 22 32 0.521 
  2 19 8 16 57 0.681 
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5.3.1.4. Thin film circular dichroism of apoA-I 
The insoluble, aggregated material that was removed from solution, prior to 
obtaining the solution CD spectra, was analysed by thin film circular dichroism. 
This allowed determination of the secondary structure of the apoA-I aggregates, 
rather than the protein that was left in solution.  
Thin film CD of the aggregated material formed in the absence of heparin 
produced a spectrum that appeared similar to apoA-I at pH 7, with spectral 
minima at 208 and 222 nm, suggestive of a high helical content remaining 
(Figure 5.17).  
However, the material formed in the presence of heparin produced a 
spectrum that appeared to consist of both α-helical and β-sheet contributions. 
The spectrum maximum shifts from 193 nm to 195 nm, which is consistent with 
a conversion from α-helical to β-sheet. The spectra minimum at 222 nm, one of 
the identifying features of α-helices, becomes red shifted to 226 nm, and the 
intensity of the spectral minimum at 208 nm, is also reduced. These are all 
suggestive of an increase in β-sheet content (Chan et al., 2015).  
Differential spectra, obtained by subtracting the heparinated sample from 
the sample of apoA-I alone, can be assigned to conformational changes occurring 
in the presence of heparin. This spectrum infers the presence of 40 % β-sheet 
content. However, this technique cannot determine whether the entire, 
heparinated aggregate contains 40 % β-sheets, or whether just the region that 
differs from the un-heparinated sample contains 40% β-sheets.   
Therefore, thin film CD has to be used with caution. The random 
alignment of molecules in the film leads to anisotropic sampling, and it has been 
reported that thin film CD overestimates β-sheet content (Noguez, 2014). 
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Figure 5.17. Thin-film far UV circular dichroism spectrum of apoA-I aggregates 
formed at pH 4, in the absence and presence of heparin.  
 
5.3.1.5 Stability of oxidised apoA-I 
Oxidation of apoA-I has been shown to induce its aggregation into amyloid-like 
aggregates, with typical fibril morphology, at a more physiologically relevant pH 
than the wild type apoA-I. As such, the structure of oxidised apoA-I was probed 
with CD. 
Oxidised apoA-I was incubated in 10mM phosphate buffer, rather than 
McIlvaine buffer. This meant that CD scans could be acquired from 185-260 nm 
without excessive noise below 200 nm, caused by the citrate in the McIlvaine 
buffer. 
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In experiments mirroring those described in section 5.3.1.1, oxidised 
apoA-I underwent repeated scans of high intensity UV radiation, in order to 
determine whether the oxidised apoA-I was prone to UV degradation. Figure 
5.18 indicates that oxidised apoA-I at pH 7.5 remains stable to UV radiation, 
similar to wild type apoA-I. 
 
 
Figure 5.18 25 repeated scans of oxidised apoA-I (72 μM) at pH 7 with far UV 
synchrotron radiation to determine the stability of the peptide under UV 
radiation. Numbers represent the number of repeated exposures to UV radiation.   
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5.3.1.6. Secondary structure of oxidised apoA-I 
Circular dichrosim spectra of oxidised apoA-I were obtained, in order to 
determine the secondary structural content. At pH 7.5, oxidised apoA-I has been 
shown to be stable and is not predisposed to aggregation (Chan et al., 2015). The 
spectrum of oxidised apoA-I, shown in Figure 5.19A, can be fitted with the 
CONTINLL algorithm, resulting in the secondary structural values shown in 
Figure 5.19B. These percentages confirm a predominantly helical conformation. 
However, the helical content of 46 % for the oxidised apoA-I is considerably 
lower than the 60 % α-helices in the un-oxidised apoA-I. This is concurrent with 
previous studies, which determined that the secondary structural content 
decreased by approximately 10 % upon oxidation of methionine residues (Chan 
et al., 2015). This 10 % reduction in helical content appears to have rearranged 
into unstructured regions, in agreement with Wong et al. (2010). It is thought 
that this decreased structural stability is what drives the aggregation of oxidised 
apoA-I into amyloid species.  
Oxidised apoA-I at pH 6 was not studied by solution CD, due to the 
inaccuracy of the fitting observed at pH 4, in the presence of heparin. Instead thin 
film CD of oxidised apoA-I was attempted, in order to determine the secondary 
structural contributions of the aggregated material. However, upon drying down 
the insoluble aggregates, as done previously with native apoA-I at pH 4, the thin 






























Figure 5.19 (A) CD spectra of oxidised apoA-I (72 μM) at pH 7.5, with the 
CONTINLL fitting, using dataset SMP56. (B) Secondary structural content of 
oxidised apoA-I at pH 7.5, estimated using the CONTINLL algorithm.  
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5.3.1.7 Circular dichroism of apoA-I (46-59) 
ApoA-I (46-59) was shown in Figure 4.17 to readily assemble into ThT-
responsive aggregates, characteristic of amyloid. As such, the aggregation of 
apoA-I (46-59) was monitored for 4 hours with circular dichroism. At pH 7 
(Figure 5.20B), apoA-I retains a predominantly random coil structure, with a 
spectra minimum around 195-200 nm and a maximum around 215 nm. Upon 
acidification to pH 4, the spectra in Figure 5.20A remains relatively unchanged, 
still suggestive of random coil structure. However, after incubation for 4 hours at 
pH 4, the spectra changes dramatically to one more associated with β-sheets.  
 However, upon fitting with CONTINLL algorithms, the secondary 
structure shows no difference, following aggregation (Table 5.3). This does not 
match the dramatic change in the shape of the spectra. As such, the fittings were 
not deemed to accurately represent the data and were rejected. Therefore, the 
structure of apoA-I (46-59) aggregates will be further studied by natural 
abundance SSNMR.   
 
Table 5.3 Percentage secondary structure of apoA-I (46-59) at pH 7 and pH 4 
after 0 and 4 hours incubation. 
   
Condition Time Percentage secondary structure 
  
α-helix β-sheet Turn Unordered 
pH 7 0 hours 5 40 22 33 
 
4 Hours 5 40 22 32 
pH 4 0 Hours 5 40 22 34 
 
4 Hours 4 37 22 36 
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Figure 5.20 Circular dichroism of apoA-I (46-59) at the aggregation inducing pH 
4 (A), and neutral pH 7 (B) where apoA-I (46-59) was shown to be stable and did 
not spontaneously aggregate.  
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5.3.2. Thermal stability studies of apoA-I 
5.3.2.1 Thermal stability of native, soluble apoA-I 
Thermal stability experiments were carried out on a bench top instrument, 
rather than at Diamond Light Source. At Diamond, high concentrations of apoA-I 
meant shorter path lengths could be used. Due to the lower radiation intensity of 
the bench top instrument, measurement required a longer path length, as such, 
the contribution from the citrate buffer at low wavelengths caused a high level of 
noise. Therefore, the spectra presented for thermal stability analysis of both 
apoA-I and oxidised apoA-I at 7.2 μM is shown from 200-250 nm.  
Far UV circular dichroism measurements of apoA-I at pH 7, across a 
temperature range of 20-90 °C, were taken in order to determine whether the 
structure of apoA-I was dependent on temperature, and if so, what temperature 
induced a change in the native fold. At 20 °C, apoA-I produced a CD spectrum 
consistent with the scans of apoA-I in Figure 5.21, suggesting a high content of 
α-helical secondary structure. As the temperature increased, the intensity of the 
troughs at 208 nm and 224 nm, characteristic of α-helical contributions, reduced. 
As the temperatures exceeded 60 °C, the spectra appeared to take on a more 
random coil characteristic (Figure 5.21A), consistent with apoA-I undergoing 
thermal destabilisation. The isodichroic point around 203 nm is suggestive of a 
local 2 state population. This is confirmed by the spectra from these two separate 
species, shown in Figure 5.21B. The contribution of these two structural 
variants of apoA-I can be plotted against temperature, using the Global 3 Thermo 
Analysis software. The point where the 2 lines converge highlights a temperature 
of 57.5 °C, at which 50 % of the initial, mostly helical structure has converted into 























Figure 5.21 (A) Far UV circular dichroism spectrum of apoA-I at neutral pH 
incubated at increasing temperatures, (B) the 2 distinct species at the extremes 
of the temperature range and (C) the fractional composition of the 2 species at 
each temperature. Data was analysed by Global 3 thermo analysis software.  
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5.3.2.2. Thermal stability of oxidised apoA-I 
Oxidation of methionine residues in apoA-I has been shown to reduce the 
secondary structural content of soluble apoA-I by approximately 10 % (Chan et 
al., 2015). However, one study has found that oxidation of methionine residues 
causes partial unfolding of the protein, and inhibition of dimerisation (Wong et 
al., 2010). Both of these studies deduced an increased susceptibility to thermal 
destabilisation, compared to the un-oxidised apoA-I.  
Figure 5.22 shows that oxidised apoA-I undergoes two major transitions 
between 20 and 90 °C. At 20 °C oxidised apoA-I produces a CD spectra that 
appears similar to the native, soluble apoA-I (Figure 5.22A and B), thus, is 
qualitatively presumed to contain a high proportion of α-helices, due to the 
presence of spectral minima at 208 and 222 nm. Upon increasing the 
temperature above 30 °C, the spectra of oxidised apoA-I shows a decrease in 
intensity at 222 nm, and a blue shift of the 208 nm peak to approximately 205 
nm, consistent with the formation of unordered structures. This is characteristic 
of protein unfolding. This is also similar to the transition of un-oxidised apoA-I at 
pH 7 from helical to random coil (Figure 5.21B), although oxidation decreases 
the temperature at which this conversion occurs by 25 °C. This effect has been 
reported elsewhere, but to a much lower extent (Wong et al., 2010). Upon further 
heating above 70 °C, CD spectra of oxidised apoA-I produces spectral minima at 
208 and 222 nm, but at reduced intensities, consistent with refolding into α-helix 
structures, which has not been shown before. The lack of an isodichroic point at 
203 nm confirms the 2-state transition observed in Figure 5.21 no longer occurs. 
























Figure 5.22  (A) Far UV circular dichroism spectrum of oxidised apoA-I at pH 7.5 
incubated at increasing temperatures, (B) the 3 distinct species determined by 
the Global 3 Thermo Analysis software and (C) the fractional composition of the 
3 species at each temperature. 
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5.3.3. Solid-state NMR 
Since CD analysis of proteins can only give an estimation of the overall secondary 
structural content, SSNMR was utilised in order to determine local structural 
features at a higher resolution. Chapter 3 describes the recombinant expression 
of uniformly 13C and 15N isotopically labeled apoA-I, allowing analysis by SSNMR. 
Chapter 4 details the conditions that promoted the aggregation of apoA-I into 
insoluble material, characteristic of amyloid. This work allows a more in-depth 
study of the global structure of apoA-I, in particular the folding pattern of the 
native and aggregated forms of the protein, via a combination of one and two-
dimensional SSNMR experiments.   
 
5.3.3.1 Structure of native apoA-I 
Initial SSNMR experiments were used to determine the structure of the native 
apoA-I protein at pH 7, where it has been shown to remain stable and avoid 
aggregation. Two-dimensional, 13C-13C CP-MAS SSNMR spectra were obtained for 
lyophilised apoA-I at pH 7. Cross-peaks identify nuclei in close proximity, such as 
those that are directly bonded, with the transfer of magnetisation from one 
nucleus to another during the mixing phase.  
Figure 5.23 shows broad lines (±5 ppm) for the lyophilised sample 
(black), suggesting a degree of heterogeneity, which is common for SSNMR 
analysis of amyloid fibrils formed by full-length proteins (Morris et al., 2012). In 
addition to this heterogeneity, the overlap of individual amino acid peaks, caused 
by the large size of apoA-I, prevented a full residue assignment of the spectrum. 
However, the spectrum is suitably well resolved to observe cross-peaks from 
several amino acid species, in particular alanine, leucine, valine, threonine and 
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serine. The chemical shift patterns of these residues alone can be used to infer 
secondary structural content of the overall protein, given their uniform 
distribution throughout the apoA-I sequence (Figure 2.3). The spectrum of 
lyophilised apoA-I at pH 7 contains Cα-Cβ and Cα-carbonyl carbon cross-peaks 
for these amino acid residues with chemical shifts, which are characteristic of α-
helices, as shown in Table 5.4.  
 
Table 5.4 Average chemical shift (ppm) of amino acids, according to their 
secondary structural content (Wang and Jardetzky, 2002). 
 Cα  Cβ  C-amide  
 α-helix β-sheet Random 
Coil 
α-helix β-sheet Random 
Coil 
α-helix β-sheet Random 
Coil 
Ala 54.86 50.86 52.67 18.27 21.72 19.03 179.58 175.3 177.39 
Gly 47.02 45.08 45.34    176.31 173.01 174.3 
Leu 57.54 53.94 54.85 41.4 44.02 41.87 178.42 175.16 176.61 
Pro 65.52 62.79 63.53 31.08 32.45 31.87 178.34 176.41 176.91 
Ser 60.87 57.14 58.35 62.81 65.39 63.88 176.51 173.52 174.33 
Thr 65.89 61.1 61.59 68.64 70.82 69.75 176.62 173.47 174.62 
Val 65.69 60.72 61.8 31.41 33.81 31.68 177.75 174.66 175.76 
 
 
The spectrum also shows a strong resemblance to a simulated spectrum of apoA-
I (Δ185-243), which was produced from the predicted chemical shifts from the 
PDB 3R2P model determined by SHIFTX2 (Han et al., 2011). This provides strong 
evidence that the native protein at pH 7 is in a predominantly α-helical structure. 
It should be noted that the simulated spectrum corresponds to the apoA-I (Δ185-
243) protein, whereas the lyophilised apoA-I spectrum contains signals from the 
full-length peptide (minus the first 2 residues). Therefore, the experimental 
spectrum contains signals from the remaining residues, 185-243, which are not 
present in the Mei and Atkinson model. These residues in apoA-I are believed to 
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be involved in lipid binding, and thus, have a highly variable secondary structure, 
consisting of either α-helical or random coil structures (Chetty et al., 2009). If 
this C-terminal region was in a random coil conformation, Cα-Cβ cross-peaks 
from threonine 197, 200, 237 and 242 and serine 201, 204, 224 and 228 residues 
would appear with chemical shifts of 61.6/69.8 ppm for the threonine residues 
(green circle), and 58.3/63.8 ppm for the serine residues (blue circle) (Figure 
5.23). The Cα-Cβ cross-peaks for threonine and serine residues in α-helical 
conformations occur closer to the diagonal. Since no cross-peaks occur in the 
region associated with random coil, the spectra suggests that under the 
conditions studied here, the C-terminus of apoA-I is in an α-helical conformation.   
 
Figure 5.23 2D 13C-13C SSNMR spectra with DARR mixing of lyophilised apoA-I at 
pH 7 (black) and a simulated spectrum from the apoA-I (Δ185-243) model (Mei 
and Atkinson, 2011) in red. The blue and green circles highlight chemical shift 
regions associated with Thr and Ser residues in random coil conformations.   
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5.3.3.2 One-dimensional solid-state NMR of apoA-I aggregates 
Proton-decoupled 15N CP-MAS NMR spectra of apoA-I were acquired for 
lyophilised apoA-I at pH 7, and for the fibrillar material formed at pH 4 and pH 5 
in the presence of heparin (Figure 5.24). Chemical shifts of the backbone amide 
nitrogen, in addition to the Cα, carbonyl and Cβ positions, are highly sensitive to 
protein secondary structure. Figure 5.24 also includes the predicted 15N 
chemical shift spectra for the apoA-I (Δ185-234) structure shown in red (Mei and 
Atkinson, 2011). 
Figure 5.24A shows the amide 15N chemical shifts for the native 
lyophilised apoA-I, centred around ≈119 ppm. This is consistent with the 
chemical shift of amide nitrogen atoms in α-helical conformation, which range 
from 114.8 ppm to 121.7 ppm, with an average of 118.3 ppm (Wang and 
Jardetzky, 2002). The experimental spectrum agrees with the simulated 
spectrum for apoA-I (Δ185-234), suggesting that at pH 7, lyophilised apoA-I 
shows a strong resemblance to the Mei and Atkinson (2011) model. The spectra 
in Figures 5.23 and 5.24 also confirm that the lyophilisation of apoA-I does not 
affect the native structure.  
Upon aggregation at pH 4, at both 36 and 18 μM (Figure 5.24 B and C), 
and at pH 5 at 36 μM (Figure 5.24 D) in the presence of heparin, apoA-I 
produces a 15N spectrum peak centred around ≈121 ppm. Average chemical 
shifts for amino acid residues in β-sheet (122 ppm) and random coil (119.5 ppm) 
conformations are higher than those seen in corresponding α-helical (118.3 
ppm) conformations (Wang and Jardetzky, 2002). In all three spectra of apoA-I at 
acidic pH, the experimental spectrum of the apoA-I aggregates show a deviation 
from the apoA-I (Δ185-234) simulated spectra.  
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In summary, although the spectra do not provide site-specific information, the 
1D 15N spectrum confirms the aggregation of apoA-I at acidic pH, in the presence 
of heparin, causes a structural rearrangement. This results in a shift from its 
















Figure 5.24 15N 1D SSNMR showing the backbone amide region of (A) 
lyophilised apoA-I at pH 7 and (B-D) aggregated apoA-I formed in the presence 
of heparin. Specific aggregation inducing conditions were (B) pH 4 with 36 μM 
apoA-I, (C) pH 4 with 18 μM apoA-I, and (D) pH 5 with 36 μM apoA-I. The 
simulated spectra for the apoA-I (Δ185-234) model, calculated using the 
SHIFTX2 online server, is shown in red.  
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5.3.3.3. Two-dimensional ssNMR of apoA-I aggregates 
Two-dimensional 13C-13C CP-MAS SSNMR spectra for hydrated apoA-I aggregates, 
formed in the absence and presence of heparin (Figure 5.25), give more detail 
on the structural composition of the aggregates than was possible with one-
dimensional studies (Figure 5.24).  ApoA-I alone (red) shows a high similarity to 
apoA-I aggregates formed in the presence of heparin (black), despite the 
differences observed via XRD, TEM, CD and ThT, which suggested a different 
aggregation mechanism occurred in the presence of heparin. Both samples 
produce spectra with broad, overlapping peaks. The overlap is less than that 
observed for the lyophilised apoA-I at pH 7 in Figure 5.23, however, a sequential 
assignment is still not feasible.  
The 2D spectrum of aggregated apoA-I (Figure 5.25) contains cross-
peaks for Ala, Val, Leu, Ser and Thr residues that correspond to α-helical 
contributions, as observed with the lyophilised apoA-I at pH 7 in Figure 5.23. 
However, in addition to these α-helical cross-peaks, additional sets of cross-
peaks for each of these residues are present, with chemical shifts associated with 
β-sheets. This suggests that upon aggregation, apoA-I undergoes a structural 
rearrangement, from a highly helical native structure, into a combination of α-
helices and β-sheets. All 5 of the amino acids identified in Figure 5.25 are 
uniformly distributed throughout the apoA-I sequence (Figure 2.3), meaning 
that it was not possible to locate the unique regions of the peptide that 
correspond to α-helices or β-sheets.  
In summary, apoA-I aggregates, formed both in the absence and presence 
of heparin, contain both α-helical and β-sheet contributions, suggesting a partial 
conversion from its native α-helical content.  
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Figure 5.25 Two-dimensional 13C-13C CP-MAS SSNMR spectrum with DARR 
mixing of apoA-I aggregates formed in the absence (red) or presence (black) of 
heparin, showing the amide (left) and high field (right) carbon regions. 
Annotations of α and β refer to cross-peaks with chemical shifts consistent with 
the residues in an α-helical or β-sheet conformation.   
 
5.3.3.4 Oxidised apoA-I 
Chemical oxidation of apoA-I, with H2O2, was shown to induce aggregation into 
amyloid-like aggregates in Chapter 4, which are ThT-responsive and have an 
appearance of more typical amyloid morphology, compared to the aggregates 
formed by un-oxidised apoA-I (Figure 4.22). Here, the SSNMR spectra of 
oxidised apoA-I (blue) is very similar to the to the spectra of un-oxidised apoA-I 
aggregates formed at pH 4 in the presence of heparin (black), as shown in Figure 
5.26. Both spectra contain cross-peaks corresponding to both α-helical and β-
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sheet conformations, and are virtually superimposable. Therefore, it is 
reasonable to assume that the oxidised and heparinated aggregates have similar 
structures, and thus, are created as a result of the same changes to the core 
structure. 
 
Figure 5.26 Two-dimensional 13C-13C CPMAS SSNMR spectra with DARR mixing 
of apoA-I aggregates formed at pH 4 in the presence of heparin (black) and 
oxidised apoA-I aggregates at pH 6 (blue). 
 
5.3.3.5. β-sheet model of apoA-I 
The N-terminal residues 1-80 and 1-100 of apoA-I are known to readily form into 
amyloid structures when cleaved from full-length apoA-I (Das et al., 2016; Das et 
al., 2014). A model for apoA-I (1-90) with a high percentage of β-sheet structure 
was produced by Professor David Middleton. This model consisted of residues 
14-59 (incorporating the 2 hot spot regions 14-22 and 53-38) in an anti-parallel 
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β-strand conformation, with a turn encompassing Gly 33, Gly 37 and Gln 39, with 
disordered flanking regions. Back calculation of the 13C chemical shifts of this 
structure allowed a simulated 2D 13C-13C SSNMR spectrum to be produced. The 
13C SSNMR spectrum of apoA-I aggregates formed in the presence of heparin 
(black), and the simulated spectrum for the simulated apoA-I (1-90) aggregated 
peptide (blue), are shown in Figure 5.27. The apoA-I (1-90) β-sheet simulation 
produces theoretical cross-peaks, which are concurrent with many of the cross-
peaks for apoA-I in the presence of heparin. In particular, the simulated spectrum 
matches with the cross-peaks assigned to β-sheet conformations in the full-
length apoA-I, but does not superimpose onto the α-helical cross-peaks. This 
suggests that the apoA-I aggregates contain the N-terminal 1-90 residues in 






Figure 5.27 Two-dimensional 13C-13C CP-MAS SSNMR spectrum with DARR 
mixing of apoA-I aggregates formed in the presence of heparin (black) and a 
simulated spectrum for the model apoA-I (1-90) as entirely β-sheets (blue).  
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5.3.3.6 Structure of apoA-I 46-59 
The structure of apoA-I (46-59) was probed through natural abundance 13C 1D 
SSNMR. Figure 4.17 indicates that apoA-I readily forms amyloid-like material at 
pH 4, which is consistent with a conversion from random coil to β-sheet 
structures, as shown by the circular dichroism spectra in Figure 5.20. A natural 
abundance 13C SSNMR spectrum of apoA-I (46-59) aggregates for the α-carbon 
region is shown in Figure 5.28, alongside simulated spectra for the peptide 
sequence in entirely α-helical, random coil and β-sheet conformation, produced 
by Professor D. Middleton. The spectrum for the apoA-I (46-59) fibrils is in good 
agreement with the simulated β-sheet spectrum, and the small discrepancies 



























Figure 5.28 Cα region of the 13C SSNMR spectrum of apoA-I (46-59) fibrils 
(black) with simulated spectra of the peptide in entirely α-helical (A) random coil 
(B) and β-sheet (C) conformations shown in red.  
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5.4 Discussion 
ApoA-I solutions at pH 7 were analysed by CD and shown to be resistant to UV 
decay, and stable up to 57.4 °C. Upon deconvolution of the CD spectrum, the 
estimated secondary structure was consistent with the crystal structure deduced 
by Mei and Atkinson (Mei and Atkinson, 2011), with 60 % in α-helical and >10 % 
in β-sheet conformations. Upon acidification of apoA-I, a structural 
rearrangement occurred, resulting in a decrease in α-helical content and an 
increase in β-sheet. This conversion is enhanced in the presence of heparin. This 
is consistent with the formation of amyloid species, which convert into a highly 
ordered β-sheet conformation, prior to becoming insoluble fibrils that can no 
longer be measured by CD. In contrast to the solution CD, the thin-film CD 
appeared to remain helical in the absence of heparin, and produce a spectrum 
that contained signal contributions from both α-helices and β-sheets in the 
presence of heparin, with 40 % of the protein in a β-sheet conformation. 
A combination of α-helices and β-sheets is something that is not commonly 
observed with amyloid formation. Usually, natively helical proteins refold into β-
sheet structures, with minimal native content remaining (Ding et al., 2003). 
Therefore, the structure of the apoA-I aggregates was assessed by SSNMR.  
Initial SSNMR studies were carried out on lyophilised apoA-I at pH 7, but 
due to broad and overlapping lines, sequential assignment of the spectrum was 
not possible. However, the spectrum was suitably resolved to identify 5 amino 
acids (Ala, Leu, Val, Ser and Thr) with cross-peaks correlating to their inclusion 
in α-helical structures. When the experimental spectrum was superimposed with 
a simulated spectrum for the apoA-I (Δ185-243) model deduced by Mei and 
Atkinson (2011), the two spectra were complementary.  
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NMR spectra of apoA-I aggregates, both those formed in the absence and 
presence of heparin, were acquired and compared to the native lyophilised apoA-
I. Interestingly, the cross-peaks that correlated with α-helical elements in the 
lyophilised apoA-I occurred in the spectra of the aggregated material. However, 
novel cross-peaks for these amino acids within β-sheet structures were also 
present. Unfortunately, all 5 of these amino acids are uniformly distributed 
throughout the apoA-I sequence, so determining where the α-helical or β-sheet 
regions are within apoA-I was not possible. These findings confirmed the thin 
film CD spectra, which suggested the aggregates consisted of a combination of α-
helical and β-sheet structures. Spectrum for oxidised apoA-I at pH 6 appeared 
similar to the wild type apoA-I aggregates, with both α-helical and β-sheet 
contributions. 
 
5.4.1 Current model for apoA-I amyloidosis  
A current theory detailing the mechanism of apoA-I amyloidosis is 
proposed by Das et al., (2014; 2016). Three N-terminal “hot spot” regions, 
consisting of residues 14-22, 53-58 and 69-72, are protected from spontaneous 
aggregation by their incorporation in the 4-helical bundle, which makes up the 
majority of the native N-terminus. Destabilisation of this 4-helical bundle, by 
mutation or oxidation, leads to the spontaneous aggregation of the hot spots into 
β-sheet structures, which extend up to residues 76-81. This short sequence, 
EKETEG acts as a natural β-sheet breaker at neutral pH, resulting in apoA-I (1-
76) consisting of β-sheets, and the remaining C-terminus retaining its native fold. 
This opens apoA-I up to cleavage, in particular at residue 83, forming N-terminal 
fragments that deposit as amyloid in familial apoA-I amyloidosis.  
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However, upon protonation of the glutamic acid at acidic pH, the EKETEG 
sequence loses its β-sheet breaking ability, allowing the β-sheet to propagate into 
the C-terminus, forming full-length apoA-I amyloid. 
  ApoA-I (1-90) in a β-sheet conformation was modeled and back 
calculation of the 13C chemical shifts produced a simulated NMR spectrum. The 
simulated spectrum superimposes well onto the apoA-I aggregates, with the 
simulated correlating with the β-sheet cross-peaks for the experimental 
spectrum. This suggests that the full-length apoA-I aggregates contain the first 1-
90 residues in a β-sheet conformation. However, this spectrum does not rule out 
other structural possibilities, including β-sheet formation in other areas. 
 
5.4.2 Refinement of the model for apoA-I amyloidosis   
Based on the SSNMR data presented here, a modification of the current model for 
apoA-I amyloidosis is proposed. Following acidification or oxidation, the apoA-I 
N-terminus becomes less stable, leading to the exposure of the hot spot regions 
at residues 14-22, 53-58 and 69-72. This allows their spontaneous aggregation 
into β-sheet structures in the N-terminus, which extend up to the β-sheet 
breaking sequence at residues 76-81, in keeping with the current theory. 
However, it is proposed here that the remaining apoA-I sequence, incorporating 
approximately residues 76-243, retains its native α-helical structure, even at 
acidic pH, as modeled in Figure 5.29. This explains the splitting of the alanine, 
valine, leucine, threonine and serine cross-peaks into chemical shifts associated 
with both α-helical and β-sheet structures. This model is also supported by the 
CD data presented here, which suggests a decrease in the native helical content, 
resulting a mixture of α-helices and β-sheets in the aggregated material.  
 223 
It is likely that the pro-amyloidogenic effects of heparin are caused by its 
interaction with apoA-I aiding in the destabilisation of the N-terminus. This 
explains why the ThT response is concentration-dependent, but only affects the 
initial stage of aggregation, rather than the secondary elongation. 
What these data cannot deduce, for certain, is whether the α-helical and β-
sheet contributions in the CD and SSNMR spectra are present in each molecule of 
apoA-I, or whether the conditions studied here promote the formation of 2 
distinct apoA-I species. One species may consist of the native helical structure, 
whilst the other is converted to predominantly β-sheets following amyloidosis. 
The intensities of the SSNMR, and the CD spectra both consistently estimate the 
β-sheet content to be roughly 40 %. Although this figure must be treated with 
caution, the consistency and the high percentage of β-sheet is suggestive that 




Figure 5.29 Five models for aggregated apoA-I (Δ185-243) (PDB 3R2P) with the 
N-terminal 1-75 region in a non-helical conformation, whilst residues 76-180 
retain their natively helical structure. Residues 14-59, incorporating the hot spot 
regions 14-22 and 53-58 are modeled as antiparallel β-sheets, separated by a 
turn including Gly 33, Gly 37 and Gln 39. The remaining N-terminal residues are 
disordered. Figure produced by D. Middleton.  
 224 
6. Inhibition of apoA-I aggregation 
6.1. Introduction  
6.1.1. Amyloid inhibition  
The misfolding of proteins into amyloid species is linked to a whole range of 
disease states, as outlined in section 1.1.2. ISA currently recognises 30 human 
proteins capable of forming amyloid, many of which are involved in pathological 
links to amyloid-related diseases (Sipe et al., 2014). These include Aβ and tau in 
Alzheimer's disease, α-synuclein and tau in Parkinson’s disease, IAPP in type II 
diabetes, immunoglobulin light chain in AL amyloidosis, medin in aortic medial 
amyloidosis, and apoA-I in apoA-I amyloidosis, associated with atherosclerosis 
(Chiti and Dobson, 2006). From this list, it is clear that the proteins involved in 
amyloidosis are not all structurally or sequentially linked, and can include: full-
length proteins, peptide fragments or products of general protein decay (Stefani, 
2007). As such, large variety in amyloidogenic proteins makes developing 
therapeutic compounds for inhibiting their aggregation difficult, and various 
methods will be discussed in detail later in this introduction. Deposition of 
amyloid fibrils is detrimental to health, and leads to many of the diseases listed in 
Table 1.1 (Chiti and Dobson, 2006). However, in many amyloid associated 
diseases, it is the cytotoxic oligomeric intermediates that mediate the disease 
pathology (Meier et al., 2006; Kayed, 2003). Therefore, there is increased 
motivation for research into devising techniques for inhibiting the aggregation of 
native amyloidogenic proteins into both the oligomeric species, known to be 
cytotoxic; and full-length fibrils, the deposition of which causes further disease 
progression (Hard and Lendel, 2012).  
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Despite the lack of understanding of the specific mechanism behind the 
aggregation of most amyloid proteins, a general mechanism of protein unfolding, 
prior to aggregation has been found to be common to most, including apoA-I. 
This suggests that a particular method of inhibition for one species of 
amyloidogenic protein, may be suitable for other, non-related species (Hard and 
Lendel, 2012; Wang and Raleigh, 2014). The potential for this general amyloid 
inhibition strategy is highlighted by the ability of some amyloidogenic proteins to 
be seeded by amyloid fibrils from other, non-related amyloid proteins (Larsson 
et al., 2011), suggesting a common aggregation mechanism. Common methods 
for amyloid inhibition are outlined below and summarised in Figure 1.14. 
 
6.1.1.1. Targeting the protein source 
Amyloid formation is dependent on the presence of the amyloidogenic peptide, 
be it the wild type protein, a mutant protein, or a cleaved peptide. Reduction of 
the concentration of the amyloidogenic peptide, at an expression or post-
translational modification level, can be a highly effective treatment against 
systemic amyloidosis (Gillmore and Hawkins, 2006). Examples of this technique 
include anti-inflammatory drugs targeting the production of SAP in AA 
amyloidosis, chemotherapy against B-cells to reduce immunoglobulin light 
chains, such as Melphalan (Kyle et al., 1997); liver transplantation to remove the 
abnormal TTR mutant, and targeting the β and γ secretase enzymes to inhibit the 
cleavage of the amyloidogenic Aβ(1-40) and (1-42) fragments (Gillmore and 
Hawkins, 2006). Alternatively, inhibiting the interaction of amyloidogenic 
proteins with GAG’s, known to promote amyloidosis, is another promising 
general amyloid inhibitor. Fibrillex™, an N-acetylglucosamine analogue of 
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heparin, binds to amyloid precursor proteins and stops the interaction of heparin 
with amyloidogenic proteins (Gillmore and Hawkins, 2006). 
 
6.1.1.2. Promoting alternative folding pathways    
It is widely accepted that protein oligomers or aggregation intermediates, rather 
than fibrillar species, in many cases, lead to the cytotoxic entity of amyloidogenic 
proteins, manifesting in cell death and amyloid-associated disease progression 
(Kayed, 2003). In some cases, the native protein readily forms oligomeric species, 
which remain cytotoxic for a prolonged period of time. Agents that promote the 
aggregation of these proteins into the benign fibril or amyloid-like structures, 
which do not result in cytotoxicity, could reduce the disease pathology (Bodner 
et al., 2006; Madine and Middleton, 2010). GAG’s have the potential to promote 
aggregation of a protein into a non-toxic fibrillar structure, avoiding potential 
cytotoxic oligomeric species (Iannuzzi et al., 2015). Promoting the formation of 
amyloid-like structures can both avoid the cytotoxic oligomer species, and inhibit 
fibril elongation. The ZAβ3 inhibitor forms a dimer around the β-hairpin 
structure of Aβ, creating a four-stranded β-sheet, in effect stabilising the 
monomeric amyloid (W. Hoyer et al., 2008).   
 
6.1.1.3 Peptide based β-sheet breakers  
The amyloidogenic propensity of Aβ arises from a central hydrophobic hot spot 
region comprising residues 17-21, in addition to contributions from residues 32-
37 and 37-42 (Doig and Derreumaux, 2015). Such hot spot regions, which initiate 
amyloid formation, are found in all amyloidogenic proteins (Amijee et al., 2009). 
Targeting these sequences with short complementary peptides to block 
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aggregation or inhibit elongation of the extending fibril are attractive therapeutic 
techniques. Designing these inhibitors against the amyloidogenic protein 
sequence can increase specificity (Tjernberg et al., 1996; Soto et al., 1998). The 
iAβ5 β-sheet breaker peptide was shown to not only inhibit in vitro amyloidosis 
of Aβ, but also completely inhibit fibril formation in vivo in the brains of rats 
(Soto, et al., 1998). However, one problem with these short peptides is their 
potential to increase amyloidosis through elongation of the fibril (Hard and 
Lendel, 2012). As such, these short peptide sequences have since been modified 
to include proline residues, a natural β-sheet breaker (Wood et al., 1995); 
charged amino acid ends, to increase solubility; and the use of D-amino acids 
rather than L isomers, in order to avoid proteolytic cleavage (Soto et al., 1998; 
Doig and Derreumaux, 2015; Jagota and Rajadas, 2013). N-methylation of the 
backbone residues of these short peptide β-sheet breakers not only increases 
solubility of the peptide, but interferes with hydrogen bonding on the outer edge 
of the extending amyloid fibril, inhibiting further elongation (Hughes et al., 2000; 
Kokkoni et al., 2006).  
 
 6.1.1.4. Small molecule inhibition of amyloidosis 
Designing small molecules against the aggregation of amyloidogenic proteins has 
proven to be much more difficult than normal drug design, partially due to the 
lack of understanding about the aggregation mechanism of most proteins. 
Therefore, the majority of the successful small molecules act as general anti-
amyloid agents, having inhibitory effects on several amyloidogenic proteins 
(Hard and Lendel, 2012), and are often found from screening of extensive 
compound libraries. One of the issues with researching these compounds is their 
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potential interaction with fluorescent amyloid binding molecules used to 
quantify amyloid formation. For example, interactions occur between the small 
molecule rifampicin and ThT in the study of IAPP amyloidosis (Meng et al., 2008) 
and between Congo red, which can inhibit amyloidosis, and ThT (Buell et al., 
2010). Studies into the inhibition of tau aggregation screened a library of 
200,000 compounds, which identified 77 successful inhibitor compounds, based 
on 4 groups: the N-phenylamines, anthraquinones, phenylthiazolylhydrazides 
and thioxothiazolidinones (Bulic et al., 2009). This work highlighted the 
requirement for ring structures and hydrophobic patches (Figure 6.1), which 













Figure 6.1 Structure of (A) N-phenylamines, (B) 9,10-anthraquinone, (C) 
phenylthiazolylhydrazides (Pickhardt et al., 2007), and (D) thioxothiazolidinines 
(Bursavich et al., 2007), all successful inhibitors of tau aggregation.  
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Some small molecule compounds can be easily modified in order to exhibit 
different effects on amyloid aggregation. For example, inositol compounds have 
the ability to both inhibit and promote the aggregation of Aβ into β-sheet 
structures, depending on the specific orientation of the hydroxyl groups.  
 Scyllo-inositol (Figure 6.2 A) has been shown to inhibit the aggregation of 
Aβ by stabilising small, soluble Aβ complexes, with no fibrils visible by TEM. As 
with the tau compounds, hydrophilic patches were key in forming hydrogen 
bonds between the inhibitor and the soluble Aβ monomer. Removal of the 
hydroxyl groups from scyllo-inositol, to form 1-4-dideoxy-scyllo-inositol (Figure 
6.2 B), decreased the inhibitory effect, with intermediate length fibrils and 
amorphous aggregates visualised by TEM. This highlights an essential structure-
activity relationship with the hydroxyl groups. However, increasing the 
hydrophobicity of the compound with two methyl groups (Figure 6.2 C) also 
prevented the elongation of full-length fibrils, by stabilising the proto-filament 
intermediate, which often can be a cytotoxic oligomeric species (Hawkes et al., 
2010).  
 
Figure 6.2 Structure of (A) Scyllo-inositol, (B) 1-4-dideoxy-scyllo-inositol, and 
(C) 1,4,di-O-methyl-scyllo-inositol.  
 
 230 
From a screening of 169 compounds, 15 were shown to inhibit the aggregation of 
α-synuclein in vitro, including dopamine.  However, the inhibition of α-synuclein 
by dopamine and L-dopa lead to a build up in the levels of cytotoxic protofibrils 
(Conway et al., 2001). This highlights the complexity of designing amyloid 
inhibitors that are suitable for pharmacological use. 
  
6.1.2. Polyphenol compounds 
Polyphenols are natural, secondary metabolites of plants found in fruits, 
vegetables and cereals. Over 8000 natural polyphenol compounds have been 
identified and can be split into 4 main characteristic groups: phenolic acids, 













Figure 6.3 Four main groups of natural polyphenol compounds: (A) phenolic 
acid (hydroxyl-benzioc), (B) flavonoids,  (C) stilbenes and (D) lignans. 
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The most studied of the 4 polyphenol groups are the flavonoids, which are 
comprised of 2 aromatic rings connected by three carbons in an oxygenated 
heterocycle (Figure 6.3 B) (Pandey and Rizvi, 2009). The health benefits of 
polyphenol compounds are extensive, including: cardio-protective, anti-cancer, 
anti-diabetic, anti-aging, UV protection, improved metabolism, and neuro-
protective effects (Pandey and Rizvi, 2009). From a screening of over 184,000 
compounds, 25 benzothiazole compounds were found to inhibit the aggregation 
of huntingtin. This included the discovery of the green tea polyphenol 
epigallocatechin gallate (EGCG) (Ehrnhoefer et al., 2006). Later work discovered 
the inhibitory effects of EGCG on the aggregation of Aβ, α-synuclein (Ehrnhoefer 
et al., 2008; Bieschke et al., 2010) and the amyloid model κ-casein (Hudson et al., 
2009).  
 
6.1.2.1 Epigallocatechin gallate 
Green tea has long been associated with increased cardiovascular function and 
metabolic health (Wolfram, 2007). The polyphenol compounds, in particular the 
flavonoids, appear to be responsible for this. The major flavonoid in green tea is 
epigallocatechin gallate (EGCG) (Doig and Derreumaux, 2015), the structure of 
which is shown in Figure 6.4. EGCG in isolation has been shown to: reduce the 
oxidative damage to DNA, reduce the postprandial lipid response in patients with 
hypertriglyceridemia, decrease glucose plasma levels in patients suffering from 
type II diabetes mellitus, reduce the progression of atherosclerosis, inhibit 
smooth muscle cell proliferation, and increase weight loss and energy 
expenditure (Wolfram, 2007; Nagao et al., 2005; Rudelle et al., 2007; Wolfram et 










Figure 6.4 Chemical structure of epigallocatechin gallate, an amyloid inhibitor. 
 
EGCG has been shown to have amyloidosis-inhibiting effects on Aβ, α-synuclein 
and huntingtin (Ehrnhoefer et al., 2006; Bieschke et al., 2010; Ehrnhoefer et al., 
2008; Masuda et al., 2006; Doig and Derreumaux, 2015), as well as causing a 
structural remodelling of mature α-synuclein (Bieschke et al., 2010), Aβ1-40 and 
IAPP fibrils (Palhano et al., 2013).  
EGCG is thought to promote an off-pathway aggregation mechanism of 
amyloidogenic proteins into unstructured, non-toxic oligomers, which lack the 
ability to progress into amyloid fibrils (Ehrnhoefer et al., 2008).  However, the 
precise mechanism of how this occurs is currently unknown (Wang and Raleigh, 
2014). EGCG has been shown to interact with Aβ, via hydrogen bonds at residues 
1-16 and via hydrophobic interactions at residues 17-42 (Wang et al., 2010).  
EGCG is reported to inhibit the aggregation of apoA-I (1-83) and the apoA-I (1-
83/G26R) Iowa mutant, but produced mixed results on its ability to disaggregate 
preformed fibrils (Nakajima et al., 2016). As yet, no interaction has been reported 
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for full-length, wild type apoA-I with EGCG, which could be a potential therapy 
for atherosclerosis.  
 
6.1.3. Aims 
This chapter aims to determine whether green tea polyphenols, including EGCG, 
affect the aggregation propensity of apoA-I and/or the properties of the 
aggregates. The binding of EGCG to apoA-I aggregates will be determined using a 
co-sedimentation experiment, and the effects of EGCG on apoA-I aggregation will 
then be studied using ThT fluorescence. Finally, the structure of apoA-I 
aggregates formed in the presence of EGCG, and with EGCG added after 
aggregation has ceased will be determined via SSNMR and compared to apoA-I 
aggregates alone.  
 
6.2. Methods 
6.2.1 Isolation of polyphenol compounds from green tea 
2 g of green tea (Twining’s™ pure) was added to 40 mL of water. The solution 
was microwaved at 900 W of power for 2 cycles of 30 seconds, followed by 4 
cycles of 15 seconds with a minute between each heating. The solution was 
filtered through a 1μm filter paper (Whatman) and filtered with a 0.2 μm corning 
syringe filter. The solution was then freeze-dried at -70  °C and 0.0026mbar 
pressure for 24 hours, using a Christ-Alpha 2 system. 
 
6.2.2 Characterisation of compounds isolated from green tea 
A catechin mixture (Sigma) was purchased as a reference set for the polyphenol 
compounds present in green tea, to assist in the assignment of high performance 
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liquid chromatography (HPLC) spectral peaks. Analysis certificates confirming 
the mass and purity of the compounds can be found in Appendix 5. The 
reference material and mixture of compounds isolated from green tea were 
separated using HPLC, in order to characterise the unknown compounds. 
Separation was performed on a Nexera UHPLC (Shimadzu) system, with a mobile 
phase of 0.1 % orthophosphate in ultrapure water (A) or in acetonitrile (B), 
whilst the static phase consisted of a shim-pack XR-ODS 2.2 μm reverse phase 
column. The gradient elution, at a flow rate of 1 mL/min consisted of 0-3 minutes 
(5% of B), 3-10 minutes (5-20 % B), 10-13 minutes (20-50 %) and 13-13.1 
minutes (50-5 % B). Green tea extracts were diluted to 7.2 mg/ml of lyophilised 
material in water, prior to HPLC analysis. 
 
6.2.3. Effect of green tea compounds on the aggregation of apoA-I  
The ThT fluorescence experiments carried out in this section of work, mirrored 
those for the continual read experiments in Section 4.3.2. ApoA-I (7.2 μM) was 
incubated with ThT alone and in the presence of 14.4 μM heparin. Samples were 
also incubated with, or without, either pure EGCG or green tea extract at 2-fold 
molar excess to the apoA-I. After measuring the fluorescence for 10 minutes, 
concentrated HCl was added to reduce the sample to pH 4 and induce 
aggregation. ThT fluorescence measurements were taken for 300 minutes, with 
the initial increase in fluorescence (Δ FI) and total increase in ThT fluorescence 




6.2.4 Determination of compounds binding to EGCG by HPLC 
200 μL of apoA-I fibrils (formed at 36 μM) and Aβ fibrils (formed at 44 μM) were 
centrifuged for 10 minutes at 12,000 g. 200 μL of a 1/10 dilution of the 
compounds isolated from green tea was added to the fibrillar pellets, and 
incubated at 37 °C for 24 hours, with agitation. The fibrils were pelleted through 
centrifugation and the supernatant removed, prior to analysis by HPLC.  
 
6.2.5. Absorbance of EGCG 
In order to deduce whether the EGCG concentration could be measured by 
absorbance and utilised to measuring the binding of EGCG to apoA-I, EGCG at a 
range of concentrations from 0.01 mM to 1 mM was scanned across a UV range of 
190 to 360 nm. The maximum absorbance intensity at 274 nm was recorded.  
 
6.2.6. Binding of EGCG to apoA-I 
ApoA-I (36 μM) was incubated in the presence and absence of increasing 
concentrations of EGCG at pH 4, at 37 °C with agitation for 3 days. Following the 
production of insoluble material, EGCG was added to the apoA-I samples that did 
not contain any EGCG during fibril formation and left for 24 hours. The insoluble 
material was removed through centrifugation at 13,400 rpm in a bench-top 
centrifuge. The absorbance of the supernatant at 274 nm was then measured and 
used to determine how much EGCG remained in solution. 
 
6.2.7. Solid-state NMR 
ApoA-I (36 μM) was incubated in the presence and absence of a 2-fold molar 
excess of EGCG at pH 4, at 37°C with agitation for 3 days, in order to form 
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insoluble aggregates. Following the production of insoluble material, EGCG was 
added to the apoA-I samples that did not contain any EGCG during fibril 
formation, and left for 24 hours. Fibrils were harvested through centrifugation at 
12,000 g for 10 minutes. The aggregates were frozen in liquid nitrogen, prior to 
centrifugation into a zirconium 3.2 mm rotor with a Kel-F cap (Bruker, U.K). 
 
6.2.7.1 One-dimensional solid-state NMR 
One dimensional proton-decoupled 15N CP-MAS SSNMR experiments were 
carried out on a Bruker Avance 400 MHz spectrometer, operating at a magnetic 
field of 9.3 Tesla, equipped with a 3.2 mm HXY MAS probe at 25 °C. Hartmann-
Hahn cross-polarisation was achieved at a proton nutation frequency of 78 kHz, a 
2 ms contact time, 100 kHz proton decoupling with SPINAL-64 applied during 
the signal acquisition, and a recycle delay of 2 ms. MAS was controlled at a 
frequency of 8 kHz ± 1 Hz. Each spectrum was the result of accumulating 20,000- 
100,000 transients. Direct polarisation (DP) experiments were the same except 
the CP step was replaced with a 3.5 ms 90 ° pulse at the 13C frequency.  
 
6.2.7.2 Two–dimensional solid-state NMR 
Two-dimensional 13C-13C spectra were recorded at a magnetic field of 16.3 Tesla 
on a Bruker Avance III 700 MHz spectrometer, with a 3.2 mm HXY probe 
operating in double resonance mode, with magic angle spinning at 14 kHz and 
the temperature maintained at 4 °C. Hartmann-Hahn cross-polarisation was 
achieved with a 2 ms contact time, and 100 kHz proton decoupling with SPINAL-
64 applied during signal acquisition. During the mixing time of 10 ms, the 1H 
nutation frequency was lowered to 14 kHz, to achieve DARR mixing. 
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6.3 Results 
6.3.1 Isolation of compounds from green tea 
Green tea compounds were extracted, following methods described in section 
6.2.1. The compounds in the tea extract were then separated using HPLC, 
producing the chromatograph shown in Figure 6.5. Nine separate peaks 
corresponding to individual compounds were identified by HPLC and labelled a-i, 
according to increased retention times.    
 
 
Figure 6.5 HPLC chromatograph for the separation of compounds extracted 




In order to determine what each of the uncharacterised compounds labelled a-i 
in Figure 6.5 were, a reference catechin mixture was purchased from Sigma and 
separated using the same HPLC system. This reference set mixture contains 8 
common catechins present in green tea. Separation by HPLC matched the 
reference material provided in Appendix 5, identifying the compounds in Figure 
6.6 as (1) gallocatechin, (2) caffeine, (3) catechin, (4) epicatechin, (5) 
epogallocatechin-3-gallate (EGCG), (6) gallocathin-3-gallate, (7) epicathechin-3-
gallate, and (8) catechin-3-gallate. The structures for each of these compounds 
are shown in Figure 6.7. 
 
Figure 6.6 HPLC chromatograph of the separation of compounds present in the 
Sigma catechin reference set.  Numbers refer to (1) gallocatechin, (2) caffeine, (3) 
catechin, (4) epicatechin, (5) epogallocatechin-3-gallate (EGCG), (6) gallocathin-
3-gallate, (7) epicathechin-3-gallate, and (8) catechin-3-gallate. 
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Figure 6.7 Chemical structures for the 8 compounds in the catechin mix 
purchased from Sigma. 
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The chromatograms in Figure 6.5 and 6.6 exhibit peaks with almost identical 
retention times, apart from peak (g) in Figure 6.5, which does not match up with 
any compounds in the catechin mixture. Therefore, it is reasonable to assume 
that the compounds isolated from green tea extracts in Figure 6.5 are (a) 
gallocatechin, (b) caffeine, (c) catechin, (d) epicatechin, (e) epogallocatechin-3-
gallate (EGCG), (f) gallocathin-3-gallate, (h) epicathechin-3-gallate, and (i) 
catechin-3-gallate. Now that the compounds from the tea extract have been 
identified, they will be referred to by the numbers 1-8.  
 
6.3.2 Concentration of catechins in green tea extracts 
HPLC analysis of the reference material, which contained each of the 8 
compounds at 100 μg/ml, allows estimation of the catechin concentration in the 
green tea extract, based on the peak area. The concentration of each catechin is 
shown in Table 6.1, confirming that epigallocatechin-3-gallate (EGCG), 
highlighted in bold, is the most abundant compound in green tea. 
 
Table 6.1 HPLC retention time, peak intensity, area under the peak, reference 
concentration scaling factor, and the concentration of each of the 8 catechins in 
the green tea extract.  










Gallo-catechin 1.1 1364.3 42.8 0.31 139.3 
Caffeine 3.0 3202.6 286.9 0.86 335.0 
Catechin 3.8 18240.7 1822.8 3.61 504.4 
Epi-catechin 6.5 2481 136.5 0.82 165.8 
EGCG 6.6 22504.1 1419.0 1.50 947.2 
Gallocathin-gallate 7.5 951.1 62.3 1.84 33.9 
Epicatechin-gallate 9.0 6840.1 453.8 2.22 204.0 
Catechin-gallate 9.2 1635.5 128.3 2.33 54.9 
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6.3.3. Effect of green tea extracts on Aβ and apoA-I amyloidosis. 
EGCG has been shown previously to inhibit the aggregation of Aβ in vitro 
(Ehrnhoefer et al., 2008). Therefore, the effects of green tea extracts on the 
aggregation of Aβ were assessed by ThT fluorescence. Aβ was prepared as 
detailed in Stewart et al. (2016). Figure 6.8 confirms that incubation of Aβ (35 
μM) in conditions that promote the aggregation of apoA-I, leads to its aggregation 
into ThT responsive material after approximately 10 minutes. Inclusion of green 
tea extract at a concentration of 1.5 mM, calculated using the molecular weight of 
EGCG, inhibits the formation of ThT responsive material, confirming that the 
green tea extract inhibits Aβ amyloidosis.  
 
Figure 6.8 ThT fluorescence in the presence of Aβ (35 μM) alone, and with 1.5 
mM green tea extract.  
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Given that the data here suggests green tea extracts inhibits Aβ aggregation, in 
addition to pure EGCG, as shown by Ehrnhoefer et al., (2008), ThT experiments 
were carried out to assess the ability of both the green tea extract and pure EGCG 
to inhibit apoA-I aggregation.  
The experiment followed previous ThT procedures, and apoA-I (7.2 μM) 
was incubated, alone or in the presence of a 2-fold molar excess of heparin, 
and/or EGCG or green tea extract at pH 7, prior to addition of concentrated HCl, 
to reduce the sample to pH 4 and induce aggregation.  
 Figure 6.9A shows that in all 6 conditions (± heparin and ± EGCG/ tea 
extract), apoA-I at pH 7 showed a low ThT fluorescence, consistent with control 
samples and no amyloid formation during the entire experiment. This is 
consistent with previous findings, such as those in Figure 4.5 and 4.7, and 
confirms that EGCG does not induce a ThT response at pH 7. 
Following acidification to pH 4, apoA-I aggregates into insoluble material, 
with an increase in ThT fluorescence. This ThT response is dramatically 
enhanced in the presence of heparin (Figure 4.5 and 4.7). In samples containing 
either a 2-fold excess of EGCG, or green tea extract, the ThT fluorescence 
response shows virtually no difference, neither in the initial increase (FI), nor the 
total ThT fluorescence after 300 minutes (FT) (Figure 6.9B). This suggests that 
these catechins do not exhibit any inhibitory effects on the aggregation of apoA-I, 










Figure 6.9 ThT fluorescence of apoA-I incubated at pH 4 in the presence or 
absence of heparin, and with the addition of EGCG or green tea extract, prior to 
acidification. Measurements are the mean of 3 samples ± standard error.   
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6.3.4 Binding of green tea extracts to apoA-I.  
The binding of catechins extracted from green tea to both Aβ and apoA-I was 
assessed using co-sedimentation experiments. Green tea extract was added to 
preformed Aβ and apoA-I fibrils, and incubated with agitation for 24 hours. The 
insoluble aggregates were then removed through centrifugation, co-pelleting any 
bound catechin compounds. The remaining concentration of each compound was 
estimated using HPLC analysis. Pure EGCG was then added to apoA-I fibrils, 
incubated for 24 hours, then the fibrils and any bound EGCG were removed 
through centrifugation. The remaining concentration of EGCG left in the 
supernatant was calculated, using the absorbance of EGCG at 274 nm (Section 
6.3.4.2).  
 
6.3.4.1 Calculation of catechin binding by HPLC analysis 
EGCG has previously been shown to inhibit amyloidosis of Aβ, by binding to the 
natively unfolded protein and inhibiting its conversion into β-sheet structures 
(Ehrnhoefer et al., 2008; Bieschke et al., 2010). Therefore, we would expect to see 
a reduction in the HPLC spectrum peak for the EGCG compound (peak 5) in the 
supernatant, following incubation with Aβ.  
Figure 6.10A confirms a considerable selective reduction in peak 
intensity for compounds 2, 4, 5 and 7 corresponding to caffeine, epicatechin, 
epogallocatechin-3-gallate (EGCG), and epicathechin-3-gallate. Table 6.2 
confirms the reduction in the concentration for these 4 compounds, suggesting 
89, 100, 100 and 92 % of the caffeine, epicatechin, epogallocatechin-3-gallate 
(EGCG), and epicathechin-3-gallate, respectively, was bound to Aβ and removed 
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from the solution by co-precipitation with the Aβ. EGCG is shown to bind to Aβ at 
a higher concentration than any of the other catechin compounds.  
Upon incubation of the tea extract with apoA-I, the HPLC analysis of the 
supernatant shows a considerable reduction in the peak intensity for 
epigallocatechin-3-gallate (5), gallocathin-3-gallate (6) and epicathechin-3-
gallate (7). (Figure 6.10 B) However, from the 9 identified compounds, EGCG 
shows the greatest reduction in concentration (Table 6.2), with 232 μmoles 
binding to apoA-I. 
This data confirms that Aβ binds to EGCG, as expected, since EGCG inhibits 
the aggregation of Aβ. However, interestingly, even though EGCG does not induce 
a reduction in the aggregation of apoA-I, it appears to bind with high affinity.  
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Figure 6.10 HPLC spectrum of the supernatant, following incubation of the green 
tea extract with (A) Aβ and (B) apoA-I fibrils, and removal of the insoluble 
aggregates and associated compounds by centrifugation. HPLC spectra of the 
green tea extract control are also included for intensity comparison.
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Table 6.2 Analysis of the green tea supernatant following incubation with preformed Aβ and apoA-I fibrils. The * indicates compounds 




Aβ (8 nmoles) 
 
Control (μg/ml) Supernatant (μg/ml) Bound (μg/ml) Bound (%) Bound (μmoles) 
Gallo-catechin 343.5 301.8 41.6 12.1 27.2 
Caffeine 124.7 14.2 110.5 88.6 113.8 
Catechin 449.1 434.0 15.1 3.4 10.4 
Epi-catechin 127.3 * 127.3 100 87.7 
Epigallocathechin-3-gallate 297.7 * 297.7 100 129.9 
Gallocathin-gallate 19.1 3.8 15.4 80.2 6.7 
Epicatechin-gallate 140.0 10.9 129.1 92.2 58.4 
Catechin-gallate 65.5 20.3 45.2 69.0 20.4 
      
 
ApoA-I (7.2 nmoles) 
 
Control (μg/ml) Supernatant (μg/ml) Bound (μg/ml) Bound (%) Bound (μmoles) 
Gallo-catechin 337.1 329.9 7.3 2.2 4.7 
Caffeine 302.9 240.3 62.6 20.7 64.4 
Catechin 506.4 460.3 46.0 9.1 31.7 
Epi-catechin 154.9 156.9 0 0 0 
Epigallocathechin-3-gallate 958.7 425.5 533.2 55.6 232.7 
Gallocathin-gallate 35.2 10.3 24.8 70.6 10.8 
Epicatechin-gallate 200.3 102.3 98.0 48.9 44.3 
Catechin-gallate 52.7 43.0 9.7 18.5 4.4 
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6.3.4.2 Calculation of EGCG binding to apoA-I by absorbance 
EGCG, at a range of concentrations from 0.1 mM to 1 mM, was scanned with UV 
radiation in order to determine whether UV absorbance was a viable quantitative 
method for determining the concentration of EGCG.  
Figure 6.11A shows that the absorbance of EGCG, between 250 and 320 
nm, was dependent on the concentration of EGCG added, with the intensity of the 
peak absorbance at 274 nm increasing with higher concentrations of EGCG, and 
an average extinction co-efficient of 16,816 M-1cm-1. When EGCG concentration 
was plotted against the absorbance intensity at 274 nm, a linear relationship was 
shown (Figure 6.11B), which confirms that the intensity at 274 nm can be used 
to estimate EGCG concentration, over a range of 0 to 500 μM.  
Analysis of the supernatant remaining after the removal of aggregated 
apoA-I, and any bound catechins from the green tea extract by HPLC, indicated 
that EGCG bound to apoA-I. The next stage involved assessing whether EGCG 
bound to apoA-I during the aggregation process, or just to preformed fibrils. A 
simple method of confirming which of these interactions occur involved 
incubating apoA-I in aggregation-inducing conditions, with increasing 
concentrations of EGCG added before or after promoting fibril formation. 
Removal of the aggregated material and tightly bound EGCG by centrifugation, as 
previously, will allow the absorbance of the supernatant at 274 nm to be taken, 




Figure 6.11 (A) Concentration dependence of EGCG on absorbance intensity 
between 190 and 360nm, with a peak absorbance at 274 nm. (B) Plot of 
absorbance intensity at 274 nm against EGCG concentration, showing a linear 
relationship.  
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In order to quantify the binding potential of EGCG to apoA-I, EGCG was added at a 
range of concentrations, from 9 to 180 μM, representing ¼ to 5-fold molar 
excess, compared to apoA-I at 36 μM. Binding of EGCG to apoA-I was monitored 
under 2 conditions: (i) EGCG was added to apoA-I (36 μM) at pH 7, prior to 
acidification with concentrated HCL, which was shown in Section 4.3.2, to 
induce aggregation of apoA-I, and (ii) with EGCG added to pre-formed apoA-I 







Figure 6.12 Experiment schematic showing the aggregation of apo-I (i) with 
EGCG added, prior to induction of aggregation (+), and (ii) with EGCG added to 
preformed fibrils (- +).   
 
Figure 6.13A shows a reduction in the concentration of EGCG remaining in the 
supernatant, after removal of the apoA-I aggregates. This is consistent with EGCG 
binding to apoA-I. It also shows no difference between the amount of EGCG that 
binds to apoA-I when added before or after the induction of aggregation.  
At apoA-I: EGCG molar concentrations of 36:9 μM and 36:18 μM, no EGCG 
remains in solution following sedimentation of the insoluble apoA-I material. 
This suggests that all of EGCG has bound to the apoA-I and co-sedimented with 
the protein aggregates. At equimolar concentrations, approximately 60 % of the 
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EGCG added had bound to apoA-I and was removed through sedimentation. 
When EGCG was in a 2 and 5 fold molar excess to apoA-I 36:72 μM and 36:180 
μM, respectively, approximately 55% and 25 % of the EGCG added had bound 
and co-pelleted with apoA-I, respectively. Interestingly, this corresponds to 
approximately 34 μM at both concentrations.  Therefore, saturation of apoA-I 
with EGCG appears to occur at approximately 34 μM when the stoichiometry of 
apoA-I and EGCG is equal. Conversely, estimation of the catechin concentrations 
remaining by HPLC showed that an excess of EGCG binds to apoA-I, at a molar 
ratio of 1:32 for apoA-I to EGCG. However, this data should be treated with 
caution, since it is based on integration of the HPLC peak areas.   
The binding of EGCG to apoA-I could be modelled using the Hill equation 
(Equation 6.1) and Origin Pro software, where the bound EGGC (B) is related to 
the maximum binding (Bmax), the concentration of EGCG added (A), the hill co-
efficient (n) and the dissociation constant (kD). This produces an apparent 
dissociation constant of 29.5 μM and 40.5 μM, for EGCG binding during the 
aggregation process and to pre-formed aggregates, respectively (Figure 6.13B).   
 
𝐵 = 𝐵𝑚𝑎𝑥[𝐴]
𝑛/ 𝑘𝐷 + [𝐴]
𝑛  [6.1] 
The apparent dissociation constant for EGCG added to pre-formed fibrils 
has to be considered with caution, since only 5 data points are plotted, and 
because of the increased error in the sample containing a 5-fold molar excess. 
This binding data is calculated based on the assumption that, as shown via ThT, 
EGCG does not inhibit the aggregation of apoA-I. However, EGCG may be affecting 
the aggregation of apoA-I, or disturbing the pre-formed fibril, in a manner that is 






















Figure 6.13 (A) Concentration of EGCG remaining in solution, after pelleting the 
insoluble apoA-I material, compared to the concentration of EGCG added. EGCG 
was added either before or after aggregation. Concentrations are representative 
of triplicate samples, with standard error shown.  (B) EGCG binding to apoA-I 
modelled by the hill equation.  
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6.3.5 Secondary structure of EGCG treated apoA-I aggregates 
EGCG has been shown to remodel mature amyloid fibrils (Bieschke et al., 2010; 
Palhano et al., 2013), which has therapeutic implications as a method of 
reversing amyloid deposition in amyloid-associated disease pathology.  
 
6.3.5.1 EGCG added to preformed aggregates 
Figure 6.14A shows the two-dimensional cross-polarisation 13C-13C MAS 
spectrum for apoA-I aggregates formed at pH 4 in the absence of heparin (black), 
and following treatment of the preformed aggregates with EGCG (red). The 
spectrum of the EGCG treated aggregates contain cross-peaks for several easily 
assigned residues, with chemical shifts that correspond to both α-helical and β-
sheet content within the aggregates. This is consistent with the untreated apoA-I 
aggregates formed in the absence of heparin (black).  
However, when apoA-I aggregates are treated with EGCG, the intensities 
of the cross-peaks with chemical shifts that correspond to α-helical contributions 
are profoundly reduced, compared to those for the untreated aggregates. Caution 
should be taken when estimating the percentage contribution of secondary 
structural components, based on the intensities of chemical shifts. However, the 
dramatic decrease in the intensity of the α-helical cross-peaks, in particular for 
alanine (54.9/18.3 ppm for the Cα/Cβ), and valine (66.0/31.4 ppm for the 
Cα/Cβ) as shown in Figure 6.14 B and C, respectively, and the complete 
disappearance of the alanine α-helical cross-peak (179.6/18.3 ppm for the C-
amide/Cβ) in the carbonyl region, is sufficient to confirm that EGCG causes a 




Figure 6.14 2D 13C-13C SSNMR spectra with DARR mixing of (A) apoA-I 
aggregates formed in the absence of heparin that are untreated (black) or with 
EGCG added to preformed aggregates (red).  Figures (B) and (C) show the alanine 
and valine regions in more detail, highlighting the decrease in cross-peak 
intensity at chemical shifts associated with α-helices, upon treatment with EGCG.  
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6.3.5.2 EGCG added during aggregation of apoA-I 
After determining that the addition of EGCG to pre-formed apoA-I aggregates 
resulted in a reduction of α-helical structures, a spectrum was acquired for apoA-
I aggregates formed in the presence of EGCG.  
The spectrum of apoA-I aggregates formed in the presence of EGCG 
(Figure 6.15A blue) contains cross-peaks for several easily assignable amino 
acids, with cross-peaks associated with both α-helical and β-sheet structures. 
However, when compared to the NMR spectrum of untreated apoA-I aggregates 
(Figure 6.15A black), the inclusion of EGCG during aggregation is shown to 
result in a decrease in the intensity of the α-helical contributions. The extent of 
intensity decrease in the α-helical cross-peaks is shown for alanine (Figure 
6.15B) and valine (Figure 6.15C) residues.  
This data suggests that treatment of apoA-I with EGCG, both during and 
after aggregation into amyloid-like fibrils, causes a change in the aggregates 












Figure 6.15 2D 13C-13C SSNMR spectra with DARR mixing of (A) apoA-I 
aggregates formed in the absence of heparin that are untreated (black) or formed 
in the presence of EGCG (blue).  Figures (B) and (C) show the alanine and valine 
regions in more detail, highlighting the decrease in cross-peak intensity at 
chemical shifts associated with α-helices, upon treatment with EGCG.  
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6.3.6 Effects of EGCG on the dynamics of apoA-I aggregates. 
6.3.6.1 Dynamics of apoA-I aggregates 
Determination of the overall protein secondary structure from one-dimensional 
13C SSNMR experiments relies on the characteristic chemical shift patterns of the 
amide carbonyl, α-carbon, and β-carbons as markers for protein secondary 
structure. By utilising a range of 1D 13C SSNMR techniques, it is possible to 
deduce whether the secondary structural contribution in the NMR spectrum 
originates from either a static or dynamic region of the peptide. Section 5.1.4.9, 
and 5.1.4.10 describe the theory behind the CP and INEPT NMR experiments in 
detail, and the benefits of each. Section 5.1.4.11 describes how a combination of 
DP, CP and INEPT experiments can be used to determine the dynamics of a 
protein region. In summary, DP spectra show signals from the full protein, 
whereas, due to the requirement for dipolar interactions in CP experiments, this 
technique only collects signals from static regions of the peptide. INEPT 
experiments on the other hand, rely on J couplings. Therefore, they are able to 
detect interactions within dynamic regions of proteins.  
Figure 6.16 contains DP, CP and INEPT spectra of apoA-I aggregates 
formed at pH 4 in the absence of heparin. The DP spectrum in red produces 
broad peaks in the carbonyl and alpha carbon regions with chemical shifts of 
172.5-175.9 ppm and 51.9-54.6 ppm respectively, which are concurrent with the 
average chemical shift of amino acids in a β-sheet conformation (174.5 ppm and 
55.1 ppm for the amide and α-carbon, respectively). Shoulder peaks in the amide 
carbon region of the spectrum at approximately 180 ppm, and in the α-carbon 
region at approximately 60 ppm, is suggestive of α-helical contributions (177.5 
ppm and 59.6 ppm for the amide and α-carbons, respectively).  
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The CP spectrum in black shows a high degree of similarity to the DP 
spectrum, although individual peaks within the broad 172.5-175.9 ppm amide 
carbon peak are more resolved. The high intensity, and similarity to the DP 
spectrum suggests the apoA-I aggregates are dynamically constrained.  
Conversely, the INEPT spectrum contains no distinguishable peaks above 
the background noise. This suggests the protein contains no mobile or dynamic 
regions, in concurrence with the CP data.  
 
 
Figure 6.16 DP (red) CP (black) and INEPT (blue) MAS SSNMR of apoA-I 
aggregates formed at pH 4 in the absence of heparin.   
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6.3.6.2 Dynamics of EGCG treated apoA-I aggregates 
DP and CP spectra were acquired for apoA-I, with EGCG added to preformed 
fibrils (Figure 6.17A), and apoA-I fibrils formed in the presence of EGCG (Figure 
6.17B) in order to determine whether treatment with EGCG caused a change in 
the dynamics of the apoA-I aggregates.  
 
When EGCG was added to preformed fibrils, the DP SSNMR spectrum 
acquired (Figure 6.17A black) contains a broad peak, spanning both chemical 
shift values associated with the presence of both β-sheet and α-helices. The main 
amide carbon peak at 174 ppm matches the predicted β-sheet value of 174.5 
ppm calculated by Wang and Jardetzky (2002), whilst the shoulder at 177 ppm 
corresponds with the predicted value of 177.5 ppm for α-helical contributions. 
The α-carbon region of the spectrum contains a main peak at 53.7 ppm, 
consistent with the average chemical shift for the α-carbons in a β-sheet 
conformation (55.14 ppm). However, a the peak shoulder at 59.8 ppm is 
suggestive of α-helical contributions (Wang and Jardetzky, 2002). The line 
widths of the DP spectrum also appear narrower than the untreated apoA-I 
spectrum in Figure 6.16, suggestive of increased ordering. In summary, the DP 
spectrum for apoA-I aggregates with EGCG added after their formation, suggest 
the presence of both α-helical and β-sheet structures, as shown previously in the 
2D 13C NMR spectra, similar to the untreated aggregates.  
CP experiments of apoA-I with EGCG added to preformed fibrils (Figure 
6.17A red) produce a spectrum with a much lower intensity than the DP 
spectrum (Figure 6.17A black). This is suggestive that not all of the protein is in 
a dynamically constrained conformation, as was seen for the untreated apoA-I 
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aggregates (Figure 6.16). The peaks in the CP spectrum coincide with the 
chemical shifts for the peaks in the DP spectrum, suggesting both α-helical and β-
sheet structures remain in the static regions of the protein. 
 
The DP spectrum for apoA-I aggregates formed in the presence of EGCG (Figure 
6.17B black) is consistent with the DP spectrum of aggregated apoA-I alone 
(Figure 6.16) and apoA-I with EGCG added to preformed fibrils (Figure 6.17A). 
However, it is not as well resolved as either of these spectra. A broad peak in the 
carbonyl region, with a chemical shift of 174 ppm (Figure 6.17B black), is easily 
identifiable as β-sheet by Wang and Jardetzky (2002) who predict chemical shifts 
of 174.5 ppm for β-sheet structures. Unfortunately, the broad width of the peak 
makes any contribution from α-helices at the predicted chemical shift of 177.5 
ppm, which were observed in the DP spectrum for aggregated apoA-I alone and 
apoA-I with EGCG added after aggregation as shoulder peaks, difficult to 
distinguish.  
CP experiments produce a spectrum with much lower intensity peaks, 
compared to the DP spectrum, instantly suggestive of a less constrained 
conformation. The chemical shift pattern in the carbonyl region, in particular a 
broad line spanning both 174 ppm and 177 ppm, implies both α-helical and β-
sheet contributions are present in the static phase of the apoA-I aggregates 






Figure 6.17 1D 13C DP (black) and CP (red) SSNMR spectra of (A) apoA-I with 
EGCG added to preformed apoA-I aggregates, and (B) apoA-I aggregates formed 
in the presence of EGCG.  
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The data presented in Figure 6.16 suggests that untreated apoA-I aggregates are 
dynamically constricted. However, the inclusion of EGCG, both during 
aggregation and added pre-formed aggregates, results in a reduced CP spectra 
intensity (Figure 6.17), suggestive of increased protein dynamics. 
INEPT spectra were acquired for EGCG added to preformed apoA-I 
aggregates (Figure 6.18A), and for apoA-I aggregates formed in the presence of 
EGCG (Figure 6.18B). Both spectra contain intense peaks that were not observed 
in the untreated apoA-I INEPT spectrum (Figure 6.16). This suggests that 
treatment of apoA-I with EGCG leads to increased structural dynamics in the 
aggregated material. 
The 1D INEPT spectrum observed when EGCG was added to preformed 
fibrils is not well resolved in the aromatic or α-carbon regions, making overall 
secondary structure estimations difficult. However, the presence of a peak 
consistent with the β-carbon of threonine residues at 68.9 ppm is suggestive of 
their involvement in α-helical structures (Wang and Jardetzky, 2002).  
The two-dimensional INEPT spectrum of apoA-I aggregates formed in the 
presence of EGCG, shown in Figure 6.18B gives further insights into the 
structural arrangement of apoA-I treated with EGCG. Cross-peaks for aromatic 
13C and 1Hα are detected at chemical shifts of approximately 110-130 ppm and 
3.5-4.5 ppm, respectively.  Cross-peaks also occur in the Cα and Cβ regions with 
chemical shifts of 0-40 and 40-60 ppm, respectively. Both of these 13C chemical 
shift patterns are consistent with the 1D 13C peaks in Figure 6.18A.  
In summary, the INEPT spectra suggest that the inclusion of EGCG, either 
during aggregation, or to preformed fibrils results in an increased dynamic 
























Figure 6.18 (A) INEPT SSNMR spectra of apoA-I with EGCG added to preformed 
fibrils, and (B) 2D 13C-1H INEPT SSNMR spectra of apoA-I fibrils formed in the 
presence of EGCG. 
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6.4 Discussion  
The ability of polyphenols and catechins, in particular epigallocathin gallate 
(EGCG), to inhibit aggregation of amyloidogenic proteins has been well 
documented (Ehrnhoefer et al., 2006; Ehrnhoefer et al., 2008; Hudson et al., 
2009; Bieschke et al., 2010).  The EGCG compound has been shown to inhibit the 
aggregation of Aβ, huntingtin, α-synuclein, IAPP and amyloid models (Doig and 
Derreumaux, 2015; Ehrnhoefer et al., 2008; Bieschke et al., 2010; Masuda et al., 
2006), as well as cause a structural rearrangement in preformed fibrils (Palhano 
et al., 2013; Bieschke et al., 2010). However the precise mechanism behind this 
inhibition is still unknown. The current leading theory involves EGCG driving the 
aggregation of the amyloidogenic protein into an alternative conformation, 
possibly an oligomeric state, which is unable to undergo further aggregation into 
amyloid species (Ehrnhoefer et al., 2008). EGCG has been shown to inhibit the 
aggregation of apoA-I (1-83/G26R) (Nakajima et al., 2016), but no other 
inhibitory studies of full-length, wild type apoA-I exist. Due to the aggregation 
inhibiting effects of EGCG on other amyloidogenic proteins, including the 
mutated apoA-I (1-83/G26R) species, it was questioned whether the non-
specificity of this amyloid inhibition extended to full-length apoA-I.  
Initially, experiments were carried out in order to determine the identity 
of catechins present in a green tea extract. Analysis by HPLC and comparison to a 
catechin reference set determined 8 catechin compounds were present, the most 
abundant of which were catechin, and epigallocatechin gallate (EGCG). As such, 
the effects of the green tea extract on the aggregation of Aβ and apoA-I were 
assessed. The green tea extract was shown to inhibit the aggregation of Aβ, as 
expected, given the previously published literature on purified EGCG inhibiting 
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the amyloidosis of Aβ. However, neither the green tea extract, nor pure EGCG 
were shown to inhibit the aggregation of apoA-I.  
Despite not showing an inhibitory effect on the aggregation of apoA-I, 
experiments were carried out to determine which, if any, of the catechins present 
in green tea bound to Aβ and apoA-I. Co-sedimentation of EGCG with Aβ and 
apoA-I aggregates, and analysis of the resulting supernatant by HPLC identified 4 
compounds bound to Aβ aggregates (caffeine, epicatechin, EGCG and 
epicathingallate), whilst only EGCG bound to apoA-I aggregates with high affinity. 
Therefore, the binding of pure EGCG to apoA-I aggregates was calculated, using 
the absorbance of EGCG, which was found to bind at roughly equimolar 
concentrations. The discovery that EGCG interacts with apoA-I, despite not 
inhibiting its aggregation, is interesting and could potentially direct further 
research into apoA-I amyloid inhibitors.  
Given that EGCG was shown to bind to apoA-I, the structure of the apoA-I 
aggregates treated with EGCG was assessed through SSNMR. EGCG was either 
added to preformed fibrils, or included during the aggregation process. SSNMR 
determined that treatment with EGCG, in both conditions, lead to a structural 
rearrangement in the apoA-I aggregates. 2D SSNMR identified a reduction in α-
helical content, upon treatment with EGCG, whilst the β-sheet content appears to 
remain unchanged. This structural rearrangement coincided with an increase in 
the protein dynamics, as determined through a combination of CP and INEPT 
SSNMR experiments. However, this data cannot determine whether EGCG 
induces a structural change in apoA-I aggregates that gives rise to a more 
dynamic structure, or whether EGCG solubilises apoA-I aggregates, leading to 
increased protein dynamics.  
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In the model proposed in Chapter 5 of this thesis, the β-sheet structures 
are restricted to the N-terminal 90/100, whilst the C-terminus retains its native 
helical content. Therefore, given the data presented here, it is further proposed 
that EGCG interacts with the C-terminus of the apoA-I aggregates, both during 
and after the formation of fibrils. This interaction interferes with the α-helical 
structures, converting the C-terminus into a more dynamic structure, whilst the 
N-terminal β-sheet structures remain unaffected. The increase in dynamics of the 
helical C-terminus is confirmed by the presence of a peak in the 1D 13C INEPT 
spectrum, corresponding to threonine residues in an α-helical conformation. 5 
threonine residues are present in the C-terminus (90-243) region of apoA-I that 
is thought to be in an α-helical conformation.  
Binding of EGCG to the C-terminus would also explain why EGCG appears 
to have no effect on the aggregation of apoA-I into amyloid-like aggregates, as 
determined by both ThT and SSNMR, since the β-sheet structures characteristic 
of amyloid are confined to the N-terminus. Neither an increase in the intensity of 
the β-sheet cross-peaks is observed upon treatment with EGCG, nor is an 
enhanced ThT response. Therefore, it can be assumed that the interaction of 
EGCG with the C-terminus of apoA-I does not induce β-sheet formation in the C-
terminus, nor propagation of the N-terminal β-sheet into the remaining protein, 
as originally proposed by Das et al. (2014). 
Further work on studying the interaction of apoA-I with EGCG, in order to 
determine how the compound causes a structural reformation, and the potential 
effects it could have on the apoA-I aggregates morphology, is discussed in 
Chapter 7.  
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7. General discussion and future work 
The overall aims of the research presented in this thesis have been to study the 
conditions that induce the misfolding of apoA-I into amyloid-like structures and 
investigate the structure of these aggregates.  
 
7.1 ApoA-I aggregation 
Current literature on apoA-I aggregation identifies 2 separate mechanisms that 
result in the deposition of amyloid-like material. In acquired amyloidosis, full-
length apoA-I becomes deposited as amyloid fibrils in arteries and associates 
with atherosclerotic plaques (Das et al., 2016; Ramella et al., 2011; Ramella et al., 
2012; Mucchiano, Häggqvist, et al., 2001; Wong et al., 2010; Chan et al., 2015). In 
familial apoA-I amyloidosis, N-terminal fragments of apoA-I, incorporating 
peptides 80-100 amino acids in length, become deposited within major organs 
(Raimondi et al., 2011; Das et al., 2016; Andreola et al., 2003; Adachi et al., 2014; 
Vigushin D.M et al., 1994). In both cases, aggregation of apoA-I leads to the 
misfolding of the native apoA-I. This manifests into poor cardiac health, via 3 
processes: a reduction in the HDL driven RCT, deposition of insoluble amyloid 
increases the plaque loading in atherosclerotic lesions, and an increased 
inflammatory response at atherosclerotic sites, due to possible cytotoxic amyloid 
intermediates.  
 
7.2 Current mechanism for apoA-I aggregation  
Native apoA-I, in its lipid-free state, possesses a high helical content, between 60-
80 %, depending on the conformation of the flexible C-terminus. The current 
model describing the mechanism of apoA-I aggregation has been proposed by 
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Das et al. (2016; 2014) and details how the N-terminal 4 helical bundle inhibits 
the SRE regions, residues 14-22, 53-58, and 69-72, from spontaneously 
aggregating into β-sheet structures. Mutations in this region or oxidation of 
methionine residues lead to destabilisation of the N-terminus. This allows the 
SRE regions to rearrange into β-sheet structures. The EKETEG region, spanning 
residues 76-81, acts as a natural β-sheet breaker at neutral pH, limiting the β-
sheet propagation to the N-terminal 1-76 residues (Das et al., 2014). This 
exposed region is now more accessible to proteases that cleave the N-terminal 1-
83 peptide, resulting in its deposition as amyloid. Alternatively, upon protonation 
of the glutamic acid residues in the β-sheet breaking sequence, this protective 
property is lost. Therefore, the β-sheets formed from the SRE elements can 
propagate into the C-terminus, extending into a β-zipper, which then forms full-
length amyloid (Das et al., 2014).  
This mechanism is supported by the high number of mutations in the N-
terminal 1-80 peptide that result in destabilisation of the 4-helical bundle. This 
opens the structure up to proteolytic cleavage, explaining why N-terminal 
fragments of mutated apoA-I appear as amyloid in familial apoA-I amyloidosis.  
 
7.3 Expression of apoA-I 
Recombinant apoA-I was expressed following previously published methods 
(Oda et al., 2001; Ryan et al., 2003) with suitable yields to facilitate biophysical 
analysis described in Chapter 4. Expression in minimal media enriched with 13C 
glucose and 15N ammonium chloride allowed the first SSNMR spectrum of apoA-I 
to be collected, aiding structural analysis.  SLIM based PCR methods were utilised 
to produce plasmid DNA for several apoA-I mutants, including G26R, L44Stop, 
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L90P, K96C and R173C. Agarose gel electrophoresis confirmed the PCR reaction, 
used to incorporate mutated primers, had produced large quantities of DNA, 
whilst gene-sequencing data showed the intended mutations were successfully 
incorporated. The L44Stop mutation was unable to be expressed, and, of the 
remaining 4 mutants that were expressed, none produced a protein product that 
matched the predicted mass, when measured by electrospray ionisation mass 
spectrometry. The L90P mutant, which is of particular interest in this work, 
causes an increased rate in the aggregation of the apoA-I 1-93 peptide. DNA 
sequencing confirmed the introduction of the proline in the correct position and 
expression of the protein produced a band that appeared in the correct region on 
an SDS gel. However, upon treatment with 45 % formic acid, in order to cleave 
the his-tag between the formic acid labile Asp-Pro sequence, 2 smaller peptides 
were detected on an SDS gel and via mass spectrometry. After studying the 
sequence, the mutated proline in position 90 was found to produce a second acid 
labile Asp-Pro sequence, leading to the production of peptides corresponding to 
residues 3-89 and 90-243.  
 
7.3.1 Further work with apoA-I (3-89) and (90-243) 
Unfortunately, isolation of these two peptides from the his-tag was not 
attempted, due to time restrictions in the project and the focus on full-length 
apoA-I. However, a simple HPLC process should be able to separate out the 2,533 
Da his-tag and linker region, the 10,005 Da apoA-I (3-89) peptide, and the 17,881 
Da apoA-I (90-243) peptide.  
N-terminal fragments of apoA-I are commonly found deposited as amyloid 
in familial associated amyloidosis. Although structural analysis has already been 
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attempted on N-terminal peptides of apoA-I, the expression methods used here, 
in particular the ability to produce labelled apoA-I, would allow SSNMR analysis 
of both the soluble and aggregated peptide. Structural analysis of the aggregated 
apoA-I (3-89) peptide would confirm whether this region contains entirely β-
sheet structures. If this is the case, then it is justified to assume that the α-helical 
contributions detected by CD and SSNMR arise from the C-terminus, as proposed 
in the refined amyloidosis model in Chapter 5.  
Currently, the structure of soluble, lipid-free apoA-I is incomplete, with 
the C-terminal 185-243 residues not shown in the model proposed by Mei and 
Atkinson (2011). Isolation of the apoA-I (90-243) peptide would allow structural 
analysis of the full C-terminus region of apoA-I, and refinement of the full-length 
structure. This peptide could also be used to determine whether the C-terminus 
of apoA-I has a natural propensity to aggregate, by repeating the biophysical 
experiments carried out in Chapter 4. The current model for full-length apoA-I 
amyloidosis assumes that the C-terminus has no natural propensity to aggregate. 
It proposes that the presence of β-sheets in the C-terminus only occurs, due to 
extension of the N-terminal β-sheets. If it is found that apoA-I (90-243) can form 
amyloid in isolation, it would dispute the Das et al. (2016) model. If apoA-I (90-
243) only forms amyloid when seeded with apoA-I (3-89) amyloid, it could 
confirm the Das et al. model. However, if apoA-I (90-243) does not aggregate 
under any physiologically relevant conditions, it will support the refinement 
proposed in Chapter 5.  
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7.4 Conditions that promote aggregation of apoA-I 
In this study, apoA-I was incubated at a range of pH conditions, alone, and in the 
presence of a 2-fold molar excess of heparin. Acidic pH induced a conversion 
from soluble apoA-I into insoluble aggregates both in the absence and presence 
of heparin, with an excess of 90 % of protein precipitating out of solution.  
In the absence of heparin, the insoluble aggregates were ThT responsive, bound 
to Congo red dye and exhibited a green birefringence. However, they did not 
have the typical amyloid morphology when viewed by TEM, or produce XRD 
patterns consistent with the presence of β-sheet structures. CD experiments 
showed that after 2 hours incubation, both the remaining soluble material and 
the insoluble aggregates retained a high proportion of the native helical content.  
Conversely, when incubated with an excess of heparin, the insoluble material 
gave rise to a ThT response, a green birefringence when stained with Congo red, 
exhibited a more common amyloid morphology, and produced intense XRD 
reflections, consistent with the presence of β-sheets. ThT data confirmed the ThT 
response was heparin concentration-dependent. CD analysis of the aggregates 
determined a dramatic reduction in α-helical content, with an increase in β-sheet 
structures, which is characteristic of amyloid. The thin film CD spectra contained 
both α-helical and β-sheet contributions and, upon comparison to the aggregates 
formed in the absence of apoA-I, the β-sheet contribution was calculated to be 
approximately 40 %.  
Oxidation of apoA-I was confirmed through MS, and CD analysis 
determined a slight reduction in the α-helical content at neutral pH, suggesting 
unfolding of the native structure. This is consistent with previous analysis of 
chemical oxidation of apoA-I (Chan et al., 2015). Intrinsic fluorescence studies 
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implied that the oxidised apoA-I has a more relaxed structure, with increased 
exposure of the 4-tryptophan residues to hydrophobic environments. Upon 
incubation at pH 6, the oxidised apoA-I readily formed ThT reactive aggregates, 
with a morphology similar to the apoA-I aggregates, formed in the presence of 
heparin.  
The conditions determined here that promote aggregation of apoA-I are 
physiologically relevant. At sites of atherosclerotic lesions, where apoA-I is 
deposited, the local pH can be reduced dramatically, given the immune response 
against the oxidised LDL (Thijssen and Mensink, 2005). GAG’s, such as heparin, 
are commonly associated with amyloid deposits (Cohlberg et al., 2002). 
Oxidation of methionine residues on apoA-I by myeloperoxidsase has been 
shown to induce aggregation into amyloid species (Chan et al., 2015). 
 
7.5 SSNMR analysis of apoA-I amyloid   
The PDB contains a distinct lack of apoA-I structures determined by NMR. To 
date, only 4 structures have been deduced, corresponding to residues 142-187 
(Wang et al., 1997) 166-185 (Wang et al., 1996) and 1-93 (Mangione et al., 2001). 
This is due to the high flexibility of the apoA-I structure, which gives rise to broad 
line widths, which was observed in the SSNMR spectra obtained for this thesis. 
However, new structural information could be deduced from the 13C spectra, in 
regards to the local secondary structural content, which has previously been 
unavailable.  
Thin film CD of apoA-I aggregates, formed in the presence of heparin, 
suggested the presence of both α-helical and β-sheet content, something 
uncommon in amyloid species. SSNMR confirmed that the aggregated material 
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formed at pH 4 alone, in the presence of heparin, and upon oxidation at pH 6, all 
retained a high proportion of their native α-helical elements, whist also 
possessing cross-peaks that are consistent with the presence of β-sheet elements. 
This conflicts with the mechanism of apoA-I amyloidosis, proposed by Das et al. 
(2016), which claims that the entire aggregate consists of β-sheet in acidic 
conditions.  
Therefore, a refinement of the amyloidosis mechanism is suggested in 
Chapter 5. Destabilisation of the 4-helical bundle in native apoA-I, either by 
acidification or oxidation of the 3-methionine residues, results in the conversion 
of residues 1-90 into a non-helical conformation, with the conversion of the hot-
spot regions into β-sheets. However, the β-sheet structures are restricted to the 
N-terminus, and the C-terminus of apoA-I retains its majority α-helical content, 
as shown in Figure 5.29, unlike the mechanism proposed by Das et al. (2016).  
 
7.5.1 Future SSNMR experiments 
In order to confirm this theory, more detailed structural analysis of apoA-I via 
SSNMR is required. In addition to the experiments outlined above for the apoA-I 
(3-89) and apoA-I (90-243) peptides, spectra for amino acids located in solely 
the N or C-terminus of apoA-I would confirm the local secondary structure. 
Unfortunately, all 18 amino acids in apoA-I (excluding cysteine and isoleucine) 
are uniformly distributed among residues 1-89 and 90-243. Isoleucine could be 
mutated into either region, and its conformation probed by 13C-13C CP SSNMR, 
since the Cα -Cβ cross-peaks produced by isoleucine are easily assignable on the 
2D 13C spectrum.  
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Alanine is an attractive alternative amino acid, since their cross-peaks are one of 
the most identifiable in the complex spectrum produced by full-length apoA-I, 
and their chemical shift patterns make it easy to distinguish between their α-
helical and β-sheet signals. Only 2 alanine residues are present in the N-terminal 
(1-90) region, compared to 17 in the C-terminus, which are distributed 
throughout residues 95-229. Production of a double mutant to remove the 
alanine residues at positions 15 and 37 would result in an alanine Cα-Cβ cross-
peak, solely from the C-terminus of apoA-I. Mutation from alanine to leucine 
would have a minimal effect on the structure of apoA-I. If the cross-peak occurs 
only at chemical shifts associated with α-helical contributions, then it supports 
the refined theory. Any β-sheet signals would mean the model needs further 
revision.  
Similarly, the lone tryptophan residue in the C-terminus at position 108 
could be mutated out of the sequence, leaving the 13C cross-peaks corresponding 
to the 3 tryptophan residues in the N-terminus.  
All three of these methods could make use of the uniformly labelling 
techniques used in this chapter. Alternatively, a combination of mutagenesis and 
sporadic labelling, or addition of excess labelled amino acid to a minimal media 
expression, would produce an NMR spectra containing cross peaks from just the 
amino acid of interest, such as alanine residues only in the C-terminus.  
 
7.6 ApoA-I inhibition  
The overall aim of studying the structure of amyloidogenic proteins is to improve 
the understanding of how the soluble, native protein misfolds into amyloid, and 
thus, manifests itself in disease pathology. This can then direct the design of 
 275 
therapeutic techniques in order to control or inhibit the disease progression. 
Currently, there are no known compounds that inhibit the aggregation of apoA-I. 
EGCG, a catechin found in green tea, has been shown to inhibit the 
aggregation of several amyloidogenic proteins, including Aβ, α-synuclein and 
huntingtin. Data presented here confirms that EGCG binds to apoA-I with 
micromolar affinity, but does not cause a reduction in the production of ThT 
responsive material. However, binding of EGCG to apoA-I does induce a 
structural change in the aggregates formed at acidic pH. EGCG leads to a 
reduction in the helical content of apoA-I aggregates and an increase in the 
protein dynamics. If EGCG can inhibit the amyloidosis of apoA-I, or cause an 
alternative aggregation mechanism, this could have potential health benefits. A 
reduction in fibril formation may allow apoA-I to retain its native function in the 
atheroprotective reverse cholesterol transport, or reduce the atherosclerotic 
plaque load. Alternatively, since EGCG is known to bind to apoA-I, structural 
analogues could be designed, based on the apoA-I-EGCG interaction, as potential 
drug compounds with higher efficacy.  
Future work on the interaction of apoA-I with EGCG should focus on 
determining whether EGCG effects the aggregation of apoA-I. This will involve 
extensive biophysical analysis, similar to that carried out in Chapter 4. EGCG has 
been shown to compete with ThT for binding sites on amyloid (Palhano et al., 
2013), so alternative methods of measuring aggregation kinetics might be 
required.  Determination of whether the EGCG modified apoA-I structure induces 
cytotoxicity of the fibrils will also be important in taking this compound forward 
as a treatment model. If EGCG inhibits fibril formation, but induces the formation 
of off-pathway aggregates that are cytotoxic to endothelial or other cardiac cells, 
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the treatment mechanism fails. Alternatively, if EGCG is solubilising the fibrils, 
which is a possibility, given the increased dynamics upon treatment with EGCG, 
this could also lead to the production of cytotoxic oligomers. Therefore, cell 
viability studies are essential future work, both in the study of the inhibition of 
aggregation and treatment of preformed fibrils.  
In addition to the NMR data presented in Chapter 6, CD analysis of apoA-I 
aggregates, in particular the use of orientated thin film SRCD, could give further 
insight into the structural changes observed during the aggregation in the 
presence of EGCG, and whether EGCG added to preformed fibrils alters their 
conformation. Computer modelling of the interaction between EGCG and apoA-I 
could allow comparison to how EGCG interacts with Aβ, huntingtin and α-
synuclein, for which it is known to inhibit amyloidosis. Since EGCG appears to 
induce an alteration in the helical region of the apoA-I aggregates, the refined 
amyloidosis model would suggest an interaction involving the C-terminus of 
apoA-I. This would also explain why EGCG does not cause a reduction in the ThT 
response, caused by the β-sheet structures, located in the N-terminus. This could 
be confirmed through determining whether EGCG will bind to the apoA-I (3-89) 
and apoA-I (90-243) peptides separately.  
 
In conclusion, the research carried out in this thesis has furthered the 
understanding of apoA-I aggregation, and has begun assessing a known amyloid 
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Appendix 1 




Site-directed ligase independent mutagenesis (SLIM) primers  
Mutated triplicates are highlighted in bold with the individual changed 




Forward Long Primer  
TTG  AAC  TAG  AAG  CTG  CTG  GAC  AAC  TGG  GAC AGC  GTG  ACG  T    
Forward Short            
GAC  AAC  TGG  GAC AGC  GTG  ACG  T 
Reverse Long Primer  
CAG  CAG  CTT  CTA  GTT  CAA  TTG  TTT  GCC  CAA  GGC  GGA  TCC  T 
Reverse Short 
TTG  TTT  GCC  CAA  GGC  GGA  TCC  T   
 
L90P 
Forward Long Primer 
AGC  AAG  GAT  CCG  GAG  GAG  GTG  AAG  GCC  AAG  GTG  CAG  CCG  TAC  C  
Forward Short Primer 
GTG  AAG  GCC  AAG  GTG  CAG  CCG  TAC  C    
Reverse Long Primer 
CTC  CTC  CGG  ATC  CTT  GCT    CAT  CTC  CTG  GCG   CAG  GCC  CTC T 
Reverse Short Primer 





Forward Long Primer 
GTG  AAG  GCC  TGC  GTG  CAG  CCG  TAC  CTG   GAC GAC  TTC  CAG  A    
Forward Short Primer 
CCG  TAC  CTG  GAC  GAC  TTC  CAG A  
Reverse Long Primer     
CTG  CAC  GCA  GGC  CTT  CAC  CTC  CTC  CAG  ATC  CTT  GCT  CAT  C 
Reverse Short Primer 
CTC  CTC  CAG  ATC  CTT  GCT  CAT  C 
 
R173C 
Forward Long Primer 
CTG CGC  CAG  TGC  TTA  GCG  GCG  CGC  CTT  GAG  GCT  CTC  AAG  G 
Forward Short Primer 
GCG  CGC  CTT  GAG  GCT  CTC  AAG  G  
Reverse Long Primer 
CGC  TAA  GCA  CTG  GCG  CAG  CTC  GTC  GCT  GTA  CGG  CGC  CAG  A 
Reverse Short Primer 





Gene Sequencing of apoA-I Mutants  
The sequence in brackets contains the expressed fusion peptide, consisting of the 
hexa-histidine tag (green), the linker region (orange) and apoA-I mutant 
sequence (black) with mutants underlined. The formic acid cleavage site is 
shown as “|” and indistinguishable amino acids are shown as blue “X”s. 
 
ApoA-I E2D 
I G R P Q R F P S R N N F V Stop L Stop (E G D I H M H H H H H H G L V P R G S I D 
D | P P Q S P W D R V K D L A T V Y V D V L K D S G R D Y V S Q F E G S A L G K 
Q L N L K L L D N W D S V T S T F S K L R E Q L G P V T Q E F W D N L E K E T E 
G L R Q E M S K D L E E V K A K V Q P Y L D D F Q K K W Q E E M E L Y R Q K V E 
P L R A E L Q E G A R Q K L H E L Q E K L S P L G E E M R D R A R A H V D A L R 
T H L A P Y S D E L R Q R L A A R L E A L K E N G G A R L A E Y H A K A T E H L S 
T L S E K A K P A L E D L R Q G L L P V L E S F K V S F L S A L E E Y T K K L N T Q 
Stop) S A L E L V D L R P H S S T T T T T T E I R L L T K 
 
ApoA-I G26R 
K X X X X L X X G X X H M H H H H H H I E G X D X | X X X S P W D R V K D X X T 
V Y V D V L K D S R R D Y V S Q F E G S A L G K Q L N L K L L D N W D S V T S T F 
S K L R E Q L G P V T Q E F W D N L E K E T E G L R Q E M S K D L E E V K A K V 
Q P Y L D D F Q K K W Q E E M E L Y R Q K V E P L R A E L Q E G A R Q K L H E L 
Q E K L S P L G E E M R D R A R A H V D A L R T H L A P Y S D E L R Q R L A A R 
L E A L K E N G G A R L A E Y H A K A T E H L S T L S E K A K P A L E D L R Q G L 
L P V L E S F K V S F L S A L E E Y T K K L N T Q Stop) G A L E L V D L R P H S S T 
T T T T T E I R L L T K P 
 
ApoA-I L44Stop 
X X X X X X X F C L L Stop (E G D I H M H H H H H H G L V P R G S I D D P P Q S P 
W D R V K D L A T V Y V D V L K D S G R D Y V S Q F E G S A L G K Q L N Stop) K 
L L D N W D S V T S T F S K L R E Q L G P V T Q E F W D N L E K E T E G L R Q E M S 
K D L E E V K A K V Q P Y L D D F Q K K W Q E E M E L Y R Q K V E P L R A E L Q E 
G A R Q K L H E L Q E K L S P L G E E M R D R A R A H V D A L R T H L A P Y S D E L 
R Q R L A A R L E A L K E N G G A R L A E Y H A K A T E H L S T L S E X A K P A L E 
D L R Q G L L P V L E S F K V S F L S A L E E Y T K K L N T Q Stop S A L E L V D L R P 
H S S T T T T T T E I R L L T K P E R K L X W L L P P L X N N Stop 
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ApoA-I L90P 
X X X X X X F C L L Stop (E G D I H M H H H H H H G L V P R G S I D D | P P Q S P 
W D R V K D L A T V Y V D V L K D S G R D Y V S Q F E G S A L G K Q L N L K L L 
D N W D S V T S T F S K L R E Q L G P V T Q E F W D N L E K E T E G L R Q E M S 
K D P E E V K A K V Q P Y L D D F Q K K W Q E E M E L Y R Q K V E P L R A E L Q 
E G A R Q K L H E L Q E K L S P L G E E M R D R A R A H V D A L R T H L A P Y S 
D E L R Q R L A A R L E A L K E N G G A R L A E Y H A K A T E H L S T L S E K A K 
P A L E X L R Q X L L P V L E S F K V S F L S A L E E Y T K K L N T Q Stop) S A L E 
L V D L R P H S S T T T T T T E I R L L T K P E R K L S W L L P P L S N N Stop H N P 
L G X L N G S W X G F F A E R R N 
 
ApoA-I K96C 
X X X X X F C L L Stop (E G D I H M H H H H H H G L V P R G S I D D | P P Q S P W 
D R V K D L A T V Y V D V L K D S G R D Y V S Q F E G S A L G K Q L N L K L L D N 
W D S V T S T F S K L R E Q L G P V T Q E F W D N L E K E T E G L R Q E M S K D 
L E E V K A C V Q P Y L D D F Q K K W Q E E M E L Y R Q K V E P L R A E L Q E G 
A R Q K L H E L Q E K L S P L G E E M R D R A R A H V D A L R T H L A P Y S D E 
L R Q R L A A R L E A L K E N G G A R L A E Y H A K A T E H L S T L S E K A K P A 
L E D L R Q G L L P V L E S F K V S F L S A L E E Y T K K L N T Q Stop) S A L E L V 
D L R P H S S T T T T T T E I R L L T K P E R K L S W L L P P L X I T S I T P W G L 
Stop T G X E G F F A E R X T I S X I X R Met G R X X X R R I K R  
 
ApoA-I R173C 
X X X X X X X X X X C X X Stop (E G D I H M H H H H H H G L V P R G S I D D | P P 
Q S P W D R V K D L A T V Y V D V L K D S G R D Y V S Q F E G S A L G K Q L N L 
K L L D N W D S V T S T F S K L R E Q L G P V T Q E F W D N L E K E T E G L R Q 
E M S K D L E E V K A K V Q P Y L D D F Q K K W Q E E M E L Y R Q K V E P L R A 
E L Q E G A R Q K L H E L Q E K L S P L G E E M R D R A R A H V D A L R T H L A 
P Y S D E L R Q C L A A R L E A L K E N G G A R L A E Y H A K A T E H L S T L S E 
K A K P A L E D L R Q G L L P V L E S F K V S F L S A L E E Y T K K L N T Q Stop) S 
A L E L V D L R P H S S T T T T T T X I R L L T K P E X K L X W L L P P L X N N Stop 
H X P W G S K R V L R G F L L K X N Y I P D W X X X X R X Stop R R I Stop R X G X X 











Fittings for the calculation of rates of fluorescence increase between the FI and FT 
points. Data from this is incorporated into Figures 4.7, 4.8 and 4.10 for A, B and C 
respectively.   
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